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Abstract 
Part I: Oxidative insertion into C-H bonds is an important subfield of organic chemistry that allows for 
formation of new C-C bonds without prefunctionalization of the starting substrates, leading to more 
efficient synthesis. The mechanisms by which oxidative coupling occurs can vary amongst structurally 
similar phenols, such that there is no general catalyst that works with a broad range of phenols. By using 
an extensive library of catalysts to create profiles for groups of phenols that have similar reactivity, more 
efficient catalysts can be designed to perform oxidative coupling. Taking advantage of High Throughput 
Experimentation (HTE), 24 salen/salan chromium, copper, iron, manganese, ruthenium, and vanadium 
catalysts with a variety of previously unexplored steric and electronic effects were examined efficiently in 
the oxidative homo-coupling of a broad range of phenols. Amongst the set, several different reaction 
trends were observed. Notably, the groupings of catalysts with different metals were discovered to have 
similar reactivity profiles, allowing us to hypothesize that different metals catalysts may operate by 
similar mechanisms. 
Part II: The naturally occurring bisphenol, honokiol, has been employed in traditional Chinese, Japanese, 
and Korean herbal medicine. Recent studies reported that honokiol has strong anti-bacterial properties 
against the oral bacteria Streptococcus mutans. A library of derivatives inspired by honokiol was 
generated using novel oxidative coupling developed in the Kozlowski laboratory, in order to improve and 
better understand its bioactivity. In these studies, the anti-bacterial properties of honokiol were found not 
to be as strong as previously reported. However, 12 honokiol- inspired analogs were synthesized that 
possessed equal or better inhibitory ability relative to honokiol. 
Part III: From the library of honokiol analogs, 5,5’-(ethane-1,2-diyl)bis(2-(tert-butyl)phenol) (C2) was 
identified as highly potent against S. mutans planktonic cells. This new scaffold greatly improved upon 
the natural product, but it was unclear what structural features were causing this potent activity and what 
biological mechanism led to the effect. For this reason, 66 new analogs of C2 were designed to assess 
the structure-activity relationships (SAR) of the lead compound. Compound C2 and several of its closely 
related analogs were discovered to affect bacterial membrane stability and fluidity in S. mutans. 
Moreover, C2 has similar potency and an improved therapeutic index when compared to the commercially 
antimicrobial cetylpyridinium chloride. 
Part IV: The gram-positive bacteria, methicillin-resistant Staphylococcus aureus (MRSA), and gram-
negative bacteria, Acinetobacter baumannii, are pathogens responsible for millions of nosocomial 
infections worldwide. Due to the emerging threat of bacteria evolving resistance to more antibiotics, 
scientists are constantly looking for new classes of compounds that can treat infectious diseases. The 
bisphenolic analogs of honokiol that were most potent against oral bacteria had similar bioactivity 
against MRSA. However, all the compounds proved ineffective against A. baumannii. This inability to 
inhibit A. baumannii is due to the difficult-to-penetrate lipopolysaccharide-coated outer membrane that 
makes it challenging for antibiotics to enter gram-negative bacteria. The C2 scaffold was optimized from 
the inhibition of only gram-positive bacteria to broad-spectrum antibacterial compounds that inhibit the 
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Part I: Oxidative insertion into C-H bonds is an important subfield of organic chemistry 
that allows for formation of new C-C bonds without prefunctionalization of the starting 
substrates, leading to more efficient synthesis. The mechanisms by which oxidative 
coupling occurs can vary amongst structurally similar phenols, such that there is no general 
catalyst that works with a broad range of phenols. By using an extensive library of catalysts 
to create profiles for groups of phenols that have similar reactivity, more efficient catalysts 
can be designed to perform oxidative coupling. Taking advantage of High Throughput 
 iv 
Experimentation (HTE), 24 salen/salan chromium, copper, iron, manganese, ruthenium, 
and vanadium catalysts with a variety of previously unexplored steric and electronic effects 
were examined efficiently in the oxidative homo-coupling of a broad range of phenols. 
Amongst the set, several different reaction trends were observed. Notably, the groupings 
of catalysts with different metals were discovered to have similar reactivity profiles, 
allowing us to hypothesize that different metals catalysts may operate by similar 
mechanisms. 
Part II: The naturally occurring bisphenol, honokiol, has been employed in traditional 
Chinese, Japanese, and Korean herbal medicine. Recent studies reported that honokiol has 
strong anti-bacterial properties against the oral bacteria Streptococcus mutans. A library of 
derivatives inspired by honokiol was generated using novel oxidative coupling developed 
in the Kozlowski laboratory, in order to improve and better understand its bioactivity. In 
these studies, the anti-bacterial properties of honokiol were found not to be as strong as 
previously reported. However, 12 honokiol- inspired analogs were synthesized that 
possessed equal or better inhibitory ability relative to honokiol. 
Part III: From the library of honokiol analogs, 5,5’-(ethane-1,2-diyl)bis(2-(tert-
butyl)phenol) (C2) was identified as highly potent against S. mutans planktonic cells. This 
new scaffold greatly improved upon the natural product, but it was unclear what structural 
features were causing this potent activity and what biological mechanism led to the effect. 
For this reason, 66 new analogs of C2 were designed to assess the structure-activity 
relationships (SAR) of the lead compound. Compound C2 and several of its closely related 
analogs were discovered to affect bacterial membrane stability and fluidity in S. mutans. 
 v 
Moreover, C2 has similar potency and an improved therapeutic index when compared to 
the commercially antimicrobial cetylpyridinium chloride. 
Part IV: The gram-positive bacteria, methicillin-resistant Staphylococcus aureus 
(MRSA), and gram-negative bacteria, Acinetobacter baumannii, are pathogens responsible 
for millions of nosocomial infections worldwide. Due to the emerging threat of bacteria 
evolving resistance to more antibiotics, scientists are constantly looking for new classes of 
compounds that can treat infectious diseases. The bisphenolic analogs of honokiol that 
were most potent against oral bacteria had similar bioactivity against MRSA. However, all 
the compounds proved ineffective against A. baumannii. This inability to inhibit A. 
baumannii is due to the difficult-to-penetrate lipopolysaccharide-coated outer membrane 
that makes it challenging for antibiotics to enter gram-negative bacteria. The C2 scaffold 
was optimized from the inhibition of only gram-positive bacteria to broad-spectrum 
antibacterial compounds that inhibit the dangerous gram-negative pathogen A. baumannii.  
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CHAPTER 1.  Oxidative Coupling of Phenols: A Study on 
Detecting Reactivity Trends 
 
1.1. Background 
Oxidative insertion into C-H bonds is an important subfield of organic chemistry 
that allows for new C-C bond formation without prefunctionalization of the starting 
substrates, leading to more efficient synthesis.1 The Kozlowski group has focused on the 
oxidative coupling of phenols, using O2 as an inexpensive and environmentally friendly 
oxidant, which produces water as the only byproduct.2  Biphenyls have been found to 
possess biological and medical utility, including anticancer activity, hormonal activity, and 
drug activity.3 The mechanisms by which oxidative coupling occurs can vary amongst 
structurally similar phenols, such that there is no general catalyst that works with a broad 
range of phenols. 
In order to better understand these reactions, catalysts derived from chromium, 
copper, iron, manganese, ruthenium, and vanadium were studied. These metals were 
chosen due to their suitable redox potentials, which are favorable for oxidation of phenol 
 
1  Shilov, A. E.; Shul'pin, G. B., Activation of C-H Bonds by Metal Complexes. Chem. Rev. 
1997, 97, 2879-2932. 
2 Lee, Y. E., Cao, T., Torruellas, C., & Kozlowski, M. C. Selective Oxidative Homo- and 
Cross- Coupling of Phenols with Aerobic Catalysts. J. Am. Chem. Soc. 2014, 136, 6782–
6785. 
3 Pal, T.; Pal, A., Oxidative Phenol Coupling: A Key Step for the Biomimetic Synthesis of 
Many Important Natural Products. Curr. Sci. 1996, 71, 106–109. 
 2 
and for reoxidation by O2 to complete the catalytic cycle.4,5,6,7,8,9 Salen/salan ligands were 
utilized as ligands since prior literature has revealed that are able to stabilize metals in a 
variety of oxidation states.10,11 Three different nitrogen based backbones (R1) and three 
different substituents para to the phenol of the salen/salan ligands were chosen in order to 
investigate previously unexplored steric and electronic effects (Figure 1.1). By using this 
extensive library of catalysts to create profiles for groups of phenols that have similar 
reactivity, more efficient catalysts can be developed to perform specific oxidative homo-
couplings, cross-couplings, and asymmetric couplings. 
  
 
4 Bordwell, F. G.; Cheng, J. P., Substituent Effects on the Stabilities of Phenoxyl Radicals 
and the Acidities of Phenoxyl Radical Cations. J. Am. Chem. Soc. 1991, 113, 1736–1743. 
5 Kozlowski, M. C.; Morgan, B. J.; Linton, E. C., Total Synthesis of Chiral Biaryl Natural 
Products by Asymmetric Biaryl Coupling. Chem. Soc. Rev. 2009, 38, 3193–3207. 
6  Egami, H.; Katsuki, T., Iron-Catalyzed Asymmetric Aerobic Oxidation: Oxidative 
Coupling of 2-Naphthols. J. Am. Chem. Soc. 2009, 131, 6082–6083. 
7 Allen, S. E.; Walvoord, R. R.; Padilla-Salinas, R.; Kozlowski, M. C., Aerobic Copper-
Catalyzed Organic Reactions. Chem. Rev. 2013, 113, 6234–6458. 
8 Chu, C.-Y.; Hwang, D.-R.; Wang, S.-K.; Uang, B.-J., Chiral Oxovanadium Complex 
Catalyzed Enantioselective Oxidative Coupling of 2-Naphthols. Chem. Commun. 2001, 
980–981. 
9  Irie, R.; Masutani, K.; Katsuki. T., Asymmetric Aerobic Oxidation Coupling of 2-
Naphthol Derivatives Catalyzed by Photo-Activated Chiral (NO)Ru(II)-Salen Complex. 
Synlett 2000, 1433–1436. 
10 Yoon, T. P.; Jacobsen, E. N. Privileged chiral catalysts. Science 2003, 299 (5613), 1691-
1693. 
11 Cozzi, P. G., Metal-Salen Schiff base complexes in catalysis: practical aspects. Chem. 




Figure 1.1 Phenol Oxidative Homo-Coupling with Salen/Salan Catalysts Using Oxygen 
as the Oxidant and the ortho-ortho, ortho-para, and para-para Products. 
 
1.2. High-Throughput Screening Reproducibility 
The High-Throughput Experimentation (HTE) Center was used for phenol 
profiling as it has facilities that allow for 24 – 96 parallel reactions on a micromolar scale, 
thereby leading to fast data collection for analysis. However, concerns have been raised 
over the reproducibility of the results and whether the results translate to a bench scale.12  
The Kozlowski group previously found that the phenol 2-tert-butyl-4,5-xylenol oxidatively 
homo-coupled using metal salen/salan catalysts. An HTE screen was devised using 21 
different catalysts from our synthesized library of 94 catalysts that varied the metals and 
ligand electronic effects. One catalyst, V-Salen-Cy-tBu, selected arbitrarily, was repeated 
four times as a control to detect differences between locations on the 24 well plate.  Product 
formation was monitored via UPLC analysis. To address concerns over the reproducibility 
of running parallel reactions on a microscale, the screen was rerun and duplicated 
independently by two additional coworkers (Thomas Paniak and Kyle Niederer) for the 
 
12 Benjamini, Y.; Hochberg, Y., Controlling the false discovery rate: A practical and 











ClCH2CH2Cl, O2, 80 ℃, 24 h
H
M= CrCl, Cu(H2O), Fe(Cl), MnCl, Ru(NO)Cl, V(O)F
R1 = Ph, Cy, (R,R)-BINAM
R2 = t-Bu, MeO, NO2












same phenol. Additionally, successful bench scale reactions (0.5 mmol) of several catalysts 
showed that the HTE reactions were reproducible on a larger scale. A total of four duplicate 
trials were conducted at varying times and dates. The results are compiled in Figure 1.2, 
which is organized in order of increasing product over internal standard (P/IS) with respect 
to the average of the trials. Error bars were calculated based on the average deviation from 
the mean P/IS value of each catalyst over the four trials. As shown in Figure 1.2, all trials 
gave similar results with a low standard deviation, with the exception of the first listed V-
Salen-Cy-tBu. We suspect this effect is due to the location of V-Salen-Cy-tBu in the reactor 
block (B06); initially, there were difficulties sealing the reactor blocks at this location, 
causing the solvent to evaporate from this well. Nevertheless, these results demonstrate 
that with correct technique, the results from the HTE screenings are valid and reproducible. 
 























































































































































































































1.3. Enantioselectivity of Oxidative Homo-Coupling  
In addition to the analysis of reactivity patterns amongst the phenols, their 
effectiveness in enantioselective couplings was also assessed. The enantiomeric excess of 
the products in the microscale reactions were analyzed using the Agilent Aurora 
Supercritical Fluid Chromatography (SFC) System in the HTE Center. Products 1cd and 
1vd, both with tert-butyl groups in the ortho position, offered no enantiomeric excess from 
any of the catalysts. However, 1ad (53% ee), 1bd (47% ee), and 1cd (28% ee) all produced 
the most enantioenriched products when the Cr-Salen-Cy-tBu catalyst was employed 
(Figure 1.3). The Cr-Salen-Cy-OMe catalyst was the only other catalyst on our plate to 
provide asymmetric induction, but with significantly lower enantiomeric excess values for 
all three compounds. 
 
Figure 1.3 Enantiomeric Excess of Screened Phenols in order of Decreasing Steric 
Hindrance 
 
 Based on these observations, as the substituent hindrance decreases ortho to the 
phenol, the enantioselectivity of the reaction increases. The Kozlowski group has recently 
used reaction pathway calculations and experimental data to determine the mechanism by 
which oxidative coupling occurs with a chromium (III) catalyst, providing better 
47% ee














































understanding why the ortho substituent has such a large effect on enantioselectivity.13 The 
initial and rate determining step of the reaction is oxidation of Cr(III) to the active Cr(V) 
species, whereupon the phenol then binds to the Cr. This is followed by an H+ transfer from 
another equivalent of the phenol, leading to an oxidation of the bound phenol to form a 
reactive keto-radical intermediate. It is at this step that the phenoxide reacts with the keto-
radical to form the new C-C bond that imparts enantioselectivity. Future DFT calculations 
modeling the manner in which the phenoxide anion interacts with the keto-radical will 
elucidate if there are different pathways between substrates with smaller or larger groups 
at the ortho-position that can explain these difference in enantioselectivity.  
In order to confirm the validity of this trend, the selectivity (ln er) of the phenols 
was plotted against various parameters (Taft, Charton, and Sterimol B1) that quantify steric 
interactions. These parameters demonstrated good fits (Figures 1.4a-c) with an R2 of 
greater than 0.96 for all three graphs, showing that increasing steric bulk corrleates to 
decreased enantiomeric excess.  
  
 
13 Nieves-Quinones, Y.; Paniak, T. J.; Lee, Y. E.; Kim, S. M.; Tcyrulnikov, S.; 
Kozlowski, M. C., Chromium-Salen Catalyzed Cross-Coupling of Phenols: Mechanism 
and Origin of the Selectivity. J. Am. Chem. Soc. 2019, 141 (25), 10016-10032. 
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Figures 1.4 a. Selectivity of Phenols vs. Taft Steric Parameters14 b. Selectivity of 
Phenols vs. Charton Steric Parameters15 c. Selectivity of Phenols vs. Sterimol B1 
Parameters.16 
 
1.4. Synthesis of Phenols and Salen/Salan Catalysts  
 The reactivity patterns of 18 phenols (Figure 1.5) were screened with the above 
catalyst array to compare reactivity trends based on steric hindrance, number of 
methyl/methoxy substituents, site selectivity, and electron donating/withdrawing ability. 
In order to further elucidate the mechanism of the oxidative homo-coupling, 2,4,6-
trimethylphenol (1p) and 1-(tert-butyl)-2-methoxy-4,5-dimethylbenzene (1q) were 
included as controls since no reaction should occur when all oxidizable sites are block (1p) 
or when the hydroxyl group is protected (1q) to prevent direct coordination to a metal 
center. Various approaches were deployed to synthesize all of the phenols that were not 
 
14 Taft, R. W.; Lewis, I. C., Evaluation of resonance effects on reactivity by application of 
the linear inductive energy relationship-IV: Hyperconjugation effects of para-alkyl 
groups. Tetrahedron 1959, 5, 210-232. 
15 Charton, M. Steric effects. III. Bimolecular nucleophilic substitution. J. Am. Chem. 
Soc. 1975, 97 (13), 3694-3697. 
16 Harper, K. C.; Bess, E. N.; Sigman, M. S., Multidimensional steric parameters in the 
















































Selectivity vs. Sterics 
(Sterimol)
 8 
commercially available (the compounds purchased through Sigma Aldrich are highlighted 
in blue in Figure 1.5).  
 
Figure 1.5 Selected Phenols for Analysis of Reactivity Trends 
 
The commercially available 3,4-xylenol (1j) was used as a precursor for the 
synthesis of several key phenols (Scheme 1.1). Compound 1j was subjected to Casnati-
Skattebøl ortho-formylation to yield intermediate 4, which upon hydrogenation using Pd/C 
gave the trimethylated phenol 1a in almost quantitative yield. Compound 1d was generated 
from 1j via Friedel-Crafts ortho-alkylation and subsequent methylation produced the 
anisole product 1q. Methylation of 1j allowed for Friedel-Crafts ortho-acylation to afford 
1s. This phenol could be exhaustively reduced to produce 1b or treated with methyl 
Grignard followed by hydrogenation to generate 1c. The homo-coupled dimers of all the 
phenols were synthesizing using commercially available catalysts VO(acac)2 or Cr-Salen-
Cy-tBu.  
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Scheme 1.1 Synthesis of Phenols Testing ortho Steric Interactions 
 
 In addition to the synthesis of phenols, all of the metal catalysts used in the HTE 
screens were resynthesized in collaboration with Adriana Jemison, Kyle Niederer, and 
Thomas Paniak. First, the salicylaldehydes (Scheme 1.2) were generated and then used in 
the formation of the salen/salan ligand backbones (Scheme 1.3) that were then bound to 
the various metals (Scheme 1.4). The methoxy salicylaldehyde 8 was obtained from 3-
(tert-butyl)-2-hydroxy-5-methoxybenzaldehyde (6) via a Duff formylation. 2-(tert-
Butyl)phenol (9) underwent a Casnati-Skattebøl ortho-formylation to generate 10, 
followed by aromatic nitration to generate the nitro salicylaldehyde 11. Salicylaldehyde 12 
was commercially available through Millipore Sigma. 
Scheme 1.2 Synthesis of Salicylaldehydes 
  
The salen ligands were all synthesized through a facile imine condensation that 












































































































for purification (Scheme 1.3). The salan ligands were all formed through the reduction of 
imines using NaBH4 in THF and MeOH. 
Scheme 1.3 Synthesis of Salen/Salan Ligands
 
 Three salicylaldehydes (tert-butyl, OMe, NO2) were combined with three 
enantioenriched diamine backbones (Cy, Ph, BINAM) to synthesize nine salens and all 
were reduced to form nine salans. In collaboration with Adriana Jemison, Kyle Niederer, 
and Thomas Paniak, these 18 salens/salans were coordinated to Cr, V, Ru, Cu, Mn, Fe, 
and Co in order to generate 94 metal salen/salan catalysts. I focused on the synthesis of 
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Scheme 1.4 Synthesis of Metal Bound Salen/Salan Catalysts
 
 After the completion of the library of catalysts, large quantities were synthesized 
for a group of 24 catalysts that were representative of the larger library.  This sub-library 
allowed comparison of the reactivity trends of: salen vs salan ligands, electron donating 
(OMe) vs electron withdrawing (NO2) vs sterically hindered (tert-butyl) substituents, 
diamine backbones that cause distortions to the octahedral molecular geometry (Cy and Ph 
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Metal Ligand R1 R2
Cr Salen Cy tert-Bu
Cr Salen Cy OMe
Cr Salen BINAM NO2
Cu Salan BINAM OMe
Cu Salan Cy OMe
Cu Salan Cy tert-Bu
Cu Salan Ph OMe
Cu Salan Ph tert-Bu
Cu Salen BINAM OMe
Mn Salan Cy tert-Bu
Mn Salan Ph NO2
Mn Salan Ph OMe
Mn Salan Ph tert-Bu
Mn Salen Cy NO2
Fe Salen Ph NO2
Fe Salan Cy OMe
Fe Salan Ph OMe
Fe Salen BINAM tert-Bu
Ru Salen Cy tert-Bu
V Salen BINAM NO2
V Salen BINAM OMe
V Salen BINAM tert-Bu
V Salen Cy OMe
V Salen Ph NO2
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1.5. Analysis of Oxidative Phenol Homo-Coupling Trends  
 In collaboration with Adriana Jemison, the chosen phenols were screened against 
24 salen/salan catalysts with 17 different ligand backbones and six metals, which led to the 
observation of several notable trends. The phenols that were not expected to react, as they 
either did not have unoccupied ortho/para positions (1p) or were missing the oxidizable 
phenol (1q), did not form biphenols. Interestingly, we noticed that 1p was consumed during 
the screen leading to depleted starting material and one large byproduct for many of the 
catalysts. After Adriana Jemison scaled up the reaction to bench scale, it was found that 1p 
underwent benzylic C-H activation to form the stilbenequinone via a 6-electron, 6-proton 
oxidative process (Scheme 1.5).17 
Scheme 1.5 Dimerization of Phenol 1p 
 
Furthermore, phenols with electron withdrawing groups, 1r and 1s do not undergo 
oxidative homo-coupling with any of the catalysts screened. 
The oxidation potentials of the phenols were measured in collaboration with 
Adriana Jemison, in dichloroethane using a CHI600E Electrochemical Analyzer, in order 
to obtain quantitative values to better understand reactivity trends (Figure 1.5). More 
oxidizable phenols (1a, 1b, 1c, 1d, 1e, 1f, 1m, and 1o) with redox potentials below 1.10 V, 
yielded the highest product/internal standard (PDT/IS) ratios amongst the majority of 
 
17 Oyaizu, K.; Saito, K.; Tsuchida, E., Copper-Catalyzed Oxidative Coupling of 2,4,6-
















catalysts (Figure 1.6). An important characteristic of all of these phenols is that there is 
only one ortho-position available for reaction.  
 
Figure 1.6 Representative Oxidative Potential Trends 
 
Phenols with oxidative potentials above 1.10 V tended to produce little to no 
oxidatively homo-coupled dimer. Difficult-to-oxidize phenols with electron withdrawing 
groups, such as 1r and 1s, had high oxidation potentials and were unreactive as they gave 
little to no product while returning most of the starting material. However, many of the 
phenols with multiple sites available for coupling (1g, 1h, 1j, 1k, 1n) with oxidative 
potentials above 1.10 V and multiple sites for homo-coupling showed less starting material 
and little to homo-dimer after the reaction time, demonstrating that they are reactive but 
are not producing an identifiable product. As shown in Figure 1.7, V-Salen-BINAM-NO2 
is one of the many catalysts that follow these patterns. The phenols with an oxidation 
potentials less than 1.10 V are, for the most part, reactive and form homo-dimer (Figure 















































































0.8 1 1.2 1.4 1.6
Fe-SALAN-Ph-OMe
x axis = Ox. Pot.









0.8 1 1.2 1.4 1.6
Mn-SALAN-Ph-NO2
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homo-dimer (Figure 1.8 right graph). Furthermore, the phenols with multiple locations for 
oxidative coupling have little starting material remaining and yet do not form homo-dimer. 
Further investigation into these outcomes is needed.  
 
Figure 1.7 Example of Catalyst Demonstrating Trends found in Oxidative Potentials 
 
After analyzing the various parameters of the phenols, similarities of reactivity 
patterns among the catalysts were identified. Catalyst relative reactivity was calculated by 
finding the correlation coefficient between the PDT/IS of all the phenols (listed in 
































































































































































































































































Figure 1.8 Relative Reactivities Between Cr, Cu, and Mn Catalysts 
 
 
Figure 1.9 Relative Reactivities Between Mn, Fe, and V Catalysts 
 
Surprisingly, catalysts of different metals had similar reactivity profiles. The 
chromium catalysts, Cr-Salen-Cy-tert-Bu and Cr-Salen-Cy-OMe, the copper salan 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































manganese catalyst Mn-Salan-Ph-tert-Bu have correlation coefficients greater than 0.82 
when comparing PDT/IS across all of the screened phenols (Figure 1.8). The manganese 
catalysts Mn-Salen-Cy-NO2 and Mn-Salan-Cy-tert-bu, the iron catalyst Fe-Salan-Cy-
OMe, and the vanadium catalysts, V-Salen-BINAM-OMe and V-Salen-Cy-OMe have 
correlation coefficients greater than 0.78 with respect to one another and can also be 
grouped together (Figure 1.9). It appears that the metal is not the main factor in causing 
reactivity, but the way that the metal binds to the various salen/salan ligands. Quantitative 
parameters for the catalysts were sought to understand why these catalysts are reacting in 
similar patterns. Initially, the redox potentials of the catalysts were surveyed, but numerous 
unknown peaks were found in the cyclic voltammagrams due to the various oxidized forms 
of the catalysts as well the salen/salan ligands. Next the lmax values of the catalysts were 
measured using a UV-Vis spectrophotometer, but no discernable patterns were found 
between the catalysts. Currently, Adriana Jemison is investigating statistical relationships 
among reaction outcomes. 
The grouped metal catalysts consisted of both salen and salan ligands, all three 
diamine backbones, and all three aromatic substituents, making it difficult to draw 
conclusions without further parameterization. However, some basic trends do emerge. Four 
catalysts of varying ligands and backbones produced little to no product (Cr-Salen-
BINAM-NO2, Cu-Salen-BINAM-OMe, Fe-Salen-BINAM-tert-Bu, and Fe-Salen-Ph-NO2) 
and consumed little to no starting material of the phenols. These results show that only 
9/13 (69%) of catalysts with a salen ligand and 11/11 (100%) of catalysts with a salan 
ligand were reactive and caused oxidative coupling. Out of the catalyst diamino backbones, 
4/7 (57%) with the BINAM, 9/9 (100%) with the cyclohexyl, and 7/8 (88%) with the 
 18 
diphenyl were reactive. Finally, out of the catalyst aromatic substituents, 9/10 (90%) of the 
methoxy, 7/8 (88%) of the tert-Bu, and 4/6 (67%) of the NO2 formed meaningful amounts 
of product. From these observations, the salan ligand, cyclohexyl diamino backbone, and 
electron rich aromatic substituent are in catalysts that have a higher likelihood to 
oxidatively homo-couple. The latter is particularly interesting since the electron rich 
aromatic group stabilized the higher oxidation states of the metals. As a result, the 
complexes can be more readily oxidized by dioxygen, but are also weaker oxidants for the 
phenol oxidation.   
1.6. Summary 
The HTE center permitted a much different approach than available with bench 
scale. Specifically, a large number of combinations 18 phenols of varying steric and 
electronic with 24 metal salen/salan catalysts, which corresponds to 432 reactions, were 
successfully assessed. Phenols with an oxidation potential below 1.10 V and with only one 
free ortho/para-site were more likely to undergo oxidative homo-coupling. Harder to 
oxidize phenols with a redox potential above 1.10 V formed significantly less, if any, 
product. Di- and tri-methylated phenols were consumed during the course of the reaction, 
but generated unknown products. Catalysts of with different metals and ligands were 
discovered to have similar reactivity profiles, allowing new hypotheses to be formed about 






All non-aqueous reactions were carried out under an atmosphere of dry argon 
unless otherwise noted. Commercial reagents were used as received without additional 
purification unless otherwise noted. Anhydrous THF, toluene, dichloromethane, and 1,2-
dichloroethane were obtained from a Pure Process Technology solvent purification system. 
Reactions were monitored by thin layer chromatography (TLC) using Silicycle glass-
backed TLC plates with 250 µM silica and F254 indicator. Visualization was accomplished 
by UV light or iodine staining. All compounds with inhibitory ability greater than 250 µM 
were analyzed for purity by UPLC and characterized by 1H NMR and decoupled 13C NMR 
Nominal mass accuracy LCMS data were obtained by use of a Waters Acquity UPLC 
system equipped with a Waters TUV detector (254 nm) and a Waters SQD single 
quadrupole mass analyzer with electrospray ionization.  
1H NMR spectra were recorded on a 500 MHz spectrometer. Chemical shifts are 
reported in ppm from the solvent resonance (CDCl3 7.26 ppm, acetone-d6 2.05 ppm). Data 
are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, br = broad, m = multiplet), coupling constants, and number of protons. 
Decoupled 13C NMR spectra were recorded at 125 MHz. IR spectra were taken on an FT-
IR spectrometer. Accurate mass measurement analyses were conducted via time-of-flight 
mass analyzer GCMS with electron ionization (EI) or via time-of-flight mass analyzer 
LCMS with electrospray ionization (ESI). The signals were measured against an internal 
reference of perfluorotributylamine for EI-GCMS and leucine enkephalin for ESI-LCMS. 
The instrument was calibrated, and measurements were made using neutral atomic masses; 
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the mass of the electron removed or added to create the charged species is not taken into 
account.  
 
1-(tert-Butyl)-2-methoxy-4,5-dimethylbenzene (1q). To a 10 mL microwave vial under 
an inert atmosphere was added NaH (26.9 mg, 1.12 mmol, 2.0 equiv), 2-(tert-butyl)-4,5-
dimethylphenol (100.0 mg, 0.56 mmol, 1.0 equiv), and anhydrous THF (3.0 mL, 0.19 M). 
The vial was sealed with a septum and SO4(CH3)2 (106.1 mg, 0.84 mmol, 1.5 equiv) was 
slowly added. The septum was replaced with a crimping cap and the vessel sealed and 
reaction mixture stirred for 19 h at 60 °C. When the reaction was finished, it was quenched 
with H2O (10 mL). The mixture was extracted with dichloromethane (3 x 15 mL) and ethyl 
acetate (3 x 15 mL). The combined organic layers were washed with brine (3 x 15 mL), 
dried over Na2SO4, concentrated, and chromatographed (5% ethyl acetate/hexane) to afford 
the product as a white solid (72.2 mg, 0.38 mmol) in a 67% yield: 1H NMR (500 MHz, 
CDCl3) d 7.02 (s, 1H), 6.68 (s, 1H), 3.81(s, 3H), 2.23 (s, 3H), 2.20 (s, 3H), 1.36 (s, 9H); 
13C NMR (125 MHz, CDCl3) d 156.5, 135.5, 134.7, 128.0, 127.6, 113.6, 55.2, 34.3, 29.9, 
19.5, 19.0; IR (neat) 2957, 2922, 2853, 1463, 1378, 1261, 1209, 1076, 802, 721 cm-1; 
HRMS (ESI) m/z = 192.1514 calc for C13H20O, found 192.1491. 
General Procedure for the Preparation of Salen Ligands 
The salicylaldehyde (1.0 equiv) was added as a solid to a solution of the diamine 
(2.08 equiv) in a 1:1 mixture of methanol and absolute ethanol (0.05 M) and the reaction 






to the solution. The resulting crystalline solid was collected by filtration and washed with 




Following the general procedure, the salen ligand was obtained as a yellow solid (2.78 g, 
4.47 mmol) in 89% yield: 1H NMR (500 MHz, CDCl3) d 8.36 (s, 2H), 8.22 (d, J = 2.5 Hz, 
2H), 8.01 (d, J = 2.5 Hz, 2H), 7.34-7.24 (m, 10H), 4.91 (s, 2H), 1.46 (s, 18H); 13C NMR 
(125 MHz, CDCl3) d 166.4, 165.8, 139.6, 139.1, 137.9, 128.9, 128.4, 127.8, 126.2, 125.3, 
117.2, 79.1, 35.3, 28.9; IR (neat) 2958, 2923, 2854, 1613, 1528, 1469, 1454, 1439, 1392, 
1324, 1283, 1202, 1180, 1110, 1061, 1029, 982, 911, 783, 747, 717, 698, 614, 563 cm-1; 




Following the general procedure, the salen ligand was obtained as a yellow solid (1.52 g, 








2H), 8.00 (d, J = 2.5 Hz, 2H), 3.48 (m, 2H), 2.09 (d, J = 14 Hz, 2H), 1.97 (d, J = 8.5 Hz, 
2H), 1.80 (d, J = 8.5 Hz, 2H), 1.55-1.53 (m, 2H), 1.41 (s, 18H); 13C NMR (125 MHz, 
CDCl3) d 167.1, 164.6, 139.7, 138.8, 126.1, 125.1, 116.9, 71.5, 35.2, 32.5, 28.9, 24.0; IR 
(neat) 2923, 2854, 1635, 1611, 1529, 1467, 1391, 1326, 1283, 1222, 1203, 1179, 1144, 
1109, 980, 911, 862, 783, 747, 716 cm-1; HRMS (ESI) m/z = 525.2713 calc for C28H36N4O6, 
found 525.2705. 
General Procedure for the Reduction of Salens to Salans 
 To a solution of the salen in THF:MeOH (4:1), sodium borohydride (10 equiv) was 
slowly added. The mixture was stirred at room temperature overnight (with a change in the 
solution color from yellow to colorless, except in the cases of nitro derivatives). The 
mixture was slowly quenched via dropwise addition of water and extracted with 
dichloromethane (3 x 50 mL). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered, concentrated and chromatographed using 20% ethyl acetate/hexane 
to afford the product. 
 
6,6'-((((1S,2S)-Cyclohexane-1,2-diyl)bis(azanediyl))bis(methylene))bis(2-(tert-butyl)-
4-methoxyphenol). Following the general procedure, the salan ligand was obtained as a 
light brown resin (1.59 g, 3.18 mmol) in 80% yield: 1H NMR (500 MHz, CDCl3) d 6.80 (d, 





2H), 3.74 (s, 6H), 2.44 (m, 2H), 2.17 (m, 2H), 1.70 (m, 2H), 1.36 (s, 18H), 1.24 (t, J = 9.5 
Hz, 4H); 13C NMR (125 MHz, CDCl3) d 151.8, 150.7, 138.2, 123.5, 112.8, 111.0, 59.9, 
55.7, 50.6, 34.8, 30.9, 29.4, 24.3; IR (neat) 3309, 2927, 2857, 1604, 1448, 1431, 1390, 
1358, 1312, 1227, 1207, 1174, 1135, 1099, 1059, 990, 929, 851, 769, 751, 738 cm-1; HRMS 
(ESI) m/z = 499.3536 calc for C30H46N2O4, found 499.3541. 
 
6,6'-(([1,1'-Binaphthalene]-2,2'-diylbis(azanediyl))bis(methylene))bis(2-(tert-butyl)-
4-methoxyphenol). Following the general procedure, the salan ligand was obtained as a 
light brown solid (1.17 g, 1.75 mmol) in 80% yield: 1H NMR (500 MHz, CDCl3) d 7.94 (d, 
J = 6.5 Hz, 2H), 7.86 (d, J = 8.5 Hz, 2H), 7.82-7.78 (m, 4H); 7.50 (br, 2H), 7.33 (t, J = 7.0 
Hz, 2H), 7.23 (d, J = 7.0 Hz, 2H), 7.13 (d, J = 9.0 Hz, 2H), 7.01 (d, J = 8.0 Hz, 2H), 6.78 
(d, J = 2.5 Hz, 2H), 6.41 (br, 2H), 4.44 (d, J = 9.0 Hz, 2H), 4.32 (d, J = 9.0 Hz, 2H), 3.71 
(s, 6H), 1.32 (s, 18H); 13C NMR (125 MHz, CDCl3) d 149.5, 142.6, 133.8, 133.1, 130.1, 
130.0, 128.5, 128.30, 128.26, 127.2, 127.1, 124.7, 123.6, 122.7, 118.2, 110.9, 76.9, 55.7, 
34.9, 29.5; IR (neat) 3473, 3367, 2923, 2854, 1619, 1595, 1511, 1467, 1432, 1380, 1327, 
1225, 1147, 1059, 1023, 813, 774, 747 cm-1; HRMS (ESI) m/z = 669.3692 calc for 
C44H48N2O4, found 669.3713. 





 The salen ligand (1.0 equiv) and CrCl2 (1.1 equiv) were dissolved in THF (0.01 M). 
The mixture was stirred under argon at room temperature for 24 h. Then, the reaction 
mixture was exposed to air and stirred for an additional 24 h. The reaction mixture was 
poured into TBME (30 mL), washed with aqueous saturated NH4Cl (3 x 20 mL) and brine 
(3 x 20 mL), followed by drying with Na2SO4. After filtration, the mixture was 
concentrated in vacuo to yield the chromium catalyst.  
General Procedure for Preparation of Copper Catalysts 
To a solution of salan ligand in methanol (0.031 M), Cu(OAc)2•H2O (1 equiv) and 
powdered NaOH (2 equiv) were added. Once the salts had dissolved, the solvent was 
evaporated. The solid residue was dissolved in dichloromethane and washed with water. 
The solution was dried over Na2SO4, filtered, and concentrated in vacuo to yield the copper 
complex. 
 
(R,R)-Cu-Salan-Binam-OCH3. Light brown solid; HRMS (ESI) m/z = 731.2910 calc for 




















(S,S)-Cu-Salan-Cy-tert-butyl. Dark green solid; HRMS (ESI) m/z = 612.3716 calc for 
C36H57CuN2O2 [M+H]-H2O, found 612.3723. 
 
(S,S)-Cu-Salan-Ph-tert-butyl. Dark green solid; HRMS (ESI) m/z = 710.3873 calc for 
C44H59CuN2O2 [M+H]-H2O, found 710.3867. 
General Procedure for Preparation of Vanadium Catalysts 
 To a suspension of VOF3 (1 equiv) in dichloromethane (0.14 M), a solution of the 
salen/salan ligand (1 equiv) in dichloromethane (0.16 M) was added. The reaction mixture 
was stired for 2 h at room temperature under an Ar atmosphere. The solvent was then 
evaporated to dryness and the residue washed with water, small amounts of MeOH, and n-
hexane, and dried under vacuum to yield the vanadium complex. 
 
(R,R)-V-Salen-Binam-OCH3. Dark blue solid; HRMS (ESI) m/z = 729.2533 calc for 

















(R,R)-V-Salen-Binam-tert-butyl. Dark purple solid; HRMS (ESI) m/z = 781.3574 calc 
for C50H53N2O3V [M+H]-HF, found 781.3573. 
 
(S,S)-V-Salen-Cy-OCH3. Dark green solid; HRMS (ESI) m/z = 559.2377 calc for 
C30H39N2O5V [M+H]-HF, found 559.2352. 
 
(S,S)-V-Salen-Ph-NO2. Dark purple solid; HRMS (ESI) m/z = 687.2024 calc for 
C36H35N4O7V [M+H]-HF, found 687.2024. 
General Procedure for High Throughput Experimentation (HTE) 
 The following procedure is representative of an HTE screen. The solutions of 
catalyst (2 µmol, 50 µL) in DCE and the solutions of phenol (10 µmol, 50 µL) in DCE 




















continuously back-filled with oxygen using a desiccator fixed with a T-valve for 3 min. 
The plate was sealed and stirred at 80 °C for 24 h. After cooling to ambient temperature, 
the vials were diluted with a solution of 4,4’-biphenyl (1 µmol, 500 µL) in MeCN and then 
sealed. The contents were centrifuged for 5 min. To a separate 96-well LC plate with 1 mL 
vials were added 700 µL of MeCN, and then 30 µL of the diluted reaction mixtures. The 
mixture was then analyzed using Agilent Chemstation on a Waters Acquity UPLC-ZQ with 
sample manager holding up to 15 well plates, binary pumps, and PDA module and single 
quadrupole detector equipped with ESI system.  
Table S1.1 PDT/IS for Chromium Catalysts
 
Phenol Cr-Salen-Cy-tert-Bu Cr-Salen-Cy-OMe Cr-Salen-BINAM-NO2
3,4,5-trimethylphenol 0.25808203 1.0399733 0
3,5-dimethoxy-4-methyl 0.24367623 0.39983868 0
2-tBu-4,5-xylenol 2.54513217 2.75024161 0
2-Phenyl-4,5-xylenol 2.55050824 3.25462331 0
2,6-dimethoxyphenol 0 0 0
2-Me-xylenol 1.51510758 1.57909059 0
2-iPr xylenol 1.85769554 2.16673251 -
2-Et-4,5-xylenol 1.31192098 1.86684159 -
2,4-dimethylphenol 0.31873602 0.1830484 0
2,4,6-trimethylphenol - - -
2-Bromo-4,5-xylenol 0.27283564 0.12587371 0
2,3-dimethylphenol 0.18235685 0.03140566 0
2,3,5-trimethylphenol 0 0.11109355 0
2,5-dimethylphenol 0 0 0
3,4-dimethylphenol 0 0 0
2-Acetyl-4,5-xylenol 0 0 0
3,5-dimethylphenol 0.1218195 0 0
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Table S1.2 SM/IS for Chromium Catalysts 
 
Table S1.3 Pdt/IS for Copper Catalysts
 
Table S1.4 SM/IS for Copper Catalysts
 
Phenol Cr-Salen-Cy-tert-Bu Cr-Salen-Cy-OMe Cr-Salen-BINAM-NO2
3,4,5-trimethylphenol 0.05205476 0.17529543 2.177070602
3,5-dimethoxy-4-methyl 0 0 2.376486945
2-tBu-4,5-xylenol 0 0 2.122980553
2-Phenyl-4,5-xylenol 0 0.34468153 6.016882232
2,6-dimethoxyphenol 1.90966352 1.63114067 2.957757049
2-Me-xylenol 0.40455857 0.74573142 2.045162865
2-iPr xylenol 0.19521113 0.10252835 2.36519967
2-Et-4,5-xylenol 0 0.03351769 2.426132839
2,4-dimethylphenol 0.06196286 0 2.294292363
2,4,6-trimethylphenol 0.06953707 0.12104756 2.254832871
2-Bromo-4,5-xylenol 1.61694147 2.0824159 2.375292811
2,3-dimethylphenol 0 0 1.972428612
2,3,5-trimethylphenol 0 0 1.796565463
2,5-dimethylphenol 0 0 2.341100202
3,4-dimethylphenol 0 0.05621983 2.011411173
2-Acetyl-4,5-xylenol 4.13857935 4.92798716 4.51867244
3,5-dimethylphenol 0 1.69031277 0.682936887
Phenol Cu-Salan-BINAM-OMe Cu-Salan-Cy-OMe Cu-Salan-Cy-tert-Bu Cu-Salan-Ph-OMe Cu-Salan-Ph-tert-Bu Cu-Salen-BINAM-OMe
3,4,5-trimethylphenol 0.8953819 0.37067091 1.2980926 0.98694413 1.44434566 0
3,5-dimethoxy-4-methyl 0.14385288 0.03452998 0.65756527 0.05963953 0 0.12088879
2-tBu-4,5-xylenol 2.5073304 2.17768316 2.53198006 2.38514789 2.65362816 0.10422169
2-Phenyl-4,5-xylenol 2.03768211 1.17547428 2.76314638 0.75513057 2.07010146 0
2,6-dimethoxyphenol 0.07108537 0 0 0.08134472 0 0
2-Me-xylenol 0.50151203 0.60341933 0.81340528 0.75066895 0.9484512 0
2-iPr xylenol 1.74479925 1.77376171 2.25664282 2.19845811 2.45140149 0
2-Et-4,5-xylenol 1.53780763 0.6863011 1.18080259 1.14117365 1.36394745 -
2,4-dimethylphenol 0.28758356 0 0.16549908 0 0.27427994 0.39204507
2,4,6-trimethylphenol - - - - - -
2-Bromo-4,5-xylenol 0.14837928 0.07290119 0.08038609 0.05746397 0
2,3-dimethylphenol 0.08340762 0 0 0 0 0
2,3,5-trimethylphenol 0.42710883 0.22403818 0.30063348 0.19066938 0.27277156 0
2,5-dimethylphenol 0 0 0 0 0 0
3,4-dimethylphenol 0 0 0 0 0 0
2-Acetyl-4,5-xylenol 0.12141509 0.05425832 0 0.11269233 0 0
3,5-dimethylphenol 0 0.07632189 0.07571237 0.06128521 0 0
Phenol Cu-Salan-BINAM-OMe Cu-Salan-Cy-OMe Cu-Salan-Cy-tert-Bu Cu-Salan-Ph-OMe Cu-Salan-Ph-tert-Bu Cu-Salen-BINAM-OMe
3,4,5-trimethylphenol 0.54782729 0.11047919 0.78927843 0.68701136 0.89540835 2.07086735
3,5-dimethoxy-4-methyl 0 0 0 0 0 2.48081016
2-tBu-4,5-xylenol 0 0 0.12808292 0 0.04372855 1.92695662
2-Phenyl-4,5-xylenol 1.06368612 1.1979459 1.42656864 2.38620929 3.37647074 6.18234428
2,6-dimethoxyphenol 0.88630324 0.06784067 1.12897275 1.26890579 0.77573194 2.90822466
2-Me-xylenol 1.48173857 0.03394331 0.35126658 0 0.17191063 1.04598439
2-iPr xylenol 0.13214534 0 0.06504192 0.20998016 0.52854922 2.46406677
2-Et-4,5-xylenol 0.35713003 0.02842138 0.05917053 0.1049247 0.25483396 2.53918373
2,4-dimethylphenol 0.25408996 0.31441455 0.62686365 0.33998523 0.27788649 1.31575091
2,4,6-trimethylphenol 0.24981202 0.06538104 0 0.51003936 0.60997497 2.16339292
2-Bromo-4,5-xylenol 1.54929054 1.58489827 2.42921449 1.94969789 2.45950283 2.12296557
2,3-dimethylphenol 0.19883808 0.21196 0.43166864 0.72664439 0.64426669 2.1519753
2,3,5-trimethylphenol 0 0.05271586 0.17010256 0.13766343 0.29492058 1.99840385
2,5-dimethylphenol 0.0686088 0 0 0.04955498 0 2.05624925
3,4-dimethylphenol 0.32131279 0.86888649 1.47918473 0.7874928 1.05205405 2.1049337
2-Acetyl-4,5-xylenol 4.40635528 4.76685159 4.66293803 5.17104488 5.31328147 4.47187678
3,5-dimethylphenol 1.90297378 1.86557157 2.08406665 1.93427712 2.18027432 2.25959553
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Table S1.5 Pdt/IS for Manganese Catalysts
 
Table S1.6 SM/IS for Manganese Catalysts
 
Phenol Mn-Salan-Cy-tert-Bu Mn-Salan-Ph-NO2 Mn-Salan-Ph-OMe Mn-Salan-Ph-tert-Bu Mn-Salen-Cy-NO2
3,4,5-trimethylphenol 1.38431444 0.095793 0.85203342 1.44452296 1.30221508
3,5-dimethoxy-4-methyl 1.98339497 1.31806573 1.52984605 0.91824264 1.66403683
2-tBu-4,5-xylenol 2.68645361 2.06274266 1.9684807 2.5243882 2.1853374
2-Phenyl-4,5-xylenol 2.50323016 0.55191207 1.42146413 2.56892102 4.58859677
2,6-dimethoxyphenol 0 0.14901148 0.07660659 0 0
2-Me-xylenol 0.88853513 2.72316348 0.7820768 0.82088281 0.80802558
2-iPr xylenol 2.45261302 2.0135378 2.08990432 2.24530924 2.67296552
2-Et-4,5-xylenol 1.3523405 1.12958529 0.92193555 1.47373707 1.45604595
2,4-dimethylphenol 0.30786876 0.3510422 0.39669342 0.27607221 0.26502338
2,4,6-trimethylphenol - - - - -
2-Bromo-4,5-xylenol 0 0.11468659 0 0.10912197 0
2,3-dimethylphenol 0 0 0 0 0
2,3,5-trimethylphenol 0.28672392 0.04903947 0.19036079 0.21735128 0.77994674
2,5-dimethylphenol 0 0 0 0 0.3067755
3,4-dimethylphenol 0 0 0.0471798 0.03726428 0
2-Acetyl-4,5-xylenol 0 - 0 0 0
3,5-dimethylphenol 0.08294309 0.02367238 0 0.06440498 0.1206727
Phenol Mn-Salan-Cy-tert-Bu Mn-Salan-Ph-NO2 Mn-Salan-Ph-OMe Mn-Salan-Ph-tert-Bu Mn-Salen-Cy-NO2
3,4,5-trimethylphenol 0.46427878 0 1.78252406 0.81217706 1.32851921
3,5-dimethoxy-4-methyl 0.2628884 0 0.9906798 0 1.6242292
2-tBu-4,5-xylenol 0 0.19081353 1.06320164 0 0
2-Phenyl-4,5-xylenol 1.23245549 0 3.19125768 0.61674763 4.57144054
2,6-dimethoxyphenol 3.12923444 2.47197589 2.36395074 2.82200322 2.65605824
2-Me-xylenol 0.32769643 1.17474531 0.12571604 0.83550096 0.26551753
2-iPr xylenol 0.3852366 0 1.09575798 0.09743506 0.06010518
2-Et-4,5-xylenol 0.27814063 0 1.03938217 0.11597574 0.08448501
2,4-dimethylphenol 0.45935576 0.04602046 1.24522221 0.4028403 0.7867204
2,4,6-trimethylphenol 0.99784663 2.16039493 1.16073829 0.20153356 0.16284223
2-Bromo-4,5-xylenol 1.83046536 1.71820037 2.07378466 2.26025847 1.99467575
2,3-dimethylphenol 0.74303225 0 1.74119325 0.96627309 1.37264838
2,3,5-trimethylphenol 0.26884134 0 1.49412167 0.26491701 0
2,5-dimethylphenol 0.163879 0 1.73372865 0 0.49872062
3,4-dimethylphenol 0.64784352 0 1.52364552 0.60687971 1.26943964
2-Acetyl-4,5-xylenol 5.28654478 5.70811227 6.43496276 5.83625524 3.89454916
3,5-dimethylphenol 2.0048172 0.39180429 2.20968374 2.22656616 2.11805172
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Table S1.7 Pdt/IS for Iron Catalysts
 
Table S1.8 SM/IS for Iron Catalysts
 
Table S1.9 Pdt/IS for Ruthenium Catalyst 
Phenol Fe-Salen-Ph-NO2 Fe-Salan-Cy-OMe Fe-Salan-Ph-OMe Fe-Salen-BINAM-tert-Bu
3,4,5-trimethylphenol 0.3771734 1.07326664 1.00629687 0.1184722
3,5-dimethoxy-4-methyl 0.784638 0.82260104 0.87245459 0.40582424
2-tBu-4,5-xylenol 0.4772383 2.39434282 2.3003721 0.20595951
2-Phenyl-4,5-xylenol 0.1686691 1.9370178 0.66327926 0.1058327
2,6-dimethoxyphenol 0.4623749 0 0.06473047 0
2-Me-xylenol 0.1952262 0.8207659 0.96286985 0.08211945
2-iPr xylenol 0.4170715 2.1998441 1.99791666 0.15904305
2-Et-4,5-xylenol 0.2109392 1.39941424 0.98709357 0.07210757
2,4-dimethylphenol 0 0.08022831 0.42882313 0.16889829
2,4,6-trimethylphenol - - - -
2-Bromo-4,5-xylenol 0 0.12120472 0
2,3-dimethylphenol 0 0.05804286 0.05980519 0
2,3,5-trimethylphenol 0.0512545 0.20667957 0.09591024 0
2,5-dimethylphenol 0.2833401 0 0 0
3,4-dimethylphenol 0.2995561 0.04232874 0 0
2-Acetyl-4,5-xylenol 0 0.15334702 0.0792917 0
3,5-dimethylphenol 0 0.3339081 0.12409853 0
Phenol Fe-Salen-Ph-NO2 Fe-Salan-Cy-OMe Fe-Salan-Ph-OMe Fe-Salen-BINAM-tert-Bu
3,4,5-trimethylphenol 2.2163359 1.32201236 1.38142789 2.22461917
3,5-dimethoxy-4-methyl 2.0305844 0 0 2.36528743
2-tBu-4,5-xylenol 2.0023054 0.34117201 0.38061394 2.0833696
2-Phenyl-4,5-xylenol 6.0558912 3.66303393 1.72447168 6.21755069
2,6-dimethoxyphenol 0 3.06878424 1.97826207 2.67468494
2-Me-xylenol 0.0344418 2.30497973 1.01933623 0.05768245
2-iPr xylenol 2.1871894 0.93021183 0.93021221 2.55299376
2-Et-4,5-xylenol 1.9950361 0.96801514 0.52071649 2.13560806
2,4-dimethylphenol 1.6162506 0.69124234 0.96930942 1.51715622
2,4,6-trimethylphenol 1.9455656 0.94786817 0.45330784 2.1985983
2-Bromo-4,5-xylenol 2.5475612 2.54590295 2.17539659 2.10354898
2,3-dimethylphenol 2.4198969 1.25934978 0.66481545 2.93661908
2,3,5-trimethylphenol 1.392248 0.66496068 0.82502383 1.18377067
2,5-dimethylphenol 2.190006 1.03361234 1.20036283 2.16927587
3,4-dimethylphenol 2.290392 1.29969432 1.52997009 2.40484443
2-Acetyl-4,5-xylenol 4.6712414 4.41043314 3.40086191 3.22127227
3,5-dimethylphenol 0.1592344 2.25854357 2.21222936 2.6603506
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Table S1.11 PDT/IS for Vanadium Catalysts
 
Table S1.12 SM/IS for Vanadium Catalysts
 
  
Phenol V-Salan-BINAM-NO2 V-Salen-BINAM-OMe V-Salen-BINAM-tert-Bu V-Salen-Cy-OMe V-Salen-Ph-NO2
3,4,5-trimethylphenol 1.8259662 1.349826107 0.71948654 1.04191258 0.57465154
3,5-dimethoxy-4-methyl 0.96344062 1.254200156 2.22327958 1.04577109 1.8503517
2-tBu-4,5-xylenol 2.44908777 2.199796924 1.18018302 1.58171998 0.93721347
2-Phenyl-4,5-xylenol 2.75499697 3.464705691 1.12131838 3.63980776 1.46722331
2,6-dimethoxyphenol 0 0 0 0 0
2-Me-xylenol 1.17902251 0.782684424 0.96694976 0.77577591 0.6660255
2-iPr xylenol 3.32373574 2.199416267 1.89767845 1.96165668 3.29048155
2-Et-4,5-xylenol 1.79801007 1.622794769 1.03486808 1.63872789 0.88725665
2,4-dimethylphenol 0.29689348 0.27169758 0 0 0.22673761
2,4,6-trimethylphenol - - - - -
2-Bromo-4,5-xylenol 0 0.081452123 0 0.0506261
2,3-dimethylphenol 0 0 0 0 0
2,3,5-trimethylphenol 0.41783265 0.167647125 0.06270492 0.10786471 0.08206416
2,5-dimethylphenol 0.10136507 0 0 0.05442988 0
3,4-dimethylphenol 0 0 0 0 0
2-Acetyl-4,5-xylenol 0 0 0 0 0
3,5-dimethylphenol 0.25855714 0.202308889 0 0.11247336 0.09577758
Phenol V-Salan-BINAM-NO2 V-Salen-BINAM-OMe V-Salen-BINAM-tert-Bu V-Salen-Cy-OMe V-Salen-Ph-NO2
3,4,5-trimethylphenol 0.8180969 0.274346663 1.64870188 1.56225368 1.66634304
3,5-dimethoxy-4-methyl 0 0 0.51778365 0 0.34351328
2-tBu-4,5-xylenol 0.63528925 0 0.91946413 0.17094694 1.01627142
2-Phenyl-4,5-xylenol 3.43578997 2.197617157 5.20014602 2.28286431 5.13881171
2,6-dimethoxyphenol 1.94312972 2.177725604 2.61227727 2.39993516 2.84386397
2-Me-xylenol 0.91670642 0.077750906 2.17250058 2.27403514 1.41592282
2-iPr xylenol 0.695281 0.661430935 0.94885255 1.35240819 1.84264963
2-Et-4,5-xylenol 0.16384941 0.086224089 0.89244046 0.93218559 2.07723955
2,4-dimethylphenol 0.50339547 0.276798701 1.23538961 0.98413161 1.20416826
2,4,6-trimethylphenol 0.20688134 0.819569425 1.70411818 1.17538432 1.6052415
2-Bromo-4,5-xylenol 1.35799635 2.006727884 1.91421354 1.13189968 1.38030133
2,3-dimethylphenol 0.66907564 0.41294651 1.7658804 1.31977531 1.81904919
2,3,5-trimethylphenol 0.41264849 0.357314661 0.79393257 0.41635215 1.47598458
2,5-dimethylphenol 0.61850502 0.082210347 1.8372384 0.93858425 1.9650234
3,4-dimethylphenol 0.82401295 0.725593024 1.44760478 1.22840743 1.42023524
2-Acetyl-4,5-xylenol 4.76386168 4.496506381 5.39008729 3.70418542 4.08392332
3,5-dimethylphenol 2.09032205 1.744444006 2.21135561 2.0651276 2.18663059
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CHAPTER 2.  Honokiol-Inspired Analogs as Inhibitors of Oral 
Bacteria 
Adapted with permission from Solinski, A. E.; Ochoa, C.; Lee, Y. E.; Paniak, T.; 
Kozlowski, M. C.; Wuest, W. M. Honokiol-Inspired Analogs as Inhibitors of Oral Bacteria. 
ACS Infect. Dis. 2018, 4 (2), 118–122. Copyright 2019 American Chemical Society. 
2.1. Background 
The human oral microbiome is a complex ecosystem filled with many species of 
bacteria that can interact with the host in both commensal and pathogenic manners.18 
Streptococcus mutans is an abundantly available Gram-positive bacteria residing in the oral 
cavity that has been strongly linked with dental decay and dental caries.19,20 Due to the 
prevalence of these infections and the high cost of treatment, scientists have recently begun 
placing a higher emphasis on understanding these pathogenic systems at the molecular 
level. The commensal bacteria Streptococcus sanguinis and Streptococcus gordonii are 
early colonizers that initiate the formation of biofilm by binding glycoproteins, acidic 
proline-rich proteins, and adhesion proteins to the surface of the tooth and producing 
glucan polymers, which leads to the formation of dental plaque. 21 , 22  S. mutans and 
 
18 Forssten, S. D.; Björklund, M.; Ouwehand, A. C. Streptococcus Mutans, Caries and 
Simulation Models. Nutrients 2010, 2 (3), 290−298.  
19 Lamont, R. J.; Egland, P. G. Dental Caries. Molecular Medical Microbiology, 2nd ed.; 
2015, 945−955.   
20 Simoń-Soro, A.; Mira, A. Solving the Etiology of Dental Caries. Trends Microbiol. 
2015, 23 (2), 76−82. 
21 Davey, M. E.; O’toole, G. A. Microbial Biofilms: From Ecology to Molecular 
Genetics. Microbiol. Mol. Biol. Rev. 2000, 64 (4), 847−867.  
22Ahn, S. J.; Ahn, S. J.; Wen, Z. T.; Brady, J.; Burne, R. A. Characteristics of Biofilm 
Formation by Streptococcus Mutans in the Presence of Saliva. Infect. Immun. 2008, 76 
(9), 4259−4268. 
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Streptococcus sobrinus are able to bind to the early colonizers, produce microcolonies, and 
develop extracellular polymeric substance matrices responsible for tooth decay.23 If these 
biofilms are not treated, they will produce lactic acid that erodes dental enamels and leads 
to dental caries after 6-24 months.24,25 As a result, many researchers have started developing 
therapeutics that are able to target S. mutans. 
The naturally occurring bisphenol, honokiol (Figure 2.1), is a pharmaceutically 
active compound that has been used in traditional Chinese, Japanese, and Korean herbal 
medicine for centuries.26,27 Recent studies have found that honokiol has been linked with 
anti-cancer, anti-fungal, anti-viral, and anti-bacterial effects.28,29,30  
  
 
23 Lemos, J. A.; Quivey, R. G.; Koo, H.; Abranches, J. Streptococcus mutans: a new 
Gram-positive paradigm? Microbiology 2013, 159, 436−445.  
24 Rosan, B.; Lamont, R. J. Dental plaque formation. Microbes Infect. 2000, 2, 
1599−1607.  
25 Koo, H.; Xiao, J.; Klein, M. I.; Jeon, J. G. Exopolysaccharides Produced by 
Streptococcus Mutans Glucosyl- transferases Modulate the Establishment of 
Microcolonies within Multispecies Biofilms. J. Bacteriol. 2010, 192 (12), 3024−3032.  
26 Fujita, M.; Itokawa, H.; Sashida, Y. Honokiol, a New Phenolic Compound isolated 
from the Bark of Magnolia obovata. Chem. Pharm. Bull. 1972, 20, 212−213.  
27 Namba, T.; Tsunezuk, M.; Hatori, M. Dental Caries Prevention by Traditional Chinese 
Medicines. Planta Med. 1982, 44, 100−106.  
28 Pan, J.; Lee, Y.; Zhang, Q.; Xiong, D.; Wan, T. C.; Wang, Y.; You, M. Honokiol 
Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway. 
Cancer Prev. Res. 2017, 10, 133− 141.  
29 Wang, Z.; Shen, Y. Antifungal compound honokiol triggers oxidative stress responsive 
signaling pathway and modulates central carbon metabolism. Mycology 2016, 7, 
124−133.  
30 Chen, P.-J.; Wang, Y.-L.; Kuo, L.-M.; Lin, C.-F.; Chen, C.-Y.; Tsai, Y.-F.; Shen, J.-J.; 
Hwang, T.-L. Honokiol suppresses TNF-α-induced neutrophil adhesion on cerebral 
endothelial cells by disrupting polyubiquitination and degradation of IκBα. Sci. Rep. 
2016, 6, 26554.  
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Honokiol was reported to have potent activity against S. mutans, with a minimum 
inhibitory concentration (MIC) of 10 µg/mL (37.5 µM).31 We aimed to create a library of 
derivatives inspired by honokiol in order to improve and better understand its bioactivity. 
 
Figure 2.1 A) The early colonizer bacteria S. sanguinis and S. gordonnii initiate the 
formation of biofilms on the surface of tooth, whereupon cariogenic species S. mutans can 
bind and acidify the environment, corroding the enamel. B) Structures of the natural 
products honokiol and magnolol. Adapted with permission from Solinski, A. E.; Ochoa, 
C.; Lee, Y. E.; Paniak, T.; Kozlowski, M. C.; Wuest, W. M. Honokiol-Inspired Analogs as 
Inhibitors of Oral Bacteria. ACS Infect. Dis. 2018, 4 (2), 118–122. 
2.2. Previous Methods for Total Synthesis of Honokiol  
Honokiol is isolated from the bark and root of the Magnolia officinalis plant; 
however, separation of its naturally occurring, less bioactive, constitutional isomer, 
magnolol, has proven difficult and costly.32 As a result, scientists have discovered various 
synthetic methods for the total synthesis of honokiol.  
 
31 Sakaue, Y.; Domon, H.; Oda, M.; Takenaka, S.; Kubo, M.; Fukuyama, Y.; Okiji, T.; 
Terao, Y. Anti-biofilm and bactericidal effects of magnolia bark-derived magnolol and 
honokiol on Streptococcus mutans. Microbiol. Immunol. 2016, 60, 10−16.  
32Slalina, J.; Glatz, Z. Separation procedures applicable to lignan analysis. J. Chromatogr. 







In the decades since the first total synthesis of honokiol reported in 1986 by 
Tobinaga that used the direct coupling of quinole acetates formed by addition of 
stoichiometric Pb(OAc)4, there have been several less expensive and more environmentally 
friendly routes.33 One such route proceeds via a Suzuki-Miyaura coupling for the formation 
of the biaryl bond. Tripathi and colleagues used this method for the cross coupling of a 
dihydroxylated aryl bromide with an aryl boronic ester for the formation of a biaryl 
intermediate in their seven-step synthesis (Scheme 2.1). The allyl groups were produced 
via iodide-induced demesylation-iodination-deiodination in the presence on Zn followed 
by Et2AlCl-catalyzed Claisen rearrangement in order to produce honokiol with an overall 
45% yield.34  
Scheme 2.1 Honokiol Synthesis by Tripathi et al.
 
 
33 Takeya, T.; Okubo, T.; Tobinaga, S. Synthesis of unsymmetrical biphenyl lignans, 
honokiol and related coumpounds, utilizing quinol-acetates as reactive intermediates. 
Chem. Pharm. Bull., 1986, 34, 2066-2075.  
34 Tripathi, S.; Chan, M.-H.; Chen, C. An Expedient Synthesis of Honokiol and Its 





































In 2014, the Kumar group disclosed a four-step synthesis of honokiol with an 
overall yield of 68% (Scheme 2.2). Their synthesis began with formation of an anisole 
organomagnesium intermediate that formed a biaryl core when coupled with 4-iodoanisole 
using a Pd(PPh3)4 catalyst. After bromination, the bis-Gringard reagent was formed for 
Kumada coupling with allyl bromide catalyzed by Pd(PPh3)4. Demethylation of methoxy 
substituents produced honokiol.35   
Scheme 2.2 Honokiol Synthesis by Kumar et al.
 
However, these examples, and several more including the syntheses by Takeya, 
Esumi, Chen, Denton, Harada, and Wright use of materials such as palladium based 
catalysts and boronic acids that are not desirable on an industrial scale due to toxicity of 
 
35 Srinivas, J.; Singh, P., P.; Varmam, Y. K.; Hyder, I.; Kumar, H., M., S. Concise total 
synthesis of honokiol via Kumada cross coupling. Tetrahedron Lett. 2014, 55, 4295-
4297.  
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byproducts, high costs, and inefficient mass economy.36,37,38,39,40,41 In 2014, the Reddy group 
devised an alternative six-step synthesis that did not require the use of rare metal catalysts 
(Scheme 2.3). The drawback to this route is that the final step is a low yielding Claisen 
rearrangement that produces honokiol and isohonokiol in a 2:3 mixture.42 Although no 
precious metal catalyst are needed, syntheses that produce multiple isomers in an 
unfavorable ratio are not amendable for large scale application. 
 
36 Takeya, T.; Okubo, T.; Tobinaga, S. Synthesis of Unsymmetrical Biphenyl Lignans, 
Honokiol and Related Compounds, Utilizing Quinol-acetates as Reactive Intermediates. 
S. Chem. Pharm. Bull. 1986, 34, 2066–2075.  
37 Esumi, T.; Makado, G.; Zhai, H.; Shimizu, Y.; Mitsumoto, Y.; Fukuyama, Y. Efficient 
synthesis and structure–activity relationship of honokiol, a neurotrophic biphenyl-type 
neolignane. Bioorg. Med. Chem. Lett. 2004, 14, 2621–2625.  
38 Chen, C.-M.; Liu, Y.-C. A concise synthesis of honokiol. Tetrahedron Lett. 2009, 50, 
1151–1152.  
39 Denton, R. M.; Scragg, J. T.; Galofré, A. M.; Gui, X.; Lewis, W. A concise synthesis of 
honokiol. Tetrahedron 2010, 66, 8029–8035.  
40 Harada, K.; Arioka, C.; Miyakita, A.; Kubo, M.; Fukuyama, Y. Efficient synthesis of 
neurotrophic honokiol using Suzuki–Miyaura reactions. Tetrahedron Lett. 2014, 55, 6001–
6003.  
41 Wright, A. M.; O’Neil, G. W. Total synthesis of honokiol by selective samarium-
mediated allylic benzoate reduction. Tetrahedron Lett. 2016, 57(31), 3441-3443. 
42 Reddy, B. V. S.; Rao, R. N.; Reddy, N. S. S.; Yadav, J. S.; Subramanyam, R. A Short 
and Efficient Synthesis of Honokiol via Claisen Rearrangement. Tetrahedron Lett. 2014, 
55, 1049-1051.  
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Scheme 2.3 Honokiol Synthesis by Reddy et al.
 
2.3. Synthesis of Honokiol using Oxidative Coupling of Phenols 
 The Kozlowski group has focused on the oxidative coupling of phenols, which 
allows to oxidative insertion into C-H bonds to form new C-C bonds without 
prefunctionalization of the starting substrates.43 Dioxygen is used as an inexpensive and 
environmentally friendly oxidant, which produces water as the only byproduct, and less 
costly salen metal catalysts, compared to the palladium used in cross-couplings of 
Grignards and boronic acids (Figure 2.2).44  
 
43 Lee, Y.-E.; Cao, T.; Torruellas, C.; Kozlowski, M. C. Selective Oxidative Homo- and 
Cross-Coupling of Phenols with Aerobic Catalysts. J. Am. Chem. Soc. 2014, 136, 6782-
6785. 
44 White, M. C. C-H Bond Functionalization and Synthesis in the 21st Century: A Brief 
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Figure 2.2 A) Example of conditions for an oxidative cross coupling of phenols. B) 
Common set of reagents used for a Suzuki coupling. 
 
 In collaboration with Colgate-Palmolive, Dr. Young Eun Lee developed a selective 
phenol cross coupling strategy that has been used to accomplish synthesis of honokiol 
amendable to production scale (Scheme 2.4). First, 2-tert-butyl-6-methylphenol and 2-tert-
butyl-4-methylphenol, two commercially available phenols, were oxidatively cross 
coupled using 2.5 mol% Cr-salen-Cy catalyst and oxygen as the oxidant. A retro Friedel-
Crafts reaction was performed within the same reaction vessel without any filtration or 
work up to remove the tert-butyl groups giving an 85% yield. The phenols were then 
methylated using dimethylsulfate in quantitative yield and benzylic bromination was 
accomplished using N-bromosuccinimide and azobisisobutyronitrile in a 57% yield. The 
allyl groups were instilled via a Kumada coupling using vinyl Grignard and CuI in 75% 
yield. Finally, deprotection of the phenols occurred with BBr3•DMS in 90% to afford 
honokiol at 34% overall yield on a gram scale.45 
 
45 Jaracz, S.; Kozlowski, M.; Eun Lee, Y.; Kim, S. M. Improved Synthesis of Honokiol. 



























Scheme 2.4 Honokiol Synthesis, by Dr. Young Eun Lee, using Oxidative Cross-Coupling
 
2.4. Synthesis of Cross-Coupled Analogs  
 After the successful total synthesis of honokiol by Dr. Young Eun Lee using the 
novel oxidative cross coupling developed by the Kozlowski group, the scope of the method 
to unite aryl structures become a focus. Further, generation of different bisphenolic 
derivatives would provide a means to probe the structure-activity relationship of honokiol. 
The resulting analog library was organized into several groups based on similarities in 
structure (Figure 2.3). Group A is a bisphenol scaffold most closely related to the structure 
of honokiol with substituents of varying sterics in different positions. Group B consists of 
several phenol-naphthol coupled moieties as the oxidation potential of naphthols is much 
lower than that of phenols, allowing for oxidative coupling with a larger tolerance for 
electron withdrawing substituents, such as bromides and esters.46 The derivatives in group 
C were synthesized to probe the optimal linkage between the two phenols. 
 
46 Kozlowski, M. C.; Morgan, B. J.; Linton, E. C. Total Synthesis of Chiral Biaryl Natural 
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Figure 2.3 Synthesized Honokiol-Inspired Analog Groups 
 
 The oxidative cross-coupling of phenols and naphthols was done with 5–10 mol% 
of the easily synthesizable Cr-salen-cy catalyst (also commercially available) using O2 as 
the oxidant in 1,2-dichloroethane between 50–80 °C (Figure 2.4). Figure 2.5 illustrates all 
of the derivatives in Group A and B synthesized using this technique in collaboration with 
Dr. Young Eun Lee and Thomas Paniak. 
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Figure 2.5 Honokiol-Inspired Cross Coupled Analogs 
 
 Compound C1 was generated by aldol condensation of acetone with meta-
anisaldehyde, followed by reduction using H2 and catalytic Pd/C and a Wolff-Kishner 
reduction. Compound C2 was formed by McMurry coupling of meta-anisaldehyde, 
reduction of the alkene with H2 and catalytic Pd/C, deprotection of the phenols with BBr3, 
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Scheme 2.5 Synthesis of Analogs C1 and C2 
 
2.5. Discrepancies in Bioactivity of Honokiol 
 Our initial interest in this project started was based on the report that honokiol had 
strong inhibitory activity against S. mutans. However, prior literature described the MIC 
of honokiol as 10 µg/mL (37.5 µM) under aerobic conditions. Notably, S. mutans growth 
is inhibited under such conditions. 47  Our collaborator, Amy Solinski from the Wuest 
laboratory at Emory University, performed MIC assays in a microaerophilic environment, 
a 5% CO2-supplemented atmosphere that resembles the human oral cavity, and found that 
honokiol only inhibits the growth of S. mutans at 250 µM (66.6 µg/mL). Upon employing 
aerobic conditions in the assay, the MIC of honokiol improved to 125 µM (33.3 µg/mL). 
It is clear that honokiol does have the ability to inhibit S. mutans, albeit weakly, but its 
already low efficacy further decreases under physiologically relevant conditions. Further 
testing found that honokiol was not bactericidal or able to inhibit the growth of biofilms at 
its MIC or lower concentrations.48 
 
47 Ahn, S.-J.; Ahn, S.-J.; Browngardt, C. M.; Burne, R. A. Changes in Biochemical and 
Phenotypic Properties of Streptococcus mutans during Growth with Aeration. Appl. 
Environ. Microbiol. 2009, 75 (8), 2517–2527. 
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2.6. Bioactivity of Synthesized Bisphenols Against Oral Bacteria 
After establishing that the natural product honokiol is a poor inhibitor of S. mutans, 
the MIC, minimum biofilm inhibitory concentration (MBIC), and minimum bacteriocidal 
concentration (MBC) of the synthesized compounds were evaluated against S. mutans and 
the early colonizers, S. sanguinis and S. gordonnii by Amy Solinski.  
  
 
Honokiol-Inspired Analogs as Inhibitors of Oral Bacteria. ACS Infect, Dis. 2018, 4 (2), 
118-122. 
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Table 2.1. Summary of MIC (S. mutans, S. sanguinis, and S. gordonii) and MBC (S. 
mutans) Values for Synthesized Analogs 
 
 
Of the 26 synthesized bisphenolic derivatives of honokiol, 12 compounds were 
identified that inhibited better than or equivalent to honokiol (£250 µM), and four 
compounds were fournd that exhibited strong inhibition of S. mutans at or below 16 µM. 
Compound C2 was the most promising analog with an MIC of 2 µM, seven dilutions more 
potent than honokiol. The subsequent MBC assay revealed that C2 leads to 99.9% bacterial 
cell death at 4 µM, demonstrating that this compound is most likely acting via a bactericidal 
 47 
mechanism.49 The next most bioactive analog, B5, had an MIC of 8 µM, but an MBC of 
125 µM. This difference of four dilutions between inhibition and cell death implies that 
there is a bacteriostatic mechanism that leads to inhibition through a different mechanism 
than C2. Analogs B8 and B11 both inhibited S. mutans at 16 µM and had similar MBC 
values within one or two dilutions, acting in a bactericidal mechanism akin to C2. The 
ability of derivatives to inhibit the growth of S. mutans biofilm was assessed by Amy 
Solinski using crystal violet analysis and identified that the MBIC values were within one 
dilution of the MIC. This observation is due to the analogs overall inhibiting the growth of 
S. mutans and not due to the compounds specifically targeting the biofilm. 
2.7. Summary 
In these studies, the anti-bacterial properties of honokiol were found not to be as 
strong as previously reported when S. mutans is grown under conditions that closely 
resemble the human oral cavity. However, using the novel oxidative coupling developed 
in the Kozlowski laboratory, 12 honokiol-inspired analogs were synthesized that possessed 
equal or better inhibitory ability relative to honokiol. Compounds C2 and B8 were of note, 
the former due to its extremely strong bioactivity with an MIC of 2 µM (0.67 µg/mL) that 
is proceeding through a bactericidal mechanism, and the latter due to its similarly strong 
bioactivity with an MIC of 8 µM (2.96 µg/mL) via a bacteriostatic mechanism.  
  
 
49 Macia, M. D.; Rojo-Molinero, E.; Oliver, A. Antimicrobial susceptibility testing in 




All non-aqueous reactions were carried out under an atmosphere of dry argon 
unless otherwise noted. Commercial reagents were used as received without additional 
purification unless otherwise noted. Anhydrous THF, toluene, dichloromethane, and 1,2-
dichloroethane were obtained from a Pure Process Technology solvent purification system. 
Reactions were monitored by thin layer chromatography (TLC) using Silicycle glass-
backed TLC plates with 250 µM silica and F254 indicator. Visualization was accomplished 
by UV light or iodine staining. All compounds with inhibitory ability greater than 250 µM 
were analyzed for purity by UPLC and characterized by 1H NMR and decoupled 13C NMR 
Nominal mass accuracy LCMS data were obtained by use of a Waters Acquity UPLC 
system equipped with a Waters TUV detector (254 nm) and a Waters SQD single 
quadrupole mass analyzer with electrospray ionization.  
1H NMR spectra were recorded on a 500 MHz spectrometer. Chemical shifts are 
reported in ppm from the solvent resonance (CDCl3 7.26 ppm, acetone-d6 2.05 ppm). Data 
are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, br = broad, m = multiplet), coupling constants, and number of protons. 
Decoupled 13C NMR spectra were recorded at 125 MHz. IR spectra were taken on an FT-
IR spectrometer. Accurate mass measurement analyses were conducted via time-of-flight 
mass analyzer GCMS with electron ionization (EI) or via time-of-flight mass analyzer 
LCMS with electrospray ionization (ESI). The signals were measured against an internal 
reference of perfluorotributylamine for EI-GCMS and leucine enkephalin for ESI-LCMS. 
The instrument was calibrated, and measurements were made using neutral atomic masses; 
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the mass of the electron removed or added to create the charged species is not taken into 
account.  
General Procedure A for Oxidative Coupling of Phenols 
 
 To a 10 mL microwave vial was added phenol A (0.1 mmol), phenol B (0.15 mmol), 
and Cr-Salen-Cy catalyst (0.01 mmol). The vial was sealed with a septum and ClCH2CH2Cl 
(2.5 mL) was added. Oxygen was added via active purge. The septum was replaced with a 
crimping cap and the vessel was sealed and reaction mixture stirred for the indicated time 
at 80 °C. After the reaction mixture was filtered through a plug of silica and concentrated, 




(B10). Following general procedure A at 55 °C for 2 d, the cross-coupled product was 
obtained as a yellow solid (0.022 g, 0.056 mmol) in a 56% yield: 1H NMR (500 MHz, 
CDCl3) d 10.24 (s, 1H), 8.20 (s, 1H), 7.63 (d, J = 9 Hz, 1H), 7.32 (d, J = 9 Hz, 1H), 7.31 
(s, 1H), 7.12 (s, 1H), 5.32 (s, 1H), 5.01 (s, 1H), 3.89 (s, 3H), 3.27 (septet, J =  6.9 Hz, 2H), 
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150.2, 148.6, 135.2, 133.7, 129.2, 127.3, 127.0, 126.2, 125.1, 122.2, 121.2, 114.3, 112.1, 
52.3, 27.3, 22.9, 22.7; IR (neat) 3521, 2961, 1682, 1523, 1472, 1442, 1415, 1386, 1346, 
1323, 1294, 1243, 1198, 1171, 1150, 1122 cm-1; HRMS (EI-TOF) m/z = 394.1906 calc for 
C24H26O5 [M]+, found 394.1905. 
 
1-(3-(tert-Butyl)-4-hydroxy-5-methylphenyl)naphthalen-2-ol (B1). Following 
general procedure A at 55 °C for 2 d, the cross-coupled product was obtained as a white 
solid (4.4 mg, 0.0144 mmol) in a 13% yield: 1H NMR (500 MHz, CDCl3) d 7.79 (m, 2H), 
7.46 (d, J = 7.0 Hz, 1H), 7.33 (m, 2H), 7.26 (d, J = 8.5 Hz, 1H), 7.17 (d, J = 0.75 Hz, 1H), 
7.06 (d, J = 0.75 Hz, 1H), 5.27 (s, 1H), 4.96 (s, 1H), 2.34 (s, 3H), 1.45 (s, 9H); 13C NMR 
(125 MHz, CDCl3) d 152.9, 150.4, 137.1, 133.7, 131.0, 129.1, 128.9, 128.0, 127.9, 126.3, 
125.0, 124.8, 124.3, 123.1, 121.4, 117.1, 34.8, 29.8, 16.1; IR (neat) 3523, 2956, 2924, 1620, 
1597, 1481, 1465, 1435, 1389, 1362, 1345, 1313, 1263, 1223, 1190, and 1174 cm-1; HRMS 
(EI-TOF) m/z = 306.1620 calc for C21H22O2 [M]+, found 306.1632. 
 
1-(4-Hydroxy-3,5-diisopropylphenyl)-6-(1H-pyrazol-1-yl)naphthalen-2-ol 
(B13). Modifying general procedure A, 2 equiv of phenol A (0.0113 g, 0.0634 mmol) and 










coupled product was obtained as a brown solid (6.9 mg, 0.0179 mmol) in a 28% yield: 1H 
NMR (500 MHz, CDCl3) d 8.08 (s, 1H), 8.00 (s, 1H), 7.82 (d, J = 9.0 Hz, 1H), 7.75 (d, J = 
0.8 Hz, 1H), 7.73 (dd, J = 9.0, 1.2 Hz, 1H), 7.55 (d, J = 9.0 Hz, 1H), 7.31 (d, J = 9.0 Hz, 
1H), 7.11 (s, 2H), 6.49 (t, J = 2.0 Hz, 1H), 5.34 (s, 1H), 5.05 (s, 1H), 3.26 (septet, J = 7.0 , 
2H), 1.31 (d, J = 5.5 Hz, 6H), 1.30 (d, J = 6.0 Hz, 6H); 13C NMR (125 MHz, CDCl3) d 
150.6, 150.5, 141.2, 135.9, 135.3, 132.3, 129.1, 129.1, 127.1, 126.6, 126.3, 125.3, 122.0, 
119.2, 118.5, 117.0, 107.7, 27.5, 23.0, 22.9; IR (neat) 3244, 2962, 2928, 2871, 1603, 1519, 
1471, 1397, 1352, 1263, 1198, 1168, 1144, 1043, 954, 918 cm-1; HRMS (ESI-TOF) m/z = 
387.2073 calc for C25H26N2O2 [M]+, found 387.2086. 
 
3',5'-Diallyl-2-isopropyl-5-methyl-[1,1'-biphenyl]-4,4'-diol (A10). Following general 
procedure A at 55 °C for 2 d, the cross-coupled product was obtained as a yellow oil (1.1 
mg, 0.0034 mmol) in a 4% yield: 1H NMR (500 MHz, CDCl3) d 6.93 (s, 1H), 6.90 (s, 2H), 
6.76 (s, 1H), 6.04 (m, 2H), 5.12-5.2 (m 5H), 4.57 (s, 1H), 3.43 (d, J = 7.5 Hz, 4H), 3.00 
(septet, J = 7.0 Hz, 1H), 2.22 (s, 3H), 1.12 (d, J = 7.0 Hz, 6H); IR (neat) 3376, 2960, 1780, 












 1-(3-Allyl-5-(tert-butyl)-4-hydroxyphenyl)-6-bromonaphthalen-2-ol (B8). 
Following general procedure A for 2 d, the cross-coupled product was obtained as a red-
orange solid (0.0681 g, 0.1656 mmol) in an 85% yield: 1H NMR (500 MHz, CDCl3) d 7.95 
(d, J = 2.0 Hz, 1H), 7.68 (d, J = 9.0 Hz, 1H), 7.40 (dd, J = 7.0 Hz, 2.0 Hz, 1H), 7.32 (d, J 
= 9.0 Hz, 1H), 7.27 (d, J = 9.0 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 
6.07 (m, 1H), 5.47 (s, 1H), 5.31 (m, 3H), 3.49 (d, J = 6.0 Hz, 2H), 1.43 (s, 9H); 13C NMR 
(125 MHz, CDCl3) d 154.1, 150.8, 138.5, 136.0, 132.4, 130.7, 130.2, 130.0, 129.7, 128.5, 
128.3, 126.9, 126.5, 124.7, 121.7, 118.4, 118.0, 117.1, 36.4, 35.1, 29.9; IR (neat) 3517, 
2956, 1725, 1587, 1500, 1475, 1414, 1376, 1362, 1339, 1263, 1226, 1196, 1170, 1144, 
1068, 1043, 957, 892, 878, 820, 737, 465, 455 cm-1; HRMS (ESI-TOF) m/z = 411.0960 
calc for C23H24BrO2 [M+H]+, found 411.0939. 
 
6-Bromo-1-(3-(tert-butyl)-4-hydroxy-5-propylphenyl)naphthalen-2-ol (B12). 
To a solution of 1-(3-allyl-5-(tert-butyl)-4-hydroxyphenyl)-6-bromonaphthalen-2-ol 
(0.010 g, 0.024 mmol) in ethanol (1 mL, 0.02 M) at room temperature was added hydrazine 
monohydrate (0.010 g, 0.194 mmol). The reaction mixture was heated to reflux and stirred 
for 22 h. After concentration, the resulting solid was treated with H2O and extracted using 
ethyl acetate (5 x 10 mL). The combined organic fractions were dried over Na2SO4, 
concentrated, and chromatographed (hexane/EtOAc, 10:1)2. The reduced product was 
obtained as a tan solid (9.3 mg, 0.0225 mmol) in a 93% yield: 1H NMR (500 MHz, CDCl3) 






= 9.0 Hz, 1H) 7.27 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 2.0 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 
5.32 (broad, 1H), 5.08 (broad, 1H), 2.62 (dd, J = 6.5, 1.5 Hz, 2H), 1.71 (m, 2H), 1.45 (s, 
9H), 1.03 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) d 152.6, 150.6, 137.3, 132.2, 
130.0, 129.9, 129.8, 129.4, 128.9, 128.0, 127.5, 126.7, 124.2, 121.7, 118.2, 116.8, 34.7, 
32.0, 29.6, 22.6, 14.0; IR (neat) 3520, 2957, 2925, 1588, 1446, 1377, 1362, 1339, 1316, 
1262, 1223, 1186, 1168, 1144, 1122, 1068, 1016 cm-1; HRMS (EI-TOF) m/z = 412.1038 
calc for C23H25BrO2 [M]+, found 412.1059. 
 
1-(3-(tert-Butyl)-4-hydroxy-5-propylphenyl)-6-methoxynaphthalen-2-ol 
(B11). To a stirring solution of allylated phenol (0.012 g, 0.033 mmol) in dry methanol 
(0.8 mL) was added Pd/C (0.010 mg). The reaction flask was evacuated and backfilled with 
H2 (3 times). The reaction mixture was stirred under H2 atmosphere for 36 hours and then 
filtered through Celite and concentrated. Chromatography (hexane/EtOAc, 10:1) provided 
the reduced product that was obtained as a tan solid (0.0021 g, 0.0058 mmol) in an 18% 
yield (~15% impure): 1H NMR (500 MHz, CDCl3) d 7.67 (d, J = 8.5 Hz, 1H), 7.37 (d, J = 
9.0 Hz, 1H), 7.23 (d, J = 9.0 Hz, 1H), 7.16 (d, J = 2.0 Hz, 1H), 7.13 (d, J = 2.0 Hz, 1H) 
7.03 (m, 2H), 5.14 (broad, 1H), 5.04 (s, 1H), 3.91 (s, 3H), 2.62 (dd, J = 7.0, 1.5 Hz, 2H), 
1.72 (m, 2H), 1.45 (s, 9H), 1.03 (t, J = 7.5 Hz, 3H); IR (neat) 3522, 2959, 1601, 1516, 1465, 







CHAPTER 3.  A Bisphenolic Honokiol Analog Outcompetes 
Oral Antimicrobial Agent Cetylpyridinium Chloride via a 
Membrane-Associated Mechanism 
Adapted with permission from Ochoa, C.; Solinski, A. E.; Nolan, M.; Dekarske, M. M.; 
Wuest, W. M.; Kozlowski, M. C., A bisphenolic honokiol analog outcompetes oral 
antimicrobial agent cetylpyridinium chloride via a membrane-associated mechanism. 
ACS Infect. Dis. 2020, 6 (1), 74-79. Copyright 2019 American Chemical Society. 
 
3.1. Background 
 The microbiota in the human oral cavity consists of many bacterial species acting 
as a defense against external pathogens.50 The majority of these microorganisms exist in 
symbiosis with the host, but environmental changes can cause the equilibrium to shift and 
oral infections can form.51 Streptococcus mutans naturally resides in the human oral cavity 
and is a common etiologic agent of dental caries, which is one of the most costly diseases 
in the world and is implicated in other illnesses, such as diabetes and endocarditis.52,53 As 
a result, research has focused on understanding this disease state by studying model 
organisms for oral pathogenesis.54 Commensal streptococcus species, such as S. gordonii 
and S. sanguinis, initiate biofilm formation by binding to a thin film of glycoproteins, 
 
50 Forssten, S. D.; Björklund, M.; Ouwehand, A. C. Streptococcus Mutans, Caries and 
Simulation Models. Nutrients. 2010, 2 (3), 290-298. 
51 Sakamoto, M.; Umeda, M.; Benno, Y. Molecular Analysis of Human Oral Microbiota. 
Journal of Periodontal Research. 2005, 40 (3), 277-285. 
52 Lamont, R. J.; Egland, P. G. Dental Caries. In Molecular Medical Microbiology: 
Second Edition; 2014, 945-955. 
53 Simón-Soro, A.; Mira, A. Solving the Etiology of Dental Caries. Trends in 
Microbiology. 2015, 23 (2), 76-82. 
54 Kilian, M.; Chapple, I. L. C.; Hannig, M.; Marsh, P. D.; Meuric, V.; Pedersen, A. M. 
L.; Tonetti, M. S.; Wade, W. G.; Zaura, E. The Oral Microbiome - An Update for Oral 
Healthcare Professionals. Br. Dent. J. 2016, 221 (10), 657-666. 
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mucins, acidic proline-rich proteins, and bacterial cell debris on the enamel surface of a 
tooth, leading to the formation of dental plaque.55,56 The acidogenic bacteria S. mutans and 
Streptococcus sobrinus then bind to the early colonizers via cell-to-cell interactions and 
form biofilms by producing extracellular polymeric substance matrices.57,58 If not removed, 
these biofilms can produce sufficient lactic acid to erode dental enamel, which will 
eventually lead to dental caries after 6-24 months.59,60 Many researchers have focused on 
the development of compounds that target S. mutans as potential therapeutics.61 ,62 For 
example, the naturally occurring product honokiol was isolated from Magnolia officinalis 
and reported to have potent activity, with a minimum inhibitory concentration (MIC) of 10 
 
55 Davey, M. E.; O’toole, G. A. Microbial Biofilms: From Ecology to Molecular 
Genetics. Microbiol. Mol. Biol. Rev. 2000, 64 (4), 847-867. 
56 Ahn, S. J.; Ahn, S. J.; Wen, Z. T.; Brady, J.; Burne, R. A. Characteristics of Biofilm 
Formation by Streptococcus Mutans in the Presence of Saliva. Infect. Immun. 2008, 76 
(9), 4259-4268. 
57 de Soet, J. J.; Holbrook, W. P.; van Amerongen, W. E.; Schipper, E.; Homburg, C. H.; 
de Graaff, J. Prevalence of Streptococcus Sobrinus in Relation to Dental Caries in 
Children from Iceland and The Netherlands. ASDC J. Dent. Child. 1990, 57 (5), 337-342. 
58 Tanzer, J. M.; Livingston, J.; Thompson, A. M. The Microbiology of Primary Dental 
Caries in Humans. J. Dent. Educ. 2001, 65 (10), 1028-1037. 
59 Balakrishnan, M.; Simmonds, R. S.; Tagg, J. R. Dental Caries Is a Preventable 
Infectious Disease. Australian Dental Journal. 2000, 45 (4), 235-45. 
60 Koo, H.; Xiao, J.; Klein, M. I.; Jeon, J. G. Exopolysaccharides Produced by 
Streptococcus Mutans Glucosyltransferases Modulate the Establishment of 
Microcolonies within Multispecies Biofilms. J. Bacteriol. 2010, 192 (12), 3024-3032. 
61 Solinski, A. E.; Koval, A. B.; Brzozowski, R. S.; Morrison, K. R.; Fraboni, A. J.; 
Carson, C. E.; Eshraghi, A. R.; Zhou, G.; Quivey, R. G.; Voelz, V. A.; et al. Diverted 
Total Synthesis of Carolacton-Inspired Analogs Yields Three Distinct Phenotypes in 
Streptococcus Mutans Biofilms. J. Am. Chem. Soc. 2017, 139 (21), 7188–7191. 
62 Yang, H.; Abouelhassan, Y.; Burch, G. M.; Kallifidas, D.; Huang, G.; Yousaf, H.; Jin, 
S.; Luesch, H.; Huigens, R. W. A Highly Potent Class of Halogenated Phenazine 
Antibacterial and Biofilm-Eradicating Agents Accessed Through a Modular Wohl-Aue 
Synthesis. Sci. Rep. 2017, 7 (1), 2003. 
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µg/mL against S. mutans63 However, this activity was measured in an aerobic environment, 
which is not representative of the oral cavity.64 We became interested in the honokiol 
scaffold after designing cross coupling methodology that enabled efficient synthesis of 
honokiol and analogs thereof. 
 
Figure 3.1 Structures of relevant compounds against S. mutans. Reprinted with permission 
from Ochoa, C.; Solinski, A. E.; Nolan, M.; Dekarske, M. M.; Wuest, W. M.; Kozlowski, 
M. C., A bisphenolic honokiol analog outcompetes oral antimicrobial agent 
cetylpyridinium chloride via a membrane-associated mechanism. ACS Infect. Dis. 2020, 6 
(1), 74-79. 
 
63 Wang, X.; Wang, Y.; Geng, Y.; Li, F.; Zheng, C. Isolation and Purification of Honokiol 
and Magnolol from Cortex Magnoliae Officinalis by High-Speed Counter-Current 
Chromatography. J. Chromatogr. A 2004, 1036 (2), 171-175. 
64 Sakaue, Y.; Domon, H.; Oda, M.; Takenaka, S.; Kubo, M.; Fukuyama, Y.; Okiji, T.; 
Terao, Y. Anti-Biofilm and Bactericidal Effects of Magnolia Bark-Derived Magnolol and 









MIC = 250 µM (66.6 µg/mL)
Cetylpyridinium chloride (CPC)
MIC = 2 µM (0.68 µg/mL) 
Lysis20 = 16 µM (5.4 µg/mL)
Compound C2
MIC = 2 µM (0.65 µg/mL)
Lysis20 = 63 µM (20.6 µg/mL)
Cl
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Our collaborator, Amy Solinski, determined that the MIC of honokiol was 250 µM 
(66.6 µg/mL) when grown in biologically relevant conditions (5% CO2-supplemented).65 
From the analog library described in Chapter 2, 5,5’-(ethane-1,2-diyl)bis(2-(tert-
butyl)phenol) (C2) was identified as highly potent against S. mutans planktonic cells with 
an MIC of 2 µM (0.65 µg/mL; Figure 3.1). This new scaffold greatly improved upon the 
natural product, but it was unclear what structural features were causing this potent activity 
and what biological mechanism led to the effect. For this reason, 66 new analogs of C2 
were designed to assess the structure-activity relationships (SAR) of the lead compound. 
Moreover, this study aimed to gauge the potency and toxicity profiles of these biaryl 
analogs relative to commercial antimicrobials such as cetylpyridinium chloride (CPC). 
CPC is a notable compound used in toothpastes, mouthwashes, throat sprays, and breath 
sprays. It has been found to reduce the amount of plaque due to its high affinity for Gram-
positive bacterial cell membranes, such as those of S. mutans.66,67,68 However, CPC has also 
been shown to have toxic effects at higher concentrations.69 Disclosed herein is the SAR 
 
65 Solinski, A. E.; Ochoa, C.; Lee, Y. E.; Paniak, T.; Kozlowski, M. C.; Wuest, W. M. 
Honokiol-Inspired Analogs as Inhibitors of Oral Bacteria. ACS Infect. Dis. 2018, 4 (2), 
118–122. 
66 Albert-Kiszely, A.; Pjetursson, B. E.; Salvi, G. E.; Witt, J.; Hamilton, A.; Persson, G. 
R.; Lang, N. P. Comparison of the Effects of Cetylpyridinium Chloride with an Essential 
Oil Mouth Rinse on Dental Plaque and Gingivitis - a Six-Month Randomized Controlled 
Clinical Trial. J. Clin. Periodontol. 2007, 34 (8), 658-667. 
67 Ayad, F.; Prado, R.; Mateo, L. R.; Stewart, B.; Szewczyk, G.; Arvanitidou, E.; 
Panagakos, F. S. A Comparative Investigation to Evaluate the Clinical Efficacy of an 
Alcohol-Free CPC-Containing Mouthwash as Compared to a Control Mouthwash in 
Controlling Dental Plaque and Gingivitis: A Six-Month Clinical Study on Adults in San 
Jose, Costa Rica. J. Clin. Dent. 2011, 22 (6), 204-212. 
68 Mankodi, S.; Bauroth, K.; Witt, J. J.; Bsoul, S.; He, T.; Gibb, R.; Dunavent, J.; 
Hamilton, A. A 6-Month Clinical Trial to Study the Effects of a Cetylpyridinium 
Chloride Mouthrinse on Gingivitis and Plaque. Am. J. Dent. 2005, 9A-14A. 
69 Lin, G. H. Y.; Voss, K. A.; Davidson, T. J. Acute Inhalation Toxicity of 
Cetylpyridinium Chloride. Food Chem. Toxicol. 1991, 29 (12), 851-854. 
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report of analog C2, the identification of a mechanism of action associated with the 
bacterial membrane, a similar inhibition profile of C2 against S. mutans relative to CPC, 
and better performance of C2 relative to CPC in a preliminary toxicity test.   
3.2. Lead Compound C2 Analog Synthesis 
Synthesis of analogs to probe the role of linker length, the phenol groups, ring 
substitution, and sterics were completed according to the methods shown in Schemes 3.1-
3.8. Analog 4P with a zero-carbon linker was generated from meta-biphenol 1 via Friedel-
Crafts ortho-alkylation (Scheme 3.1).  
Scheme 3.1 Synthesis of Zero-Carbon Linker Analog 
 
The one-carbon linker skeleton (Scheme 3.2) was generated by Grignard addition and 
hydrogenation to form 3H. Subsequent demethylation followed by Friedel-Crafts ortho-
alkylation provided 3N. Friedel-Crafts ortho-acylation deprotected the phenol while 
instilling the ortho-acetyl group concurrently to yield 3J. 
Scheme 3.2 Synthesis of One-Carbon Linker Analogs 
 
The two-carbon linker was explored with different positioning of the phenolic 

























CH3COCl1. 3-MethoxyphenylMgBr    THF, rt, 3h





generated by McMurry coupling of the corresponding aldehyde (5, 6, 8) to generate alkenes 
3O, 3R, 3A, 3T, and 3V, which were hydrogenated using Pd/C to afford the corresponding 
alkanes 3P, 3S, 3B, 3D, 3U, 3W. Further combinations of phenol deprotection, Friedel-
Crafts ortho-acylation, Friedel-Crafts ortho-formylation,70 Friedel-Crafts ortho-alkylation, 
and O-acylation provided the majority of the two-carbon linker derivatives (Schemes 3.3-
3.5). Compound 4C was formed through Grignard addition and reduction of 4N. Friedel-
Crafts ortho-acylation, Grignard addition, and hydrogenation of 3D produced the iso-
propyl analog 4D (Scheme 3.4).   
Scheme 3.3 Synthesis of ortho-Phenol Analogs
 
 
70 Hofsløkken, N. U.; Skattebøl, L. Convenient Method for the Ortho-Formylation of 
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Scheme 3.4 Synthesis of meta-Phenol Analogs of Decreasing Substituent Size
 
Scheme 3.5 Synthesis of para-Phenol Analogs 
 
 Analogs that contained varying numbers of tert-butyl substituents in different 
positions were prepared from the synthesized compound 3B by Marcus Nolan, an 1st year 
undergraduate student that worked with our laboratory in summer 2018 (Scheme 3.6). 
Through his efforts, we isolated the mono (3AF), tri (4I), and tetra (4J) tert-butyl 
substituted variants of C2. Further, he discovered that the Friedel-Crafts reaction yields 
both mono (4F) and di (4G) para-alkylated product when performed in an equal mixture 
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Scheme 3.6 Synthesis of Analogs with Varying Amounts of tert-Butyl Substituents
 
 The O-alkylated phenols were synthesized from C2 (Scheme 3.7). Analogs 3AF 
and 4K were formed in the same reaction with methyl bromide and excess base. Compound 
4O was synthesized through mono O-alkylation of C2 using n-octyl bromide. 
Scheme 3.7 Synthesis of Protected Phenol Analogs
 
The three-carbon linker compound was obtained by aldol reaction of 9 with 2 
followed by exhaustive reduction to obtain 3AD (Scheme 3.8). Phenol deprotection 
followed by Friedel-Crafts ortho-alkylation generated 4Q. 
Scheme 3.8 Synthesis of 3 Carbon Linker Analogs
 
Together, these methods permitted synthesis of 45 different compounds with 


































































2. NaBH4, CHCl3/MeOH (1:4)
14%
1. BBr3, CH2Cl2
2. t-BuOH, H2SO4, 
    CH2Cl2
12%
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Synthesized structures were supplemented with commercially available bibenzyl 
compounds (3AG-3AR) (Figure 3.2); notably, none of the commercial analogs exhibited 
potency. 
 












































































































































Figure 3.3 Structures of Bisphenolic Analogs 4A – 4R 
3.3. Structure-Activities Relationships Analysis Against S. mutans 
Figure 3.4 Chemical structures of the synthesized analogs with inhibitory activity against 
S. mutans. Highlighted in this figure are key characteristics of the compounds that affect 
biological activity. The size of the groups on the ring, the length of the linker between 
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all affect efficacy. All compounds with MIC < 250 μM were ≥90% pure as judged by 
UPLC. Reprinted with permission from Ochoa, C.; Solinski, A. E.; Nolan, M.; Dekarske, 
M. M.; Wuest, W. M.; Kozlowski, M. C., A bisphenolic honokiol analog outcompetes 
oral antimicrobial agent cetylpyridinium chloride via a membrane-associated mechanism. 
ACS Infect. Dis. 2020, 6 (1), 74-79. 
The synthesized analogs were tested by Amy Solinski of the Wuest Group in 
triplicate against S. mutans planktonic growth (Table 3.1). From this data, the SAR 
observations can be divided into several categories: steric interactions at the ortho position, 
phenol protection, positioning of aryl substituents, and linker length (Figure 3.4).  
Importantly, the corresponding monomer of C2 (4M) did not exhibit bioactivity, 
illustrating the importance of the biaryl motif for the observed inhibition. Analogs 3A – 
3M and 3O – 3AD, none of which possessed alkyl groups on the aromatic rings, were 
inactive proving the importance of the tert-butyl groups in compound C2. According to 
these results, there is a “goldilocks” response in terms of the steric functionality. 
Derivatives that contained smaller substituents ortho to the phenol (4B, 4C, 4D) also led 
to a decrease in efficacy, establishing that one tert-butyl substituent on each aromatic ring 
is optimal (Figure 3.4, left panel).  
In previous work, the bis-hydroxyl functionality of C2 was found to be a significant 
feature of the active structure (Figure 3.4, second panel). Here, we discover that potency 
can be maintained if one hydroxyl group is alkylated with a small group such as a methyl 
(3AE). If both hydroxyls are alkylated, as is the case with 4K, there is a more drastic drop 
in activity, leading to the conclusion that the hydroxyl groups are creating important 
binding contacts, most likely through hydrogen bonds. Larger alkylating groups, as found 
in 4O, also cause large decreases in potency, possibly due to a lack of hydrogen donators 
as well as changes in overall solubility. 
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Altering the substituents on the aryl rings can alter the projection of the key 
functional groups, and these changes can result in drastic change the inhibition (Figure 
3.4, third panel). Analogs 4H and 4G show that slight modification in the substitution 
pattern allows potency to be retained. However, larger changes, such as in 4R, cause 
slightly decreased inhibition due to hydroxyl proximity to the linker. We postulate that 4R 
is not able to bind as well as C2 to the target due to misalignment of the hydrogen bonding. 
Additionally, the optimal number of tert-butyl groups was found to be two (C2, 4G), as 
analogs with additional (4J, 4I) and fewer (3AF, 4F) tert-butyl substituents have lower 
bioactivity.  
Finally, the testing of analogs with differing linker lengths (4Q, 4P) showed that 
the ideal length is one (3N) or two carbons (C2) (Figure 3.4, fourth panel). 
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Table 3.1. Comprehensive MIC Data. Adapted with permission from Ochoa, C.; 
Solinski, A. E.; Nolan, M.; Dekarske, M. M.; Wuest, W. M.; Kozlowski, M. C., A 
bisphenolic honokiol analog outcompetes oral antimicrobial agent cetylpyridinium 




3.4. Investigation into the Mechanism of Action for Inhibition 
 
These antimicrobials were hypothesized to function via a membrane-specific 
mechanism due to similar SAR trends seen in previous work from the Wuest group.71,72 
Further, attempts made by the Wuest Group to generate a resistant mutant of S. mutans, 
after treatment with C2, were unsuccessful. Three colonies were isolated and tested, but 
resistance to the activity of C2 was not observed. Failure to select for resistant colonies is 
a hallmark of membrane-targeting mechanisms. 73  For that reason, the effect of the 
compounds on bacterial membrane integrity was investigated. The following biological 
assays were all performed by Cristian Ochoa, Amy Solinski, and Madeline Dekarske at 
Emory University. Depolarization (DiBAC4(3)) and cell lysis (Propidium Iodide, PI) of the 
bacterial cell membrane were analyzed between 2-250 µM (Figure 3.5a-d, Figures S1-
S9).  Analog C2 (Figure 3.5a) did not have a significant depolarization response when 
compared to the DMSO vehicle control (Figure S9) and the commercial oral antimicrobial, 
CPC (Figure 3.5b). CPC, known to act via a lytic mechanism, showed higher levels of 
membrane depolarization, causing a response as low as 8 µM (Figure 3.5b). Nevertheless, 
both C2 and CPC demonstrated a lytic response, denoted by an increase in PI fluorescence 
(Figure 3.5c-d). To visualize the membrane effects of C2, TEM images were obtained of 
 
71 Kim, W.; Zhu, W.; Hendricks, G. L.; Van Tyne, D.; Steele, A. D.; Keohane, C. E.; 
Fricke, N.; Conery, A. L.; Shen, S.; Pan, W.; et al. A New Class of Synthetic Retinoid 
Antibiotics Effective against Bacterial Persisters. Nature 2018, 556, 103-107 
72 Kim, W.; Steele, A. D.; Zhu, W.; Csatary, E. E.; Fricke, N.; Dekarske, M. M.; 
Jayamani, E.; Pan, W.; Kwon, B.; Sinitsa, I. F.; et al. Discovery and Optimization of 
NTZDpa as an Antibiotic Effective Against Bacterial Persisters. ACS Infect. Dis. 2018, 4 
(11), 1540-1545 
73 Hurdle, J. G.; O’Neill, A. J.; Chopra, I.; Lee, R. E. Targeting Bacterial Membrane 
Function: An Underexploited Mechanism for Treating Persistent Infections. Nature 
Reviews Microbiology. 2011, 9 (1), 62-75 
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compound treated cells, and lysis was observed at high concentrations (Figure 3.5g, red 
arrow).  
 
Figure 3.5 Comparison of the mechanism of action of C2 and CPC. a-b) Cellular 
membrane depolarization measured DiBAC4(3) recorded for 1 hour. c-d) Cellular lysis 
measured with PI recorded for 1 hour. e-f) Confirmation of cellular membrane 
permeability measured with SYTOX™ Green for 20 minutes. g) TEM images of DMSO 
vehicle control and C2 (2 and 125 µM) treated S. mutans cells. Reprinted with permission 
from Ochoa, C.; Solinski, A. E.; Nolan, M.; Dekarske, M. M.; Wuest, W. M.; Kozlowski, 
M. C., A bisphenolic honokiol analog outcompetes oral antimicrobial agent 
cetylpyridinium chloride via a membrane-associated mechanism. ACS Infect. Dis., 2020, 
6 (1), 74-79. 
To further understand the differences between C2 and CPC, a SYTOX™ Green 
Nucleic Acid Stain was utilized to measure membrane permeabilization. The bacterial 
membrane was permeabilized by C2 from 32 µM to 250 µM (Figure 3.5e). Compound C2 
has a more striking effect, responding with a higher maximum fluorescence, when 























C2 affects the membrane stability and fluidity, which is evidenced in both the lytic (Figure 
3.5c) and permeabilization activity (Figure 3.5e). The lack of depolarization events leads 
to the conclusion that C2 does not interfere with the membrane potential. Thus, the 
inhibitory activity must stem from a more physical mode of action, akin to the mechanism 
demonstrated by bithionol and nTZDpa. 74  Other active analogs were tested and 
demonstrate similar membrane effects (See SI).  
3.5. Inherent Toxicity of Synthesized Analogs  
Table 3.2 Hemolysis values were calculated with defibrinated sheep blood and reported 
as Lysis20 values which refer to 20% cell lysis compared to the Triton X control. 
Adapted with permission from Ochoa, C.; Solinski, A. E.; Nolan, M.; Dekarske, M. M.; 
Wuest, W. M.; Kozlowski, M. C., A bisphenolic honokiol analog outcompetes oral 
antimicrobial agent cetylpyridinium chloride via a membrane-associated mechanism. 
ACS Infect. Dis. 2020, 6 (1), 74-79. 
 
 
74 Kim, W.; Zou, G.; Hari, T. P. A.; Wilt, I. K.; Zhu, W.; Galle, N.; Faizi, H. A.; 
Hendricks, G. L.; Tori, K.; Pan, W.; et. al. Selective Membrane-Targeting Repurposed 
Antibiotic with Activity against Persistent Methicillin-Resistant Staphylococcus aureus. 




3N 63 µM 32
4B - -
4G 32 µM 8





CPC 16 µM 8
C2 63 µM 32
Honokiol >500 µM N/A
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Collaborator Amy Solinski calculated minimum bactericidal concentration (MBC) 
values to determine if the cell permeabilization promoted by the analogs led to 
bacteriostatic or bactericidal cell inhibition to better understand the overall mechanism. 
Colony Forming Units (CFU) were used to determine viability with the MBC referring to 
a 3-log reduction in growth, corresponding to 99.9% bacterial death (Table 3.2). In 
accordance with previous work, the active compounds demonstrated bactericidal 
mechanisms, since the MBC values were within a four-fold range relative to the MIC 
values. 
Due to the bactericidal effect, the toxicity of C2 relative to CPC was explored. 
Hemolysis values were determined using defibrinated sheep blood (Table 3.2). 
Interestingly, CPC exhibits significant hemolytic activity with a Lysis20 of 16 µM. Based 
on these results, CPC has a therapeutic index (TI) of 8, which is expressed as the ratio 
Lysis20/MIC. Conversely, equally potent analog C2 has a Lysis20 of 63 µM, yielding a 
higher TI of 32 again hinting at a mechanism of action that is disparate from that of CPC. 
This finding establishes the potential of compound C2 for use in dental health agents based 
on its superior TI. 
3.6. Bioactivity of Compound C2 Analogs Against Commensal Bacteria 
With the perspective of being used as a dental agent, these analogs were surveyed 
for inhibition of other commensal bacteria in the oral microbiome. The inhibition values 
reported above were all determined with S. mutans, one of the major agents in dental caries, 
but only one bacterium implicated in cavity formation. In an attempt to understand the 
broader impact of these compounds on the oral microbiome, the most potent analogs were 
tested against commensal bacteria S. gordonii and S. sanguinis, and the pathogenic species 
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S. sobrinus. The analogs demonstrated comparable activity against these strains (Table 
3.3). 
Table 3.3 Biological activity of honokiol analogs against oral microbiome bacteria. MIC 
for S. mutans, S. gordonii, S. sanguinis and S. sobrinus are reported in µM. MBCs were 
executed with S. mutans and reported based off CFU/mL counts of bacterial cell 
viability. Adapted with permission from Ochoa, C.; Solinski, A. E.; Nolan, M.; Dekarske, 
M. M.; Wuest, W. M.; Kozlowski, M. C., A bisphenolic honokiol analog outcompetes 
oral antimicrobial agent cetylpyridinium chloride via a membrane-associated mechanism. 




Through this SAR study, the critical structural attributes of S. mutans inhibitor C2 
have been delineated and a potential mechanism of action has been outlined. Compound 
C2 causes inhibition at high concentrations by disrupting the membrane permeability of S. 
mutans. Through MBC calculations, it was determined that C2 is acting in a bactericidal 
fashion. While membrane effects are prevalent, other possible targets contributing to 
Compound S. mutans S. gordonii S. sanguinis S. sobrinus S. Mutans MBC
3N 2 µM 2 µM 2 µM 4 µM 2 µM
4B >250 µM 250 µM 250 µM >250 µM -
4G 4 µM 1 µM 1 µM 2 µM 4 µM
4H 2 µM 4 µM 8 µM 8 µM 2 µM
4I >250 µM >250 µM 63 µM 250 µM -
4K >250 µM >250 µM >250 µM >250 µM -
4P 32 µM 32 µM 32 µM 32 µM -
4R 8 µM 8 µM 8 µM 8 µM 8 µM
CPC 2 µM 1 µM 0.5 µM 0.5 µM 8 µM
C2 2 µM 1 µM 1 µM 1 µM 4 µM
Honokiol 250 µM - - - -
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polypharmacology cannot be ruled out; future work will focus on confirming these 
findings. 
3.7. Conclusions 
In summary, the results presented in this work establish the potential of this new 
class of synthetically accessible bisphenolic compounds for antibacterial oral care. 
Compound C2 possesses favorable properties for further development and an improved 
therapeutic index when compared to the ubiquitous CPC. Future work will investigate its 
translational potential as a next generation oral care product and will be reported in due 
course. 
3.8. Biological Methods 
Materials: The bacterial strain Streptococcus Sobrinus SL1 [CCM 6070, CNCTC 
9/89], was purchased from the American Type Culture Collection. Streptococcus mutans 
wild-type strain UA159 was provided by Dr. Bettina Buttaro from Temple University 
Medical School, Philadelphia, PA. Streptococcus gordonii strain DL1 and Streptococcus 
sanguinis strain 10904 were provided by Dr. Robert G. Quivey from University of 
Rochester Medical School. Bacteria were routinely maintained on in BactoTM Todd- 
Hewitt (TH) agar plates and liquid cultures were grown in in BactoTM Todd-Hewitt broth 
(THB). For growth of biofilms, THB was supplemented with 0.1% sucrose. Incubation was 
stagnant at 37 °C with 5% CO2. Optical density (OD) measurements were performed on a 
Molecular Devices SpectraMax iD3 plate reader for S. mutans, S. gordonii and S. 
sanguinis. Optical density (OD) measurements were performed on a BioTek plate reader 
spectrophotometer for S. sobrinus.  
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Minimum Inhibitory Concentration (MIC) Assay (S. sobrinus): Stock solutions of 
bibenzyl analogs, 10 mM, were serial diluted in brain heart infusion in flat-bottom 96-well 
microtiter plates (volume 100 µL).  Bacterial cultures were grown overnight and then 
inoculated into the 96-well plate (total volume 200 µL). Plates are inoculated at 37 °C for 
20-24 hours after which the OD630 values were evaluated with a BioTek Plate Reader 
spectrophotometer. The MIC is determined as the lowest concentration of compound 
resulting in no bacterial growth visible to the naked eye and the difference of measured and 
background OD630 is less than 0.1. DMSO controls corresponding to each test 
concentration were performed. Biological triplicates were performed to confirm results. 
Minimum Inhibitory Concentration (MIC) Assay (S. mutans, S. gordonii, S. 
sanguinis): Stock solution of bibenzyl analogs, 10 mM, were serial diluted in THB media 
in flat-bottom 96-well microtiter plates (total volume 100 μL). Bacterial cultures were 
grown to mid-exponential phase, back diluted to an OD of 0.1 and then inoculated into the 
96-well plate to reach a final volume of 200 μL.  Plates were incubated at 37 °C in 5% CO2 
for 20-24 hours upon which time wells are evaluated visually for bacterial growth. The 
MIC is determined as the lowest concentration of compound resulting in no bacterial 
growth visible to the naked eye. DMSO controls corresponding to each test concentration 
were performed. Biological triplicates were performed to confirm results.  
S. mutans biofilm model. Stock solution of bibenzyl analogs, 10 mM, were serial 
diluted in THB media supplemented with 0.1% sucrose (w/v) in flat-bottom 96-well 
microtiter plates (total volume 100 μL). Bacterial cultures are grown to mid-exponential 
phase, back diluted to an OD of 0.1 and then inoculated into the 96-well plate to reach a 
final volume of 200 μL. Plates are incubated at 37 °C in 5% CO2 for 24 hours (early stage 
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biofilm) upon which time wells are evaluated visually for bacterial growth. DMSO controls 
corresponding to each test concentration were performed. Biological triplicates were 
performed to confirm results.  
S. mutans MBIC50 assay. Biofilms were prepared with above procedure, evaluated 
visually, OD600 of bacterial growth was recorded, and then emptied by inverting carefully, 
as to not disturb the biofilm. Wells were washed with 200 μL of phosphate buffer solution 
(PBS) and dried overnight at 37°C. Once dry, plates were incubated for 10 min at room 
temperature with 200 μL of 1% w/v crystal violet in DI H2O. Excess crystal violet was 
removed by aspirating off the liquid and performing DI H2O rinses until the run off was 
colorless. Plates were then inverted and dried overnight at 37°C. Crystal violet stained 
biofilm was redissolved with 200 μL of 10% acetic acid in DI H2O. The crystal violet plate 
with acetic acid solution was allowed to incubate at room temperature for 10-30 minutes 
to allow for full dissolution. Then 100 μL was transferred to a fresh flat-bottom 96-well 
plate for absorbance measurements at 595 nm. DMSO controls corresponding to each test 
concentration were performed. Three biological replicates were performed.  Crystal violet 
reading was set relative to bacterial growth (OD595/OD600) to allow for appropriate 
comparison of biofilm mass formation. MBIC50 refers to the concentration at which biofilm 
growth is inhibited by 50% compared to the control. 
Hemolysis Assay (Lysis20) Hemolysis assays were performed on mechanically 
defibrinated sheep blood (Hemostat Labs: DSB030). 1.5 mL of blood was placed into a 
microcentrifuge tube and centrifuged at 10,000 rpm for ten minutes. The supernatant was 
removed and then the cells were resuspended with 1 mL of phosphate-buffered saline 
(PBS). The suspension was centrifuged as previously, the supernatant was removed, and 
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cells were resuspended two more times. The final cell suspension was diluted twentyfold 
with PBS. The twentyfold suspension dilution was then aliquoted into microcentrifuge 
tubes containing compound serially diluted in PBS. TritonX (1% by volume) served as a 
positive control (100% lysis marker) and sterile PBS served as a negative control (0% lysis 
marker). Samples were then placed in an incubator at 37 ◦C and shaken at 200 rpm. After 
1 hour, the samples were centrifuged at 10,000 rpm for ten minutes. The absorbance of the 
supernatant was measured with a UV spectrometer at a 540 nm wavelength.75 
SYTOX Assay. Bacterial overnight cultures were regrown to mid-log phase in THB 
media and the culture was centrifuged and washed with PBS three times. Cells were then 
suspended in the same volume of PBS corresponding to the original regrow volume, and 
SYTOX green solution (5 mM in DMSO) was added to reach a final concentration of 5 
μM. Cells were incubated at room temperature and in the dark for 30 minutes. 150 µL of 
cells were then added to a black, clear bottom 96-well plate. Fluorescence was recorded 
for 10 minutes in plate reader to allow equilibration (excitation wavelength 485 nm and 
emission wavelength 525 nm). In a new 96-well plate, test compounds (10 mM DMSO 
stock solutions) were serially diluted in PBS. 50 μL of serially diluted compound was 
added to the SYTOX prepared cells in the plate reader and fluorescence was recorded 
overtime (excitation wavelength 485 nm, emission wavelength 525 nm). Biological 
 
75 Adapted from: Peng, L.; DeSousa, J.; Su, Z.; Novak, B.M.; Nevzorov, A.A.; Garland, 
E.R.; Melander, C. Chem. Comm. 2011, 47, 4896-4898. 
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triplicates were completed. Controls: DMSO vehicle control, PBS control, and CPC 
positive control.76   
Detecting Membrane Depolarization and Rupture. Bacterial overnight cultures 
were regrown to mid-log phase in THB media and the culture was centrifuged and washed 
with PBS three times. Cells were then suspended in the same volume of PBS corresponding 
to the original regrow volume. To 20 mLs of cell suspension, 500 µl of 1 M sterile filter 
glucose solution was added (Final glucose concentration = 24.4 mM). Cells were incubated 
for 15 minutes at 37˚C. Then 100 µl of 50 µM solution of DIBAC4(3) was added (Final 
concentration = 243 nM). Next, 400 µl of 2 mg/ml solution of PI was added (Final 
concentration 19 µg/ml). The sample was mixed thoroughly and 150 µL of sample was 
added into the wells of a black, clear bottom 96-well plate. The plate was then placed in a 
pre-warmed (37˚C) fluorescence detection plate reader. The measurements were recorded 
until readings stabilized (~40 mins). In a new 96-well plate, test compounds (10 mM 
DMSO stock solutions) were serially diluted in PBS. The fluorescence plate was ejected, 
50 µl of test compound was added and then quickly returned to the plate reader. 
Fluorescence was recorded overtime (measurements below). Biological triplicates were 
completed. Controls: DMSO vehicle control, PBS control, and CPC positive control.   
  
 
76 Adapted from Steele, A. D.; Ernouf, G.; Lee, Y. E. and Wuest W.M. Diverted Total 
Synthesis of the Baulamycins and Analogues Reveals an Alternate Mechanism of Action. 




1. DiBAC4(3) measures changes in polarity. (490 nm excitation and 516 nm emission) 
detection 
2. PI measures cell rupture. (535 nm excitation and 617 nm emission) detection77 
TEM Imaging. Cells were grown to mid-log phase in THB media, centrifuged, and 
washed with PBS three times. Cells were then suspended to the original volume with PBS. 
The cells were then incubated with test compound for 30 minutes at 37˚C.  Following 
treatment, cells were collected, washed, and prepared for transmission electron microscopy 
by fixing the cells in 2.5% glutaraldehyde in 0.1 M cacodylate buffer. Images were 
recorded on a JEOL JEM-1400 Transmission electron microscope at the Integrated Cellular 
Imaging Core at Emory University.  
 
77 Adapted from Clementi, E. A., Marks, L. R., Roche-Håkansson, H., Håkansson, A. P. 
Monitoring Changes in Membrane Polarity, Membrane Integrity, and Intracellular Ion 
Concentrations in Streptococcus pneumoniae Using Fluorescent Dyes. J. Vis. Exp. (84), 
e51008, (2014). 
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3.9. Synthetic Procedures 
General Consideration 
All non-aqueous reactions were carried out under an atmosphere of dry argon unless 
otherwise noted. Commercial reagents were used as received without additional 
purification unless otherwise noted. Anhydrous THF, toluene, dichloromethane, and 1,2-
dichloroethane were obtained from a Pure Process Technology solvent purification 
system. Bibenzyls 3A, 3D, 3G, 3H, 3I, 3O, 3P, 3R, 3S, 3T, 3U, 3V, and 3W were 
prepared according to the literature.1-4 Compounds 3C, 3Z and 4M were purchased from 
Sigma Aldrich. Reactions were monitored by thin layer chromatography (TLC) using 
Silicycle glass-backed TLC plates with 250 μM silica and F254 indicator. Visualization 
was accomplished by UV light or iodine staining. All compounds with inhibitory ability 
greater than 250 μM were analyzed for purity by UPLC and characterized by 1H NMR 
and decoupled 13C NMR. All final compounds were found to have >95% purity by 
UPLC unless otherwise noted. Nominal mass accuracy LCMS data were obtained by use 
of a Waters Acquity UPLC system equipped with a Waters TUV detector (254 nm) and a 
Waters SQD single quadrupole mass analyzer with electrospray ionization. LC gradient 
A 500 μL/min: 30 second hold 95:5 (water:acetonitrile 0.1% v/v formic acid), 2 minute 
gradient to 5:95, and 30 second hold. LC gradient B 500 μL/min: 30 second hold 50:50 
(water:acetonitrile 0.1% v/v formic acid), 2 minute gradient to 5:95, and 30 second hold. 
Acquity UPLC BEH C18, 1.7 μm, 2.1 x 50 mm column. 
 1H NMR spectra were recorded on a 500 MHz spectrometer. Chemical shifts are 
 88 
reported in ppm from the solvent resonance (CDCl3 7.26 ppm, acetone-d6 2.05 ppm). 
Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, br = broad, m = multiplet), coupling constants, and number of protons. 
Decoupled 13C NMR spectra were recorded at 125 MHz. IR spectra were taken on an 
FT-IR spectrometer. Accurate mass measurement analyses were conducted via time-of-
flight mass analyzer GCMS with electron ionization (EI) or via time-of-flight mass 
analyzer LCMS with electrospray ionization (ESI). The signals were measured against an 
internal reference of perfluorotributylamine for EI-GCMS and leucine enkephalin for 
ESI-LCMS. The instrument was calibrated, and measurements were made using neutral 
atomic masses; the mass of the electron removed or added to create the charged species is 
not taken into account.  
General Procedure A: Grignard Addition to Aryl Aldehydes  
 
To a solution of salicylaldehyde (1.0 mmol) in anhydrous THF (0.2 M) was slowly added 
a solution of Grignard reagent (4.5 mmol, 1.0 M in diethyl ether) at 0 °C. The reaction 
mixture was stirred for 2-3 h at room temperature. The reaction mixture was cooled to 
0 °C and quenched via drop-wise addition of saturated ammonium chloride solution (5 
mL). After stirring at room temperature for 10 min, the product was extracted with 
diethyl ether (5 x 20 mL). The combined organic fractions were dried over Na2SO4, 













2-Hydroxy-2-(3-methoxyphenyl)cyclohexan-1-one (3E). Following general 
procedure A, the product was obtained as a clear yellow liquid (0.266 g, 1.20 mmol) in 
45% yield: 1H NMR (500 MHz, CDCl3) d 7.30 (t, J = 7.8 Hz, 1H), 6.89-6.85 (m, 3H), 4.47 
(s, 1H), 3.80 (s, 3H), 2.98-2.95 (m, 1H), 2.56-2.51 (m, 1H), 2.45 (m, 1H), 2.07-2.04 (m, 
1H), 1.88-1.70 (m, 4H); 13C NMR (125 MHz, CDCl3) d 212.7, 160.3, 141.6, 130.3, 118.8, 
113.6, 112.7, 80.2, 55.5, 39.11, 39.05, 28.4, 23.2; IR (neat) 3341, 2937, 1676, 1599, 1585, 
1487, 1454, 1433, 1317, 1256, 1153, 1040, 872, 784, 735, 699, 564, 465 cm-1; HRMS (ESI-
TOF) m/z = 220.1099 calc for C13H16O3 [M]+, found 220.1095.  
 
5,5'-(Ethane-1,2-diyl)bis(2-(1-hydroxyethyl)phenol) (4E). Following general 
procedure A, the product was obtained as an amorphous white solid (39 mg, 0.13 mmol) 
in 70% yield: 1H NMR (500 MHz, Acetone-D6) d 8.57 (s, 2H), 7.06 (d, J = 8.0 Hz, 2H), 
6.69-6.68 (m, 4H), 5.10-5.06 (m, 2H), 4.84 (s, 2H), 2.79 (s, 4H), 1.44 (d, J = 6.5 Hz, 6H; 
13C NMR (125 MHz, Acetone-D6) d 155.0, 141.9, 128.5, 126.1, 119.4, 115.9, 68.1, 37.1, 
23.7; IR (neat) 3318, 2927, 1619, 1580, 1428, 1371, 1250, 1122, 1067, 1008, 958, 872, 815 
cm-1; HRMS (EI-TOF) m/z = 266.1307 calc for C18H18O2 [M-2H2O]–, found 266.1315. 










To a solution of the arene (1.0 equiv) dissolved in dichloromethane (0.2 M) at 0 °C was 
added R2OH (2.2 equiv) and H2SO4 (2.0 equiv). The resultant mixture was stirred for 18 h 
and monitored via TLC. When the complete, the mixture was quenched with a saturated 
solution of NaHCO3 (10 mL), extracted with dichloromethane (5 x 15 mL) and ethyl 
acetate (5 x 15 mL), and washed with brine (5 x 10 mL). The combined organic fractions 
were dried over Na2SO4, concentrated, and chromatographed using 10% ethyl 
acetate/hexane to afford the product. 
 
5,5'-Methylenebis(2-(tert-butyl)phenol) (3N). Following general procedure B, the 
product was obtained as an amorphous light brown solid (8.9 mg, 0.03 mmol) in 12% yield: 
1H NMR (500 MHz, CDCl3) d 7.16 (d, J = 8.0 Hz, 2H), 6.70 (dd, J = 8.0, 1.5 Hz, 2H), 6.43 
(d, J =1.5 Hz, 2H), 4.63 (s, 2H), 3.77 (s, 2H), 1.37 (s, 18H); 13C NMR (125 MHz, CDCl3) 
d 154.4, 140.2, 134.1, 127.3, 121.3, 117.3, 40.5, 34.5, 29.9; IR (neat) 3521, 2956, 2912, 
2870, 1614, 1573, 1514, 1483, 1414, 1391, 1362, 1333, 1296, 1262, 1185, 1136, 1080, 
977, 811, 762, 734, 502 cm-1; HRMS (EI-TOF) m/z = 312.2089 calc for C21H28O2 [M]+, 














Bis(4-(tert-butyl)-3-methoxyphenyl)methane (4L). Following general procedure B, 
the product was obtained as a light yellow liquid (13 mg, 0.04 mmol) in 18% yield: 1H 
NMR (500 MHz, CDCl3) d 7.18 (d, J = 8.2 Hz, 2H), 6.73 (m, 4H), 3.91 (s, 2H), 3.80 (s, 
6H), 1.36 (s, 18H); 13C NMR (125 MHz, CDCl3) d 158.5, 139.9, 135.9, 126.5, 120.6, 112.3, 
55.0, 41.4, 34.5, 29.8; IR (neat) 2955, 1608, 1570, 1501, 1464, 1411, 1359, 1254, 1172, 
1087, 1041, 811 cm-1; HRMS (EI-TOF) m/z = 340.2402 calc for C23H32O2 [M]+, found 
340.2397. 
 
2-(tert-Butyl)-5-(3-hydroxyphenethyl)phenol (4AF). Following general procedure 
B, the product was obtained as a dark yellow solid (46 mg, 0.17 mmol) in 18% yield: 1H 
NMR (500 MHz, CDCl3) d  7.04-7.00 (m, 3H), 6.87 (dd, J = 8.0, 2.0 Hz, 1H), 6.75 (dd, J 
= 6.5, 2.0 Hz, 2H), 6.58 (d, J = 8.0 Hz, 1H), 2.81 (s, 4H), 1.39 (s, 9H); 13C NMR (125 MHz, 
Acetone-D6) d 157.3, 155.5, 143.5, 140.5, 133.1, 129.1, 126.3, 119.4, 119.1, 116.2, 115.2, 
112.7, 37.3, 36.7, 33.9, 29.0; IR (neat) 3400, 2954, 2864, 1653, 1611, 1513, 1442, 1419, 
1364, 1211, 1085, 821, 758, 553, 515 cm-1; HRMS (EI-TOF) m/z = 270.1620 calc for 








4-(tert-Butyl)-3-(3-hydroxyphenethyl)phenol (4F). Following general procedure B, 
the product was obtained as a red gel (0.396 g, 1.47 mmol) in 34% yield: 1H NMR (500 
MHz, CDCl3) d 7.34 (d, J = 8.0 Hz, 1H), 7.27 (t, J = 7.6 Hz, 1H), 6.91 (d, J = 7.6 Hz, 1H), 
6.87-6.82 (m, 3H), 6.57 (s, 1H), 6.22 (s, 1H), 5.48 (s, 1H), 2.92-2.90 (m, 4H), 1.56 (s, 9H); 
13C NMR (125 MHz, CDCl3) d 155.5, 154.1, 143.9, 140.8, 133.8, 129.6, 127.1, 121.0, 
120.5, 116.6, 115.3, 112.9, 37.4, 36.8, 34.3, 29.7; IR (neat) 3389, 2955, 2867, 1699, 1613, 
1589, 1483, 1455, 1417, 1391, 1363, 1297, 1263, 1202, 1153, 1079, 1023, 1000, 941, 860, 
818, 788, 735, 694, 677, 632, 572, 537, 501 cm-1; HRMS (EI-TOF) m/z = 270.1620 calc 
for C18H22O2 [M]+, found 270.1613. >95% purity. UPLC tR = 2.47 min gradient A. 
 
3,3'-(Ethane-1,2-diyl)bis(4-(tert-butyl)phenol) (4G). Following general procedure B, 
the product was obtained as a brown solid (0.660 , 2.02 mmol) in 47% yield: 1H NMR (500 
MHz, Acetone-D6) d 8.06 (s, 2H), 7.09 (d, J = 8.0 Hz, 2H), 6.70 (d, J = 2.0 Hz, 2H), 6.64 
(dd, J = 8.0, 2.0 Hz, 2H), 2.73 (s, 4H), 1.37 (s, 18H); 13C NMR (125 MHz, Acetone-D6) d 
154.7, 141.1, 134.1, 127.1, 120.3, 116.9, 36.9, 34.5, 29.9; IR (neat) 3520, 2955, 2868, 1703, 
1615, 1574, 1517, 1483, 1454, 1416, 1391, 1363, 1297, 1263, 1187, 1137, 1079, 1023, 
960, 859, 818, 736, 696, 635, 572, 502 cm-1; HRMS (EI-TOF) m/z = 326.2246 calc for 






2,4-Di-tert-butyl-5-(4-(tert-butyl)-3-hydroxyphenethyl)phenol (4J). Following 
general procedure B, the product was obtained as a brown gel (39 mg, 0.10 mmol) in 11% 
yield: 1H NMR (500 MHz, CDCl3) d 7.06 (d, J = 2.0 Hz, 1H), 6.98 (m, 2H), 6.89 (dd, J = 
8.0, 2.0 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 5.03 (s, 1H), 4.64 (s, 1H), 2.81 (s, 4H), 1.43 (s, 
18H), 1.40 (s, 9H); 13C NMR (125 MHz, CDCl3) d 152.1, 151.8, 135.7 (2C), 135.6, 134.0 
(2C), 132.5, 127.1, 126.6, 124.8, 116.3, 38.0, 37.6, 34.4, 34.2 (2C), 30.3 (2C), 29.6; IR 
(neat) 3643, 3519, 2955, 2868, 1704, 1646, 1608, 1506, 1483, 1434, 1419, 1391, 1363, 
1317, 1248, 1232, 1200, 1121, 1084, 1022, 932, 885, 814, 768, 741, 704, 620, 494 cm-1; 
HRMS (EI-TOF) m/z = 382.2872 calc for C26H38O2 [M]+, found 382.2888. 89% purity. 
UPLC tR = 2.88 min gradient B. 
 
5,5'-(Ethane-1,2-diyl)bis(2,4-di-tert-butylphenol) (4I). Following general procedure 
B, the product was obtained as an amorphous yellow solid (7.3 mg, 0.02 mmol) in 2% 
yield: 1H NMR (500 MHz, CDCl3) d 6.98 (m, 4H), 5.02 (s, 2H), 2.82 (s, 4H), 1.43 (s, 36H); 
13C NMR (125 MHz, CDCl3) d 151.7, 135.6 (2C), 132.7, 124.8 (2C), 37.9, 34.2 (2C), 30.3 






HRMS (EI-TOF) m/z = 438.3998 calc for C30H46O2 [M]+, found 438.3995. 93% purity. 
UPLC tR = 3.02 min gradient A. 
 
4,4'-Di-tert-butyl-[1,1'-biphenyl]-3,3'-diol (4P). Following general procedure B, the 
product was obtained as a white solid (42 mg, 0.14 mmol) in 53% yield: 1H NMR (500 
MHz, Acetone-D6) d 8.33 (s, 2H), 7.23 (d, J = 8.0 Hz, 2H), 7.04 (d, J = 1.8 Hz, 2H), 6.96 
(dd, J = 8.0, 1.8 Hz, 2H), 1.40 (s, 18H); 13C NMR (125 MHz, CDCl3) d 154.3, 139.4, 135.3, 
127.5, 119.1, 115.0, 34.4, 29.7; IR (neat) 3516, 2957, 2870, 1694, 1611, 1555, 1504, 1484, 
1420, 1399, 1387, 1361, 1293, 1264, 1241, 1187, 1138, 1104, 1078, 1049, 1022, 961, 858, 
815, 741, 567, 500 cm-1; HRMS (EI-TOF) m/z = 298.1933 calc for C26H26O2 [M]+, found 
298.1940. mp = 177 – 179 °C. >95% purity. UPLC tR = 2.79 min gradient A. 
 
5,5'-(Propane-1,3-diyl)bis(2-(tert-butyl)phenol) (4Q). Following general procedure 
B, the product was obtained as a yellow liquid (5.6 mg, 0.02 mmol) in 13% yield: 1H NMR 
(500 MHz, CDCl3) d 7.16 (d, J = 7.9 Hz, 2H), 6.70 (d, J = 7.9 Hz, 2H), 6.49 (s, 2H), 4.67 
(s, 2H), 2.56 (t, J = 7.6 Hz, 4H), 1.91 (pentet, J = 7.6 Hz, 2H), 1.39 (s, 18H); 13C NMR 
(125 MHz, CDCl3) d 154.2, 141.5, 133.6, 127.0, 120.6, 116.8, 34.7, 34.4, 31.1, 29.8; IR 





863, 816, 573 cm-1; HRMS (EI-TOF) m/z = 340.2402 calc for C23H32O2 [M]+, found 
340.2411. >95% purity. UPLC tR = 2.94 min gradient B. 
 
2,2'-(Ethane-1,2-diyl)bis(4-(tert-butyl)phenol) (4R). Following general procedure B, 
the product was obtained as an amorphous white solid (3.0 mg, 0.01 mmol) in 7% yield: 
1H NMR (500 MHz, CDCl3) d 7.16 (m, 4H), 6.80 (d, J = 8.7 Hz, 2H), 5.98 (s, 2H), 2.85 (s, 
4H), 1.30 (s, 18H); 13C NMR (125 MHz, CDCl3) d 151.5, 143.9, 127.2, 127.2, 124.6, 115.1, 
34.2, 32.4, 31.7; IR (neat) 3339, 2953, 2868, 1612, 1590, 1500, 1462, 1423, 1392, 1363, 
1265, 1219, 1180, 1153, 1121, 1105, 1087, 984, 888, 819, 752, 739, 635, 478 cm-1; HRMS 
(EI-TOF) m/z = 326.2246 calc for C22H30O2 [M]+, found 326.2237. >95% purity. UPLC tR 
= 2.47 min gradient A. 
 
4,4'-(Ethane-1,2-diyl)bis(2-(tert-butyl)phenol) (4H). Following general procedure B, 
the product was obtained as an amorphous light yellow solid (9.3 mg, 0.03 mmol) in 6% 
yield: 1H NMR (500 MHz, CDCl3) d 7.02 (d, J = 2.2 Hz, 2H), 6.87 (dd, J = 6.0, 2.2 Hz, 
2H), 6.58 (d, J = 6.0 Hz, 2H), 4.69 (s, 2H), 2.80 (s, 4H), 1.39 (s, 18H); 13C NMR (125 
MHz, CDCl3) d 152.3, 135.9, 134.0, 127.4, 126.8, 116.5, 37.8, 34.6, 29.8; IR (neat) 3528, 






769, 496 cm-1; HRMS (EI-TOF) m/z = 326.2246 calc for C22H30O2 [M]+, found 326.2233. 
>95% purity. UPLC tR = 2.78 min gradient B. 
General Procedure C: Reduction of Benzaldehydes and Benzylic Alcohols 
 
Benzaldehyde or benzylic alcohol (1.0 equiv) and 10% Pd/C (0.9 equiv) were added to 
anhydrous ethanol (0.1 M). The flask was evacuated and backfilled with H2 gas three times 
and the mixture was allowed to stir under H2 balloon for 18 h. After completion of the 
reaction, the flask was purged with argon and filtered through a bed of Celite. The solvent 
was evaporated and product was chromatographed using 10% ethyl acetate/hexane to 
afford the product. 
 
5,5'-(Ethane-1,2-diyl)bis(2-methylphenol) (4B). Following general procedure C, the 
product was obtained as a white solid (15 mg, 0.06 mmol) in 68% yield: 1H NMR (500 
MHz, Acetone-D6) d 6.95 (d, J = 7.5 Hz, 2H), 6.67 (d, J = 1.5 Hz, 2H), 6.59 (dd, J = 7.5, 
1.5 Hz, 2H), 2.74 (s, 4H), 2.14 (s, 6H); 13C NMR (125 MHz, CDCl3) d 155.1, 140.7, 130.5, 
121.4, 119.4, 114.7, 37.3, 14.9; IR (neat) 3392, 2925, 1622, 1578, 1513, 1458, 1419, 1379, 























for C16H18O2 [M]+, found 242.1316. mp = 165 – 166 °C. >95% purity. UPLC tR = 2.24 min 
gradient A. 
 
5,5'-(Ethane-1,2-diyl)bis(2-isopropylphenol) (4D). Following general procedure C, 
the product was obtained as an amorphous white solid (2.3 mg, 0.01 mmol) in 26% yield: 
1H NMR (500 MHz, CDCl3) d 7.09 (d, J = 7.8 Hz, 2H), 7.76 (d, J = 7.8 Hz, 2H), 6.59 (s, 
2H), 4.60 (s, 2H), 3.15 (hep, J = 7.4 Hz, 2H), 2.80 (s, 4H), 1.24 (d, J = 7.0 Hz, 12H); 13C 
NMR (125 MHz, CDCl3) d 152.9, 140.9, 132.1, 126.5, 121.0, 115.4, 37.4, 27.0, 22.9; IR 
(neat) 3405, 2960, 2926, 2869, 1712, 1617, 1581, 1518, 1457, 1422, 1382, 1363, 1342, 
1290, 1225, 1185, 1152, 1112, 1085, 1060, 956, 861, 818, 738, 635, 581, 492 cm-1; HRMS 
(EI-TOF) m/z = 298.1933 calc for C16H18O2 [M]+, found 298.1933. 
 
3,3'-(Ethane-1,2-diyl)diphenol (4A). To a solution of 1,2-bis(3-
methoxyphenyl)ethane (0.600 g, 2.78 mmol) in anhydrous dichloromethane (11 mL, 0.2 
M) at –78 °C was added BBr3 (1 M solution in dichloromethane, 6.4 mL, 6.40 mmol) 
dropwise under an argon flow. The mixture stirred for 30 min, then slowly raised to room 






and extracted using ethyl acetate (5 x 30 mL). The combined organic fractions were dried 
over Na2SO4, concentrated, and chromatographed (hexane/EtOAc, 10:1). The 
demethylated product was obtained as a white solid (535.6 mg, 2.50 mmol) in 90% yield: 
1H NMR (500 MHz, Acetone-D6) d 8.11 (s, 2H), 7.08 (t, J = 7.8 Hz, 2H), 6.72-6.69 (m, 
4H), 6.66-6.64 (m, 2H), 2.81 (s, 4H); 13C NMR (125 MHz, Acetone-D6) d 157.5, 143.6, 
129.3, 119.7, 115.5, 112.9, 37.6; IR (neat) 3328, 2927, 1589, 1491, 1455, 1254, 1155, 939, 
865, 783, 693 cm-1; HRMS (ESI-TOF) m/z = 214.0994 calc for C14H14O2 [M]+, found 
214.0991. mp = 130 – 134 °C. 
 
1,2-Bis(3-methoxyphenyl)cyclohexane-1,2-diol (3F). To a solution of 2-hydroxy-2-
(3-methoxyphenyl)cyclohexan-1-one (60 mg, 0.27 mmol) and vacuum dried CeCl3 (0.608 
g, 1.63 mmol) in anhydrous THF (1.0 mL, 0.3 M) was slowly added a solution of (3-
methoxyphenyl)magnesium bromide (1.0 M in diethyl ether, 1.10 mL, 1.10 mmol) at 0 °C. 
The mixture was stirred for 2-3 hours at room temperature. After cooling to 0 °C, the 
reaction was quenched via drop-wise addition of saturated ammonium chloride solution (2 
mL). After stirring at room temperature for 10 min, the product was extracted with diethyl 
ether (5 x 10 mL). The combined organic fractions were dried over Na2SO4, concentrated, 
and chromatographed (hexane/EtOAc, 10:1).5 The product was obtained as a brown liquid 
(60 mg, 0.18 mmol) in 67% yield: 1H NMR (500 MHz, CDCl3) d 7.08 (t, J = 8.0 Hz, 2H), 





6H), (td, J = 8.1, 3.3 Hz, 2H), 1.92 (q, J = 9.2 Hz, 2H), 1.72-1.65 (m, 4H); 13C NMR (125 
MHz, Acetone-D6) d 158.4, 147.7, 127.0, 119.8, 113.3, 111.6, 76.3, 54.2, 34.7, 20.8; IR 
(neat) 3480, 2934, 2863, 2835, 1600, 1582, 1486, 1464, 1429, 1313, 1289, 1252, 1197, 
1168, 1149, 1078, 1043, 1011, 997, 946, 895, 879, 851, 804, 786, 735, 700, 590, 571, 522, 
492 cm-1; HRMS (EI-TOF) m/z = 328.1675 calc for C20H24O4 [M]+, found 328.1671. 
 
Bis(3-methoxyphenyl)methane (3H). To a round bottom flask with bis(3-
methoxyphenyl)methanol (200 mg, 0.82 mmol) and 10% Pd/C (80 mg, 0.75 mmol) was 
added anhydrous ethanol (6.0 mL, 0.1 M). The flask was evacuated and backfilled with 
hydrogen gas three times and then allowed to stir for 18 h. After completion of the reaction, 
the flask was purged with argon and the mixture was filtered through a bed of Celite. The 
solvent was evaporated and the product was chromatographed (hexane/EtOAc, 10:1). The 
product was obtained as a clear liquid (118 mg, 0.52 mmol) in 63% yield: 1H NMR (500 
MHz, CDCl3) d 7.24 (m, 2H), 6.83 (d, J = 7.6 Hz, 2H), 6.79-6.78 (m, 4H), 3.96 (s, 2H), 
3.80 (s, 6H); 13C NMR (125 MHz, CDCl3) d 159.9, 142.6, 129.5, 121.5, 114.9, 111.5, 55.3, 
42.1; IR (neat) 3001, 2939, 2835, 1596, 1583, 1487, 1464, 1453, 1434, 1310, 1280, 1256, 
1190, 1149, 1089, 1044, 996, 946, 873, 774, 774, 737, 691, 572, 554 cm-1; HRMS (ESI-





1,1'-(Methylenebis(2-hydroxy-4,1-phenylene))bis(ethan-1-one) (3J). To a solution 
of bis(3-methoxyphenyl)methane (100 mg, 0.44 mmol) in anhydrous toluene (1.1 mL, 0.4 
M), TiCl4 (0.11 mL, 0.96 mmol) was added slowly. The mixture was stirred until gas 
evolution ceased. Acetyl chloride (0.09 mL, 1.31 mmol) was slowly added and the solution 
stirred for 0.25 h. The solution was brought to 100 °C and stirred for an additional1 h. The 
mixture was quenched via drop wise addition of H2O (5 mL) and then extracted with 
dichloromethane (5 x 10 mL). The combined organic fractions were dried over Na2SO4, 
concentrated, and chromatographed (hexane/EtOAc, 10:1).6 The product was obtained as 
a brown liquid (31.2 mg, 0.10 mmol) in 25% yield: 1H NMR (500 MHz, Acetone-D6) d 
12.29 (s, 2H), 7.82 (d, J = 8.0 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 6.81 (s, 2H), 3.97 (s, 2H), 
2.60 (s, 6H); 13C NMR (125 MHz, CDCl3) d 205.7, 163.5, 150.6, 132.6, 120.8, 119.2, 
118.9, 42.5, 23.4; IR (neat) 3254, 3012, 2921, 2872, 1647, 1620, 1569, 1504, 1420, 1363, 
1322, 1301, 1281, 1245, 1221, 1165, 1148, 1023, 983, 959, 822, 794, 759, 750, 704, 602 
cm-1; HRMS (ESI-TOF) m/z = 284.1049 calc for C17H16O4 [M]+, found 284.1048.  
 
4,4'-Methylenebis(2-hydroxybenzaldehyde) (3L). To a solution of 3,3'-
methylenediphenol (40.0 mg, 0.20 mmol) and anhydrous MgCl2 (38.0 mg, 0.40 mmol) in 
THF (1.0 mL, 0.2 M) was added triethylamine (0.06 mL, 0.40 mmol). The mixture was 






heating to reflux for 18 h, the mixture was quenched with 3 M aqueous HCl (20 mL), 
extracted with diethyl ether (5 x 15 mL), and washed with H2O (3 x 20 mL) and saturated 
aqueous NaCl (3 x 20 mL). The combined organic fractions were dried over Na2SO4, 
concentrated, and chromatographed (hexane/EtOAc, 10:1)7. The product was obtained as 
a white solid (10.6 mg, 0.04 mmol) in 21% yield: 1H NMR (500 MHz, Acetone-D6) d 11.03 
(s, 2H), 9.97 (s, 2H), 7.71 (d, J = 7.9 Hz, 2H), 7.00 (d, J = 7.9 Hz, 2H), 6.90 (s, 2H), 4.07 
(s, 2H); 13C NMR (125 MHz, Acetone-D6) d 196.7, 161.6, 150.2, 134.1, 120.9, 119.6, 
117.3, 41.8; IR (neat) 3262, 3076, 2856, 1644, 1622, 1569, 1498, 1450, 1410, 1381, 1344, 
1321, 1269, 1229, 1205, 1155, 1131, 983, 926, 888, 805, 733, 709, 637, 610, 598, 559, 475 
cm-1; HRMS (ESI-TOF) m/z = 256.0736 calc for C15H12O4 [M]+, found 256.0722. mp = 
139 – 140 °C. 
 
2-Hydroxy-4-(3-hydroxybenzyl)benzaldehyde (3M). To a solution of 3,3'-
methylenediphenol (40.0 mg, 0.20 mmol) and anhydrous MgCl2 (38.0 mg, 0.40 mmol) in 
THF (1.0 mL, 0.2 M) was added triethylamine (0.06 mL, 0.40 mmol). The mixture was 
stirred for 0.25 h whereupon paraformaldehyde (48.0 mg, 1.60 mmol) was added. After 
heating at reflux for 18 h, the reaction was quenched with 3 M aqueous HCl (20 mL), 
extracted with diethyl ether (5 x 15 mL), and washed with H2O (3 x 20 mL) and saturated 
solution of NaCl (3 x 20 mL). The combined organic fractions were dried over Na2SO4, 
concentrated, and chromatographed (hexane/EtOAc, 10:1)7. The product was obtained as 
a light red solid (12.3 mg, 0.05 mmol) in 27% yield: 1H NMR (500 MHz, Acetone-D6) d 




6.84 (s, 1H), 6.74-6.68 (m, 3H), 3.93 (s, 2H); 13C NMR (125 MHz, CDCl3) d 195.8, 161.8, 
155.7, 151.2, 141.0, 133.7, 129.8, 121.5, 120.7, 119.1, 117.7, 115.9, 113.5, 42.0; IR (neat) 
3365, 2925, 2852, 1651, 1627, 1589, 1569, 1502, 1490, 1454, 1371, 1322, 1279, 1227, 
1206, 1158, 1128, 1081, 1000, 975, 878, 809, 786, 749, 697, 674, 622, 557, 469 cm-1; 
HRMS (EI-TOF) m/z = 228.0786 calc for C14H12O3 [M]+, found 228.0779. mp = 136 – 138 
°C. 
 
4,4'-(Ethane-1,2-diyl)bis(2-hydroxybenzaldehyde) (4N). To a solution of 3,3'-
(ethane-1,2-diyl)diphenol (0.700 mg, 3.27 mmol) and anhydrous MgCl2 (1.24 g, 13.1 
mmol) in THF (17.0 mL, 0.2 M) was added triethylamine (1.8 mL, 13.1 mmol). The 
mixture was stirred for 0.25 h whereupon paraformaldehyde (0.784 g, 26.14 mmol) was 
added. After heating at reflux for 18 h, the reaction was quenched with 3 M aqueous HCl 
(50 mL), extracted with diethyl ether (5 x 35 mL), and washed with H2O (3 x 30 mL) and 
saturated solution of NaCl (3 x 30 mL). The combined organic fractions were dried over 
Na2SO4, concentrated, and recrystallized using acetone. The product was obtained as a 
white solid (0.400 mg, 1.48 mmol) in 45% yield: 1H NMR (500 MHz, CDCl3) d 9.83 (s, 
2H), 7.45 (d, J = 7.9 Hz, 2H), 6.80 (m, 4H), 2.94 (s, 4H); 13C NMR (125 MHz, CDCl3) d 
196.0, 162.0, 151.4, 133.9, 120.5, 119.3, 117.3, 37.3; IR (neat) 3242, 2923, 2852, 2759, 
1667, 1565, 1503, 1439, 1381, 1299, 1198, 969, 814, 736, 714, 551 cm-1; HRMS (EI-TOF) 









3,3'-(Ethane-1,2-diyl)bis(2-hydroxybenzaldehyde) (3Q). To a solution of 3,3'-
methylenediphenol (50.0 mg, 0.23 mmol) and anhydrous MgCl2 (44.4 mg, 0.47 mmol) in 
THF (1.2 mL, 0.2 M) was added triethylamine (0.07 mL, 0.47 mmol). The mixture was 
stirred for 0.25 h whereupon paraformaldehyde (56 mg, 1.87 mmol) was added. After 
heating at reflux for 18 h, the reaction was quenched with 3 M aqueous HCl (20 mL), 
extracted with diethyl ether (5 x 15 mL), and washed with H2O (3 x 20 mL) and saturated 
solution of NaCl (3 x 20 mL). The combined organic fractions were dried over Na2SO4, 
concentrated, and chromatographed (hexane/EtOAc, 10:1)7. The product was obtained as 
an amorphous white solid (4.2 mg, 0.02 mmol) in 7% yield: 1H NMR (500 MHz, CDCl3) 
d 11.32 (d, J = 0.5 Hz, 2H), 9.89 (s, 2H), 7.42 (dd, J = 7.5, 1.7 Hz, 2H), 7.33 (dd, J = 7.5, 
1.5 Hz, 2H), 6.91 (t, J = 7.5 Hz, 2H), 3.00 (s, 4H); 13C NMR (125 MHz, CDCl3) d 196.8, 
159.8, 137.4, 131.8, 130.2, 120.2, 119.4, 28.9; IR (neat) 3178, 3084, 2928, 2845, 1645, 
1615, 1484, 1443, 1385, 1352, 1325, 1265, 1239, 1218, 1153, 1076, 978, 853, 792, 756, 









Ethane-1,2-diylbis(4,1-phenylene) diacetate (3X). To a solution of 1,2-bis(4-
methoxyphenyl)ethane (50.0 mg, 0.21 mmol) in anhydrous toluene (0.5 mL, 0.4 M), TiCl4 
(50.0 µL, 0.45 mmol) was added slowly. The mixture was stirred until gas evolution 
ceased. Acetyl chloride (30.0 µL, 0.45 mmol) was added slowly and the solution stirred 
for 0.25 h. The mixture was brought to 100 °C and stirred for an additional 1 h. The mixture 
was quenched via drop-wise addition of H2O (5 mL) and then extracted with 
dichloromethane (5 x 10 mL). The combined organic fractions were dried over Na2SO4, 
concentrated, and chromatographed (hexane/EtOAc, 10:1)6. The product was obtained as 
a brown liquid (29.4 mg, 0.10 mmol) in 48% yield: 1H NMR (500 MHz, CDCl3) d 7.85 (d, 
J = 8.2 Hz, 4H), 7.29 (d, J = 8.0 Hz, 4H), 2.51 (s, 6H), 2.37 (s, 4H); 13C NMR (125 MHz, 
CDCl3) d 196.5, 143.4, 134.9, 129.0, 128.2, 25.6, 20.5; IR (neat) 2922, 1679, 1605, 1573, 
1511, 1429, 1405, 1356, 1265, 1211, 1181, 1112, 1074, 1037, 1018, 953, 814, 713, 673, 
637, 591, 567, 460 cm-1; HRMS (ESI-TOF) m/z = 299.1283 calc for C18H19O4 [M+H]+, 
found 299.1277. 
 
1,1'-(Ethane-1,2-diylbis(6-hydroxy-3,1-phenylene))bis(ethan-1-one) (3AA). To a 
solution of 1,2-bis(4-methoxyphenyl)ethane (50.0 mg, 0.21 mmol) in anhydrous toluene 








until gas evolution ceased. Acetyl chloride (30.0 µL, 0.45 mmol) was added slowly and the 
solution stirred for 0.25 h. The mixture was brought to 100 °C and stirred for 1 h. The 
mixture was quenched via drop-wise addition of H2O (5 mL) and then extracted with 
dichloromethane (5 x 10 mL)6. The combined organic fractions were dried over Na2SO4, 
concentrated, and chromatographed (hexane/EtOAc, 10:1). The product was obtained as a 
light brown solid (14 mg, 0.05 mmol) in 24% yield: 1H NMR (500 MHz, CDCl3) d 12.12 
(s, 2H), 7.38 (d, J = 2.2 Hz, 2H), 7.26 (dd, J = 8.5, 2.2 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 
2.86 (s, 4H), 2.56 (s, 6H); 13C NMR (125 MHz, CDCl3) d 204.5, 160.9, 137.1, 131.5, 130.4, 
119.5, 118.5, 37.2, 26.8; IR (neat) 3340, 3033, 2861, 1643, 1586, 1480, 1421, 1366, 1345, 
1321, 1303, 1263, 1201, 1147, 1125, 1069, 1024, 960, 886, 845, 788, 635, 541, 472 cm-1; 
HRMS (ESI-TOF) m/z 299.1283 calc for C18H19O4 [M+H]+, found 299.1293. mp = 107 – 
108 °C. 
 
(E)-1,3-Bis(3-methoxyphenyl)prop-2-en-1-one (3AB). To a flame dried round 
bottom flask was added 3-methoxybenzaldehyde (2.44 mL, 20.0 mmol), 1-(3-
methoxyphenyl)ethan-1-one (2.74 mL, 20.0 mmol), and BF3•OEt2 (1.24 mL, 10.0 mmol). 
The mixture was stirred for 4 h, then quenched with H2O (30 mL) and extracted with ethyl 
acetate (5 x 40 mL). The combined organic fractions were dried over Na2SO4, 
concentrated, and chromatographed (hexane/EtOAc, 10:1)8. The product was obtained as 
a brown liquid (0.943 g, 3.52 mmol) in 18% yield: 1H NMR (500 MHz, CDCl3) d 7.76 (d, 





15.7 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.22 (d, J = 7.7 Hz, 1H), 
7.14 (t, J = 2.1 Hz, 1H), 7.11 (ddd, J = 9, 2.7, 0.8 Hz, 1H) 6.94 (ddd, J = 8.8, 2.5, 0.5 Hz, 
1H), 3.85 (s, 3H), 3.82 (s, 3H); 13C NMR (125 MHz, CDCl3) d 190.1, 160.0, 159.9, 144.7, 
139.6, 136.3, 130.0, 129.6, 122.4, 121.12, 121.07, 119.3, 116.3, 113.5, 113.0, 55.5, 55.3; 
IR (neat) 3002, 2938, 2835, 1662, 1578, 1485, 1452, 1430, 1314, 1286, 1257, 1195, 1165, 
1088, 1028, 993, 979, 878, 847, 776, 728, 683, 568, 549, 502 cm-1; HRMS (EI-TOF) m/z 
= 268.1099 calc for C17H16O3 [M]+, found 268.1101. 
 
1,3-Bis(3-methoxyphenyl)propan-1-ol (3AC). To a flame dried round bottom flask, 
was added Pd(OAc)2 (20 mg, 0.09 mmol) and NaBH4 (33.1 mg, 0.88 mmol). (E)-1,3-Bis(3-
methoxyphenyl)prop-2-en-1-one (235 mg, 0.88 mmol) was dissolved in CHCl3 (1.0 mL, 
0.9 M) and the solution added. With a balloon as an outlet for H2 gas produced, MeOH (4.0 
mL, 0.2 M) was slowly added. After completion, the mixture was filtered through Celite. 
The solvent was evaporated, and the product was chromatographed (hexane/EtOAc, 10:1). 
The product was obtained as a clear liquid (31.6 mg, 0.12 mmol) in 13% yield: 1H NMR 
(500 MHz, CDCl3) d  7.27 (t, J = 8.0 Hz, 1H), 7.21 (t, J = 7.7 Hz, 1H), 6.94-6.92 (m, 2H), 
6.84-6.81 (m, 1H), 6.80 (d, J = 7.5 Hz, 1H), 6.76-6.73 (m, 2H), 4.66 (dd, J = 6.4, 2.2 Hz, 
1H), 3.81 (s, 3H), 3.79 (s, 3H), 2.77-2.63 (m, 2H), 2.15-1.99 (m, 2H); 13C NMR (125 MHz, 
CDCl3) d 159.8, 159.7, 147.8, 143.9, 129.1, 128.9, 120.5, 118.0, 113.9, 112.1, 111.3, 111.0, 





1316, 1256, 1191, 1151, 1039, 995, 938, 867, 780, 725, 696, 561, 502, 471 cm-1; HRMS 
(ESI-TOF) m/z = 272.1412 calc for C17H20O3 [M]+, found 272.1404. 
 
1,3-Bis(3-methoxyphenyl)propane (3AD). To a flame dried round bottom flask, was 
added Pd(OAc)2 (20 mg, 0.09 mmol) and NaBH4 (33.1 mg, 0.88 mmol). (E)-1,3-Bis(3-
methoxyphenyl)prop-2-en-1-one (0.235 g, 0.88 mmol) was dissolved in CHCl3 (1.0 mL, 
0.9 M) and the solution added. With a balloon as an outlet for H2 gas produced, MeOH (4.0 
mL, 0.2 M) was slowly added. After reaction completion, the mixture was filtered through 
Celite. The solvent was evaporated and the product was chromatographed (hexane/EtOAc, 
10:1). The product was obtained as a dark orange liquid (17 mg, 0.07 mmol) in 8% yield: 
1H NMR (500 MHz, CDCl3) d 7.20 (dd, J = 8.2, 1.2 Hz, 2H), 6.79 (d, J = 7.5, 2H) 6.75-
6.73 (m, 4H), 3.80 (s, 6H), 2.64 (t, J = 7.5, 4H), 1.96 (m, 2H); 13C NMR (125 MHz, 
Acetone-D6) d 159.8, 143.8, 129.1, 120.5, 113.9, 111.0, 54.4, 35.2, 32.8. IR (neat) 2936, 
2834, 1601, 1583, 1487, 1453, 1436, 1313, 1286, 1258, 1190, 1164, 1151, 1084, 1044, 
996, 866, 775, 752, 737, 694, 571 cm-1; HRMS (EI-TOF) m/z = 256.1463 calc for C17H20O2 
[M]+, found 256.1439. 

















To a 10 mL microwave vial was added the bibenzyl analog (1.0 equiv), K2CO3 (1.5 
equiv), and HPLC grade acetone (0.2 M). The vial was sealed with a septum and, under an 
inert atmosphere, the alkyl bromide (0.9 equiv) added. The septum was replaced with a 
crimping cap and the vessel sealed and stirred for the indicated time at 60 °C.  When the 
reaction was finished, it was quenched with H2O (15 mL). The mixture was extracted with 
dichloromethane (5 x 15 mL) and ethyl acetate (5 x 15 mL). The combined organic layers 
were washed with brine (5 x 10 mL), dried over Na2SO4, concentrated, and 
chromatographed (10% ethyl acetate/hexane) to afford the product. 
 
2-(tert-Butyl)-5-(4-(tert-butyl)-3-methoxyphenethyl)phenol (3AE). Following 
general procedure D, the product was obtained as a white solid (7 mg, 0.02 mmol) in 40% 
yield: 1H NMR (500 MHz, CDCl3) d 7.17 (d, J = 8.0 Hz, 2H), 6.74 (d, J = 8.0 Hz, 2H), 
6.64 (s, 1H), 6.50 (s, 1H), 4.62 (s, 1H), 3.78 (s, 3H), 2.84 (m, 4H), 1.39 (s, 9H), 1.35 (s, 
9H); 13C NMR (125 MHz, CDCl3) d 158.4 154.0, 141.1, 140.8, 135.9, 133.7, 127.0, 126.5, 
120.5, 119.9, 116.7, 112.0, 54.97, 37.4, 37.0, 34.6, 34.3, 29.8, 29.7; IR (neat) 3527, 2997, 
2954, 2867, 1612, 1571, 1504, 1484, 1463, 1412, 1390, 1360, 1296, 1258, 1188, 1173, 
1137, 1087, 1040, 943, 889, 853, 817, 729, 638, 572, 541, 502 cm-1; HRMS (EI-TOF) m/z 






1,2-Bis(4-(tert-butyl)-3-methoxyphenyl)ethane (4K). Following general procedure 
D, the product was obtained as a white solid (6 mg, 0.02 mmol) in 17% yield: 1H NMR 
(500 MHz, CDCl3) d 7.20 (d, J = 7.9 Hz, 2H), 6.77 (d, J = 7.9 Hz, 2H), 6.65 (s, 2H), 3.79 
(s, 6H), 2.89 (s, 4H), 1.37 (s, 18H); 13C NMR (125 MHz, CDCl3) d 158.4, 140.9, 135.8, 
126.4, 120.0, 112.1, 55.0, 37.6, 34.5, 29.8; IR (neat) 2996, 2953, 2864, 1611, 1571, 1504, 
1484, 1464, 1411, 1390, 1359, 1295, 1257, 1173, 1151, 1087, 1041, 933, 851, 817, 724, 
639, 543 cm-1; HRMS (EI-TOF) m/z = 354.2559 calc for C24H34O2 [M]+, found 354.2574. 
mp = 129 – 130 °C. >95% purity. UPLC tR = 2.88 min gradient B. 
 
2-(tert-Butyl)-5-(4-(tert-butyl)-3-(octyloxy)phenethyl)phenol (4O). Following 
general procedure D, the product was obtained as a light yellow liquid (15 mg, 0.03 mmol) 
in 49% yield: 1H NMR (500 MHz, CDCl3) d 7.19 (dd, J = 7.9, 1.8 Hz, 2H) 6.77-6.74 (m, 
2H), 6.66 (s, 1H), 6.53 (s, 1H), 4.69 (s, 1H), 3.93 (t, J = 6.5 Hz, 2H), 2.85-2.83 (m, 4H), 
1.83 (pentet, J = 7.0 Hz, 2H), 1.51 (m, 3H), 1.41 (s, 9H), 1.39 (s, 9H), 1.34-1.26 (m, 10H); 
13C NMR (125 MHz, CDCl3) d 157.8, 154.0, 141.2, 140.7, 135.6, 133.7, 127.0, 126.5, 







26.4, 22.7, 14.1; IR (neat) 3527, 2925, 2857, 1611, 1572, 1503, 1467, 1416, 1390, 1360, 
1297, 1258, 1179, 1138, 1084, 1033, 852, 817, 724, 637, 572, 502 cm-1; HRMS (EI-TOF) 
m/z = 438.3498 calc for C30H46O2 [M]+, found 438.3493. 
 
5,5'-(Ethane-1,2-diyl)bis(2-ethylphenol) (4C). In a microwave vial, 5,5'-(ethane-1,2-
diyl)bis(2-(1-hydroxyethyl)phenol) (15 mg, 0.05 mmol) was dissolved in chlorobenzene 
(0.1 M). The solution was cooled to 0 °C, then BH3•SMe2 was added slowly dropwise. The 
solution stirred at rt for 0.25 h, raised to 80 °C for 3 h, then raised to 130 °C for 18 h. The 
mixture was quenched with Na2CO3 (10 mL), extracted with dichloromethane (5 x 10 mL) 
and washed with brine (5 x 10 mL). The combined organic fractions were dried over 
Na2SO4, concentrated, and chromatographed (hexane/EtOAc, 10:1). The product was 
obtained as an amorphous white solid (10 mg, 0.04 mmol) in 74% yield: 1H NMR (500 
MHz, CDCl3) d 7.04 (d, J = 7.6 Hz, 2H), 6.72 (d, J = 7.6 Hz, 2H), 6.59 (s, 2H), 4.63 (s, 
2H), 2.80 (s, 4H), 2.59 (q, J = 7.5 Hz, 4H), 1.22 (t, J = 7.5 Hz, 6H); 13C NMR (125 MHz, 
CDCl3) d 153.2, 141.0, 129.2, 127.3, 120.9, 115.2, 37.3, 30.9, 22.6; IR (neat) 3270, 2965, 
2921, 2872, 2860, 1621, 1586, 1427, 1243, 1120, 862, 821 cm-1; HRMS (EI-TOF) m/z = 






CHAPTER 4.  Optimization to Broad-Spectrum Anti-Bacterial 
Compounds 
 
4.1. Background of MRSA and A. baumannii Antibiotics 
Methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter 
baumannii are two of the most efficacious pathogens responsible for millions of 
nosocomial infections worldwide. 78  These multi-drug resistant (MDR) bacteria are 
commonly found in intensive care units and are able to survive for extended periods of 
time in hospital environments, facilitating transmission between patients.79,80 These two 
microorganisms are most deadly in late-onset hospital-acquired pneumonia or soft-tissue 
infections through the contamination of surgical wounds.81 Due to the emerging threat of 
bacteria evolving resistance to more antibiotics, scientists are constantly looking for new 
classes of compounds that can treat infectious diseases. 
Vancomycin, the first glycopeptide antibiotic first isolated in 1954 from 
Amycolatopsis orientalis, was originally used to treat postoperative micrococcal colitis.82 
 
78 Haque, M.; Sartelli, M.; McKimm, J.; Abu Bakar, M., Health care-associated infections 
- an overview. Infect Drug Resist. 2018, 11, 2321–2333. 
79 Barrie, A.; Gorman, M., Acintobacter baumannii-The New MRSA?. Eplasty 2016, 
16:ic10. 
80 Eliopoulos, G. M.; Maragakis, L. L.; Perl, T. M., Acintobacter baumannii: 
epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 2008, 
46(8), 1254-1263. 
81 Leong, H. N.; Kurup, A.; Tan, M. Y.; Kwa, A. L. H.; Liau, K. H.; Wilcox, M. H., 
Management of complicated skin and soft tissue infections with a special focus on the 
role of newer antibiotics. Infect. Drug Resist. 2018, 11, 1959–1974. 
82 Anderson, R. C.; Higgins, H. M.; Pettinga, C. D., Symposium: how a drug is born, 
Cincinnati J. Med. 1961, 42, 49-60. 
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This drug became widely available after S. aureus evolved resistance to methicillin, and is 
the reference standard for the treatment of many infections caused by drug resistant 
bacteria.83 Still, there are several drawbacks to the usage of vancomycin. The most overt 
flaw from an industrial standpoint is that this antibiotic is an extremely large and complex 
molecule, therefore its synthesis and that of its analogs is arduous, expensive and time-
consuming (Figure 4.1).84 Further, vancomycin works by inhibiting the cell wall synthesis 
of bacteria; however, it is only effective against Gram-positive species, as it cannot 
penetrate the outer membrane of Gram-negative pathogens.85 Finally, this antibiotic has 
demonstrated several side effects, such as flushing of the upper body and low blood 
pressure, leading to many studies on its toxicity.86 
Advances in antibiotics have given rise to broad-spectrum drugs that are able to be 
applied topically. One such example is the commercially available mupirocin, a topical 
aerosol and ointment that has been shown to have strong bioactivity against pathogens that 
affect the skin flora, such as MRSA and A. baumannii.87 This drug is still commonly used 
to treat Methicillin-resistant infected burn wounds. 88  A 2008 study of several topical 
 
83 Boneca, I. G.; Chiosis, G., Vancomycin resistance: occurrence, mechanisms, and 
strategies to combat it. Expert Opin. Ther. Targets, 2003, 7(3), 311-328. 
84 Nicolaou, K. C.; Mitchell, H. J.; Jaina, Nareshkumar, F.; Wissinger, N.; Hughes, R.; 
Bando, T., Total Synthesis of Vancomycin. Angew. Chem. Int. Ed. 1999, 38, 240-244. 
85 Hammes, W. P.; Neuhaus, F. C., On the Mechanism of Action of Vancomycin: 
Inhibition of Peptidoglycan Synthesis in Geffkya homari. Antimicrob. Ag. Chemother. 
1974, 6(6), 722-728. 
86 Bamberger, D. M.; Boyd, S. E., Management of Staphylococcus aureus Infections. Am. 
Fam. Physicians 2005, 72(12), 2474-2481. 
87 Sutherland, R.; Boon, R. J.; Griffin, P. J.; Masters, P. J.; Slocombe, B.; White, A. R., 
Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. 
Antimicrob. Agents Chemother. 1985, 27(4), 495-498. 
88 Carré, N.; Sillam, F.; Dabas, J. P.; Herbreteau, N.; Pinchon, C.; Ortmans, C.; Thiolet, J. 
M.; Vandenesch, F.; Coignard, B., Staphylococcus aureus carrying Panton-Valentine 
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antibiotics in the Military Medicine journal found that mupirocin was one of the most 
efficacious antimicrobial agents against A. baumannii, warranting further research to 
determine if mupirocin can be used to treat wounded soldiers.89 Unfortunately, there are 
several similar disadvantages to mupirocin. Its principal component, pseudomonic acid A 
(PA-A) is also a complex compound with several stereocenters that requires a large time 
investment in order to synthesize derivatives (Figure 4.1). 90  The widespread use of 
mupirocin has led to many bacteria, including MRSA, garnering resistance and limiting its 
usage.91 PA-A is only isolatable from submerged cultures of Pseudomonas fluorescens 
through a procedure with numerous involved steps.92, This lab-grown bacteria that has been 
recently discovered to be infecting donated blood and causing hemolysis.93 
 
leucocidin genes nasal colonization and skin infection: screening in case of outbreak in a 
school environment. Médecine et maladies infectieuses 2008, 38, 483-488. 
89 Davis, S. C.; Pisanni, F.; Montero, R. B., Effects of commonly used topical 
antimicrobial agents on Acintobacter baumannii: an in vitro study. Mil. Med. 2008, 
172(1), 74-78. 
90 Thomas, C. M.; Hothersall, J.; Willis, C. L.; Simpson, T. J., Resistance to and synthesis 
of the antibiotic mupirocin. Nat. Rev. Microbiol. 2010, 8, 281-289. 
91 Antonov, N. K.;  Garzon, M. C.;  Morel, K. D.; Whittier, S.;  Planet, P. J.; Lauren, C. 
T., High Prevalence of Mupirocin Resistance in Staphylococcus aureus Isolates from a 
Pediatric Population. Antimicrob. Agents Chemother. 2015, 59 (6) 3350-3356. 
92 Fuller, A.; Mellows, G.; Woolford, M.; Banks, G. T.; Barrow, K. D.; Chain, E. B., 
Pseudomonic Acid: an Antibiotic produced by Pseudomonas fluorescens. Nature 
1971, 234, 416–417. 
93 Gibb, A. P.; Martin, K. M.; Davidson, G. A.; Walker, B.; Murphy, W. G., Rate of 




Figure 4.1 Lead Gram Positive Oral/Intravenous and Topical Antibiotics 
 
4.2. Background of Bisphenolic Honokiol Analogs that Target Oral Bacteria 
With a library of simple to synthesize bisphenolic analogs of honokiol that have 
shown strong inhibitory ability against oral bacteria, their effects against a range of bacteria 
were of interest. Honokiol and its derivatives have, in the past year alone, been shown to 
have a wide variety of bioactivities including impeding of breast carcinogenesis, inhibition 
of oncogenic transcription factor FOXM1, and dose-dependent suppression of the growth 
of biofilms of A. baumannii.94,95,96 Honokiol is an interesting target due to its structure and 
previously reported strong activity against the etiologic agent of dental caries, 
Streptococcus mutans. However, under physiologically relevant conditions we discovered 
 
94 Muniraj, N.; Shriver, M.; Nagalingam, A.; Siddharth, S.; Parida, S.; Saxena, N. K.; 
Sharma, D., Induction of STK11-dependent cytoprotective autophagy in breast cancer 
cells upon Honokiol treatment [abstract]. In: Annual Meeting of the American Association 
for Cancer Research; 2019 March 29-April 3; Atlanta, GA. Abstract nr 4271. 
95 Halasi, M.; Hitchinson, B.; Shah, B.N.; Váraljai, R.; Khan, I.; Benevolenskaya, E. V.; 
Gaponenko, V.; Arbiser, J. L.; Gartel, A. L., Honokiol is a FOXM1 antagonist. Cell 
Death Dis. 2018, 9, 84. 
96 Khadke, S. K.; Lee, J.; Woo, J.; Lee, J, Inhibitory Effects of Honokiol and Magnolol on 














































that honokiol exhibits poor potency with a minimum inhibitory concentration (MIC) of 
only 250 µM (66.6 µg/mL).97  
From a library of honokiol analogs, the bactericidal compound 5,5’-(ethane-1,2-
diyl)bis(2-(tert-butyl)phenol) (C2) was found to be significantly more potent with an MIC 
of 2-4 µM (0.67-1.33 µg/mL) against the oral streptococci bacteria Streptococcus gordonii, 
Streptococcus sanguinis, S. mutans, and Streptococcus sobrinus. Subsequent structure-
activity relationships (SAR) studies on the C2 scaffold determined that in order to retain 
potency there must be a biaryl motif, at least one free phenol, two tert-butyl groups, and a 
one or two carbon linker. The next goal was to determine if C2, or any of its most bioactive 
analogs, are broad-spectrum compounds that inhibit the topical bacteria MRSA HPV107 
and Acinetobacter baumannii 2208. If none of the derivatives are able to inhibit Gram-
negative bacteria, permutation of C2 was planned with the goal of developing a broad-
spectrum topical antibacterial agent that is cheaper and easier to synthesize compared to 
the commercial alternative, mupirocin. 
4.3. SAR Analysis of Oral Bacteria Inhibitors Against MRSA and A. baumannii 
 Initially, MIC assays against MRSA and A. baumannii were performed using the 
most potent oral-targeting bisphenolic analogs of honokiol (Figure 4.2). The bioactivity 
trends of these compounds against S. mutans were similar with MRSA. Compound C2 is 
the most potent, with an MIC of 4 µM (1.3 µg/mL). Positional analog 4H, which had 
previously matched the activity of C2 against S. mutans, was two dilutions less effective. 
 
97 Solinski, A. E.; Ochoa, C.; Lee, Y. E.; Paniak, T.; Kozlowski, M. C.; Wuest, W. M. 
Honokiol-Inspired Analogs as Inhibitors of Oral Bacteria. ACS Infect. Dis. 2018, 4 (2), 
118–122. 
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Compounds 3AE and 4K demonstrated that activity is retained when one phenol is 
alkylated, but lost when both phenols are protected, showing the importance of at least one 
free phenol. Altering the linker size to zero, one, or three carbons (4P, 3N, 4Q) all 
decreased potency as well, proving that two carbons are still the ideal length. Finally, one 
common theme amongst all the analogs was that none had any activity against A. 
baumannii at or below 250 µM (Table 4.1).  
Vancomycin was observed to have an MIC of 2 µM (2.90 µg/mL) against MRSA and, 
similar to the bisphenolic honokiol analogs, demonstrated no bioactivity against A. 
baumannii at or below 250 µM. These results show that several of our oral bacteria 
inhibitors, analogs C2, 3AE, 4G, 4P, and 4Q, all cause inhibition below the MIC of 
vancomycin at 2.90 µg/mL. Furthermore, all of the most active analogs against MRSA are 
synthesized through facile 2-4 step syntheses, allowing for easy derivatization compared 
to the lengthy syntheses of vancomycin derivatives.98    
 
98 Okano, A.; Isley, N. A.; Boger, D. L., Total Synthesis of Vancomycin Related 
Glycopeptide Antibiotics and Key Analogues. Chem. Rev. 2017, 117 (18), 11952-11993. 
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Figure 4.2 Structures of Oral Bacteria Inhibitors Tested Against MRSA and A. 
baumannii 
 





































































4.4. Synthesis of Initial Broad-Spectrum Lead Compound 
 This inability to inhibit A. baumannii is due to the difficult-to-penetrate 
lipopolysaccharide-coated outer membrane that makes it challenging for antibiotics to 
enter Gram-negative bacteria.99 Furthermore, compounds have to pass through porins lined 
with negatively charged amino acids whereupon they are susceptible to efflux pumps, 
making accumulation inside of the bacterial cell difficult.100 Recent comprehensive studies 
by the Hergenrother group tested over 180 compounds in order to understand what 
physiochemical properties allow for accumulation in Gram-negative bacteria. It was found 
that polar, rigid, small molecules with ionizable amine groups are the most likely to 
penetrate the charged outer membrane and accumulate in the cell.101,102 
 In order to instill ionizable primary amines, precursors used in the syntheses of the 
analogs from Chapter 3 were examined for modifiable positions. The previously 
synthesized bio-inactive compound 4N (Scheme 4.1) was chosen due to the electrophilic 
aldehyde groups that allowed for facile condensation reactions with N-Boc-1,2-
diaminoethane and N-Boc-1,6-diaminohexane and in situ reduction with excess NaBH4 to 
form analogs 5C and 5G.  
 
99 Beveridge, T.J., Structures of gram-negative cell walls and their derived membrane 
vesicles. J Bacteriol. 1999, 181(16), 4725–4733. 
100 Ferreira, R.; Kasson, P., Antibiotic Uptake Across Gram-Negative Outer Membranes: 
Better Predictions Towards Better Antibiotics. ACS Infect. Dis. 2019, 5, 2096-2104. 
101 Richter M. F.; Drown, B. S.; Riley, A. P.; Garcia, A.; Shirai, T.; Svec, R. L.; 
Hergenrother, P. J., Predictive compound accumulation rules yield a broad-spectrum 
antibiotic. Nature 2017, 545, 299–304. 
102 Drown, B. S.; Hergenrother, P. J., Going on offense against the gram-negative 
defense. PNAS 2018, 115 (26), 6530-6532. 
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Scheme 4.1 Synthesis of Electrophilic Salicylaldehyde 4N
 
These Boc-protected diamine derivatives were then deprotected using 
trifluoroacetic acid to afford compounds 5A and 5B. Upon testing the MIC of these four 
analogs against MRSA and A. baumannii, compounds 5A and 5B, with primary ionizable 
amines, did not cause inhibition of either bacteria at or below 250 µM (Scheme 4.2). 
However, the Boc-protected intermediate 5C inhibited both bacteria at 250 µM and 5G 
was even more potent with an MIC of 32 µM (22 µg/mL) against MRSA and A. baumannii. 
With this first broad-spectrum lead, further analogs of 5G were designed to assess the 
structure-activity relationships (SAR) of this lead compound. 
Scheme 4.2 Synthesis of First Broad-Spectrum Bisphenols
 
4.5. SAR Analysis of Broad-Spectrum Topical Antibiotics 
The first goal was to determin how the diamine linker length affects bioactivity. 
Using the same condensation-reduction conditions, Boc-protected derivatives with three, 
four, five, and ten carbon diamine linkers (5D, 5E, 5F, and 5H) (Scheme 4.3) were 































































































Scheme 4.3 Synthesis of Diamine Linker Analogs 
 
From this testing, compound 5G, with a six carbon diamine linker, remained the 
most active. From prior observations with oral bacteria, larger alkyl group adjacent to the 
phenol increase bioactivity. Thus, analogs were designed with a larger group on the 
benzylic position. Analog 3D was simultaneously demethylated and Friedal-Crafts ortho-
acylated via the addition of TiCl4 and acetyl chloride. This ortho-methyl ketone 
intermediate was then subjected to condensation-reduction with N-Boc-1,6-diaminohexane 
to afford 5H. The protected acylated intermediate was also subjected to condensation-
reduction with N-Boc-1,6-diaminohexane to provide 5I (Scheme 4.4). Upon testing the 
bioactivity, 5H was found to be one dilution (63 µM) less active than 5G against both 
bacteria, indicating that greater hindrance at the benzylic position does not provide 
additional efficacy. Analog 5I exhibited no potency at or below 250 µM, reinforcing that, 


































































Scheme 4.4 Synthesis of Acetyl Acyl Derivatives 
 
Potency against MRSA was lost when both phenols of the C2 scaffold were 
protected but was maintained if only one phenol was alkylated. Thus, phenol alkylation of 
was used to incorporate Boc-protected amines. Compound C2 was treated with 2-(Boc-
amino)ethyl bromide and 6-(Boc-amino)hexyl bromide to produce analogs 5J and 5K, 
respectively (Scheme 4.5). Unfortunately, neither of these derivatives were effective 
against MRSA or A. baumannii at or under 250 µM; it appears that both phenols are 
necessary for inhibition in this system. 
Scheme 4.5 Synthesis of Boc-Protected Mono-Alkylated Phenols 
 
Hypothesizing that the steric bulk of the Boc-protected amine provided activity, 
further analogs with a larger Boc-protected amine were synthesized. tert-
Butyloxycarbonyl-methyl-isothiourea was treated with 1,2-ethanediamine and 1,6-
hexanediamine in a nucleophilic displacement of sulfide in order to afford di-Boc 



























































































with 4N to yield the bulky analogs 5N and 5P (Scheme 4.6). Subsequent testing showed 
that due to the six-carbon diamine linker, 5P had a lower MIC of 32 µM (29 µg/mL) against 
A. baumannii compared to the shorter two-carbon diamine linker on 5N, which did not 
exhibit bioactivity. The addition of bulky groups does not appear to lead to greater potency.  
Scheme 4.6 Synthesis of Guanidine Analogs 
 
The final analysis for this scaffold was the determination of whether the terminal 
tert-butyl carbamate group was the cause of inhibition or if it was purely dependent on the 
steric bulk of the tert-butyl group. Compound 5O was synthesized via another 
condensation-reduction and is analogous to 5C, sans the carbamate group (Scheme 4.7). 
We found that 5O was the most potent derivative against A. baumannii, with an MIC of 32 
µM (14.0 µg/mL). This activity demonstrates that, in this system, the acivity can be 
retained or enhanced with a benzylic secondary amine and a tert-butyl group. 
Scheme 4.7 Synthesis of Lead Broad-Spectrum Compound without Boc-Protected Amine
 
 The commercially available topical antibiotic mupirocin is currently used to treat 
S. aureus and MRSA in burn victims and is currently being investigated to treat A. 












































































MIC of 500 µM (250.3 µg/mL) against A. baumannii. These results show that mupirocin 
is much more potent against the Gram-positive bacterium MRSA than any of the broad-
spectrum antibacterial compounds described herein. However, lead compounds 5G, 5P, 
and 5O all exhibit over 10x the potency of mupirocin against the resilient Gram-negative 
bacterium A. baumannii. Lead analog 5O is 18-fold more efficacious (MIC: 14 µg/mL) 
against A. baumannii compared to mupirocin and is easily synthesizable from the readily 
available starting material 3-hydroxybenzaldehyde ($148.38/500 g, Acros Organics) 
through a four-step synthesis (Schemes 4.1 and 4.7). This promising inhibitory data of our 
lead compounds warrant further investigation with in vivo assays to determine if the broad-
spectrum bisphenolic compounds can be used as a topical antibiotic, similar to mupirocin, 
against wounds infected with A. baumannii. 























4.6. Mechanism of Action Against A. baumannii 
Previous work has shown that the inhibitory action of compound C2 and its analogs  
against S. mutans stems arises from targeting the bacterial cell membrane (Chapter 3). 
Using that knowledge as a starting point, the most potent broad-spectrum analogs, 5G, 5Q, 
and 5O were assessed for a similar mechanism of action against A. baumannii. The 
fluorescent dye SYTOX Green Nucleic Acid Stain was used to measure membrane 
permeabilization over 70 minutes.  All three analogs caused some permeabilization of the 
bacterial membrane near their MICs (Figure 4.3). Compounds 5G and 5O appear to cause 
slight permeabilization of the membrane at 16 µM within 70 minutes, one dilution below 
the MIC of both analogs. These results are much clearer for these lead compounds than for 
C2, which was only able to permeabilize or lyse the membrane at four dilutions higher than 
its MIC. The mechanism of action of mupirocin differs from the bisphenolic honokiol 
derivatives, as mupirocin reversibly binds to the bacterial enzyme isoleucyl-tRNA 
synthetase, inhibiting bacterial RNA and protein synthesis.103  
 
103 Antonio, M.; McFerran, N.; Pallen, M. J., Mutations Affecting the Rossman Fold of 
Isoleucyl-tRNA Synthetase Are Correlated with Low-Level Mupirocin Resistance in 
Staphylococcus aureus. Antimicrob. Agents Chemother. 2002, 46 (2), 438-442. 
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Figure 4.3 Cellular membrane permeability of A. baumannii measured with SYTOX 
Green 
4.7. Summary 
The most potent bisphenolic honokiol analogs against oral bacterial also exhibit 
strong bioactivity against the Gram-positive bacterium MRSA (MICs of 1.40-2.50 µg/mL), 
comparable in strength to the reference standard antibiotic, vancomycin (MIC of 2.90 
µg/mL). However, these compounds are unable to inhibit the Gram-negative bacterium A. 
baumannii. The C2 scaffold then was optimized from the inhibition of only Gram-positive 
bacteria to broad-spectrum antibacterial compounds that inhibit the dangerous Gram-
negative pathogen A. baumannii. The incorporation of benzylic amines, tert-butyl groups, 
and free phenols were key characteristics that caused bacterial inhibition. Analogs 5G, 5Q, 
and 5O inhibit A. baumannii at 32 µM, a significantly lower concentration than the 
commercially available topical antibiotic mupirocin (MIC of 500 µM). Mechanism of 
action findings revealed that all three derivatives are causing bacterial membrane 
permeabilization within one dilution of the MIC. Notably, 5O has the lowest MIC (14.0 
µg/mL) and causes permeabilization at half the MIC. Future work further study of the 










































































cultivating resistance, and the testing 96 A. baumannii mutants to reveal potential targets. 
These bisphenolic honokiol derivatives are the start of a new class of broad-spectrum 
antibacterial compounds that can be used to combat the growing threat of resistant A. 
baumannii. 
4.8. Biological Methods 
Materials: The bacterial strains, Methicillin-Resistant Staphylococcus aureus 
HPV107 and Acinetobacter baumannii 2208 [81, DSM 6974] were purchased from the 
American Type Culture Collection. Bacteria liquid cultures were grown in brain heart 
infusion (BHI) broth. Incubation was stagnant at 37 °C. Optical density (OD) 
measurements were performed on a BioTek Plate Reader spectrophotometer.  
Minimum Inhibitory Concentration (MIC) Assay (MRSA, A. baumannii): Stock 
solutions of bibenzyl analogs, 10 mM, were serial diluted in BHI media in flat-bottom 96-
well microtiter plates  (volume 100 µL).  Bacterial cultures were grown overnight and then 
inoculated into the 96-well plate (total volume 200 µL). Plates are inoculated at 37 °C for 
20-24 hours after which the OD630 values were evaluated with a BioTek Plate Reader 
spectrophotometer. The MIC is determined as the lowest concentration of compound 
resulting in no bacterial growth visible to the naked eye and the difference of measured and 
background OD630 is less than 0.1. DMSO controls corresponding to each test 
concentration were performed. Biological triplicates were performed to confirm results. 
SYTOX Assay. Bacterial overnight cultures were regrown to mid-log phase in BHI 
media and the culture was centrifuged and washed with PBS three times. Cells were then 
suspended in the same volume of PBS corresponding to the original regrow volume, and 
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SYTOX green solution (5 mM in DMSO) was added to reach a final concentration of 5 
μM. Cells were incubated at room temperature and in the dark for 30 minutes. 150 µL of 
cells were then added to a black, clear bottom 96-well plate. Fluorescence was recorded 
for 10 minutes in plate reader to allow equilibration (excitation wavelength 485 nm and 
emission wavelength 525 nm). In a new 96-well plate, test compounds (10 mM DMSO 
stock solutions) were serially diluted in PBS. 50 μL of serially diluted compound was 
added to the SYTOX prepared cells in the plate reader and fluorescence was recorded 
overtime (excitation wavelength 485 nm, emission wavelength 525 nm). Biological 
triplicates were completed. Controls: DMSO vehicle control and QAC positive control.104   







104 Adapted from Steele, A. D.; Ernouf, G.; Lee, Y. E. and Wuest W.M. Diverted Total 
Synthesis of the Baulamycins and Analogues Reveals an Alternate Mechanism of Action. 





























4.9. Synthetic Procedures 
General Consideration 
All non-aqueous reactions were carried out under an atmosphere of dry argon unless 
otherwise noted. Commercial reagents were used as received without additional 
purification unless otherwise noted. Anhydrous THF and CH2Cl2 were obtained from a 
Pure Process Technology solvent purification system. All other anhydrous solvents were 
used from SureSeal bottles. Reactions were monitored by thin layer chromatography (TLC) 
using Silicycle glass-backed TLC plates with 250 µM silica and F254 indicator. 
Visualization was accomplished by UV light or iodine staining. All reactions mixtures were 
heated using RCT Digital IKA Magnetic Stirrer Plates.  
All compounds with inhibitory ability greater than 250 µM were analyzed for purity by 
UPLC and characterized by 1H NMR and proton decoupled 13C{1H} NMR. All final 
compounds were found to have >95% purity by UPLC unless otherwise noted. A Waters 
Acquity UPLC system equipped with a Waters TUV detector (254 nm) and a Waters SQD 
single quadrupole mass analyzer with electrospray ionization was used. UPLC Method A: 
Acquity UPLC BEH C18, 1.7 μm, 2.1 x 50 mm column; 500 μL/min; 30 second hold 95:5 
(water:acetonitrile 0.1% v/v formic acid), 2 minute gradient to 5:95, and 30 second hold. 
UPLC Method B: Luna Omega PS C18, 5 µm particle size, 100 Å pore size 250 x 4.6 mm 
column; 500 μL/min; 3 minute hold 100:0 (water:acetonitrile 0.1% v/v formic acid), 20 
minute gradient to 0:100, and 7 minute hold.  
1H NMR spectra were recorded on a 500 or 600 MHz spectrometer. Chemical shifts 
are reported in ppm from the solvent resonance (CDCl3 7.26 ppm, acetone-d6 2.05 ppm). 
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Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, br = broad, m = multiplet), coupling constants, and number of protons. 
Decoupled 13C{1H} NMR spectra were recorded at 125 or 150 MHz. IR spectra were taken 
on an FT-IR spectrometer. Accurate mass measurement analyses were conducted via time-
of-flight mass analyzer GCMS with electron ionization (EI) or via time-of-flight mass 
analyzer LCMS with electrospray ionization (ESI). The signals were measured against an 
internal reference of perfluorotributylamine for EI-GCMS and leucine enkephalin for ESI-
LCMS. The instrument was calibrated, and measurements were made using neutral atomic 
masses; the mass of the electron removed or added to create the charged species is not 
taken into account.  
General Procedure A 
  
To a microwave vial was added the benzylic carbonyl analog (1 equiv), the Boc-
protected diamine (2 equiv), and HPLC grade MeOH (0.05 M). The vial was sealed with a 
crimp cap and stirred at 70 °C. After 2 h, the vial was opened to air and NaBH4 (12 equiv) 
was slowly added. After stirring a further 18 h at rt, the reaction was quenched with H2O 
(20 mL). The resultant mixture was extracted with CH2Cl2 (5 x 10 mL) and EtOAc (5 x 10 
mL) and washed with brine (5 x 10 mL). The combined organic fractions were dried over 





























Purification System (Luna Omega PS C18, 5 µm particle size, 100 Å pore size 250 x 4.6 




Following the general procedure A the product was obtained as a dark brown gel (61.1 mg, 
0.11 mmol) in 98% yield: 1H NMR (500 MHz, CDCl3) d 6.88 (d, J = 7.4 Hz 2H), 6.67 (s, 
2H), 6.62 (d, J = 7.4 Hz, 2H), 4.79 (s, 2H) 3.97 (s, 4H), 3.29-3.27 (m, 4H), 2.81 (s, 4H), 
2.79-2.77 (m, 4H), 1.43 (s, 18H); 13C NMR (125 MHz, CDCl3) d 157.9, 156.2, 142.9, 
128.3, 119.9, 119.2, 116.3, 79.6, 52.1, 48.4, 40.1, 37.5, 28.4; IR (neat) 3330, 2924, 2853, 
1691, 1620, 1582, 1514, 1455, 1391, 1366, 1252, 1168, 1117, 867, 807, 736 cm-1; HRMS 





Following the general procedure A, the product was obtained as a light yellow solid (25.0 
mg, 0.04 mmol) in 50% yield: 1H NMR (500 MHz, CDCl3) d 6.91 (d, J = 7.5 Hz, 2H), 6.71 


























7.0 Hz, 4H), 1.75 (q, J = 7.0 Hz, 4H), 1.46 (s, 18H); 13C NMR (125 MHz, CDCl3) d 165.0, 
158.0, 156.2, 142.9, 131.2, 128.3, 119.1, 116.4, 79.4, 52.2, 45.4, 37.6, 30.0, 28.4; IR (neat) 
3321, 2924, 2853, 1693, 1626, 1581, 1515, 1456, 1391, 1366, 1274, 1251, 1169, 1117, 975, 
866, 813, 736, 635 cm-1; HRMS (ESI) m/z = 587.3809 calc for C32H51N4O6 [M+H]+, found 




Following the general procedure A, the product was obtained as a yellow amorphous solid 
(41.6 mg, 0.07 mmol) in 73% yield: 1H NMR (500 MHz, CDCl3) d 6.87 (d, J = 8.0 Hz, 
2H), 6.68 (s, 2H), 6.60 (d, J = 8.0 Hz, 2H), 3.94 (s, 4H), 3.11 (m, 6H), 2.81 (s, 4H), 2.67 (t, 
J = 6.5 Hz, 4H), 1.53 (m, 6H), 1.42 (s, 18H); 13C NMR (125 MHz, CDCl3) d 158.1, 156.0, 
142.9, 128.2, 120.0, 119.1, 116.3, 52.4, 48.3, 40.3, 37.5, 29.7, 28.4, 27.8, 26.8; IR (neat) 
3324, 2924, 2854, 1690, 1623, 1581, 1516, 1456, 1391, 1365, 1251, 1169, 1117, 970, 867, 
808, 736, 634 cm-1; HRMS (ESI) m/z = 615.4122 calc for C34H55N4O6 [M+H]+, found 





























Following the general procedure A, the product was obtained as a light tan solid (51.0 mg, 
0.08 mmol) in 95% yield: 1H NMR (500 MHz, CDCl3) d 6.87 (d, J = 8.0 Hz, 2H), 6.68 (s, 
2H), 6.60 (d, J = 8.0 Hz, 2H), 4.63 (s, 2H), 3.93 (s, 4H), 3.09 (d, J = 8.0 Hz, 4H), 2.80 (s, 
4H), 2.65 (t, J = 7.0 Hz, 4H), 1.55-1.52 (m, 4H), 1.42 (s, 18H), 1.36-1.34 (m, 6H); 13C 
NMR (125 MHz, CDCl3) d 158.2, 156.0, 142.9, 128.1, 120.0, 119.0, 116.3, 79.1, 52.5, 48.5, 
40.4, 37.5, 29.9, 29.2, 28.4, 24.3; IR (neat) 3322, 2926, 2855, 1693, 1582, 1516, 1457, 
1391, 1365, 1251, 1171, 867 cm-1; HRMS (ESI) m/z = 643.4435 calc for C36H59N4O6 




Following the general procedure A, the product was obtained as a white solid (112.3 mg, 
0.17 mmol) in 85% yield: 1H NMR (500 MHz, CDCl3) d 6.85 (d, J = 7.5 Hz, 2H), 6.67 (s, 
2H), 6.59 (d, J = 7.5 Hz, 2H), 4.67 (s, 2H), 3.92 (s, 4H), 3.07 (m, 4H), 2.80 (s, 4H), 2.01 
(s, 2H), 1.52-1.47 (m, 6H), 1.47 (s, 18H), 1.42-1.31 (m, 10H); 13C NMR (125 MHz, CDCl3) 
d 158.2, 156.0, 142.9, 128.1, 120.1, 119.0, 116.3, 79.1, 52.5, 48.5, 40.4, 37.5, 30.0, 29.5, 
28.4, 26.7, 26.5; IR (neat) 3336, 2923, 2853, 1695, 1516, 1461, 1365, 1251, 1171 cm-1; 
HRMS (ESI) m/z = 671.4748 calc for C38H63N4O6 [M+H]+, found 671.4743; UPLC tR = 

















hydroxyphenethyl)-2-hydroxybenzyl)amino)heptyl)carbamate (5H). Following the 
general procedure A, the product was obtained as a dark brown gel (38.7 mg, 0.06 mmol) 
in 80% yield: 1H NMR (500 MHz, CDCl3) d 6.87 (d, J = 7.5 Hz, 2H), 6.71 (s, 2H), 6.65 (d, 
J = 7.5 Hz, 2H), 4.60 (br, 2H), 3.90 (q, J = 6.5 Hz, 2H), 3.10-3.08 (m, 4H), 2.84 (s, 4H), 
2.62 (m, 4H), 1.54-1.46 (m, 10H), 1.46 (s, 18H), 1.33-1.29 (m, 12H); 13C NMR (125 MHz, 
CDCl3) d 157.0, 156.0, 142.6, 127.9, 119.1, 116.6, 82.6, 79.1, 58.7, 47.3, 40.4, 37.4, 30.0, 
29.7, 29.5, 28.5, 26.7, 26.4; IR (neat) 3356, 3308, 2925, 2855, 1694, 1619, 1581, 1513, 
1456, 1391, 1365, 1271, 1250, 1169, 1121, 1041, 867, 814, 736, 640 cm-1; HRMS (ESI) 




methoxyphenethyl)-2-methoxybenzyl)amino)heptyl)carbamate (5I). Following the 
general procedure A, the product was obtained as a light brown gel (24.5 mg, 0.03 mmol) 
in 47% yield: 1H NMR (500 MHz, CDCl3) d 7.41 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 8.5 Hz, 
2H), 6.67 (m, 2H), 5.04 (m, 1H), 4.93 (m, 1H), 4.72 (br, 2H), 3.76 (s, 6H), 3.09-3.06 (m, 


























13C NMR (125 MHz, CDCl3) mixture of rotamers d 158.8, 156.0, 139.7, 135.9, 135.7, 
126.7, 115.1, 112.0, 66.0, 65.9, 55.2, 41.8, 34.4, 34.3, 33.0, 30.0, 29.7, 28.4, 26.5, 24.4; IR 
(neat) 3347, 2927, 2856, 1689, 1608, 1579, 1502, 1454, 1391, 1365, 1271, 1247, 1167, 
1110, 1080, 1040, 1006, 868, 814, 781, 730, 604 cm-1; HRMS (ESI) m/z = 727.5374 calc 
for C42H71N4O6 [M+H]+, found 727.5371; UPLC tR = 2.13 min method A. 
 
5,5'-(Ethane-1,2-diyl)bis(2-(((3,3-dimethylbutyl)amino)methyl)phenol) (5O). 
Following the general procedure A, the product was obtained as a brown solid (40.9 mg, 
0.09 mmol) in 98% yield: 1H NMR (500 MHz, CDCl3) d 6.89 (d, J = 7.6 Hz, 2H), 6.71 (s, 
2H), 6.63 (d, J = 7.6 Hz, 2H), 3.96 (s, 4H), 2.83 (s, 4H), 2.68 (t, J = 8.0 Hz,  4H), 1.46 (t, J 
= 8.0 Hz, 4H), 0.91 (s, 18H); 13C NMR (125 MHz, CDCl3) d 158.2, 142.9, 128.1, 120.0, 
119.0, 116.4, 52.6, 45.2, 43.6, 37.6, 29.9, 29.5; IR (neat) 3297, 2955, 2923, 2854, 1622, 
1582, 1514, 1457, 1391, 1365, 1276, 1154, 1118, 967, 868, 812, 736, 635 cm-1; HRMS 































product was obtained as a light tan solid (32.4 mg, 0.04 mmol) in 51% yield: 1H NMR (500 
MHz, CDCl3) d 7.74 (br, 2H), 6.96 (d, J = 7.5 Hz, 2H), 6.86 (s, 2H), 6.64 (d, J = 7.5 Hz, 
2H), 4.33 (s, 4H), 3.59-3.55 (m, 8H), 2.82 (s, 4H), 1.50, (s, 18H), 1.45 (s, 18H); 13C NMR 
(125 MHz, CDCl3) Boc signals are coincident d 162.7, 162.4, 156.8, 144.3, 131.0, 120.0, 
119.1, 118.5, 79.0, 45.2, 44.8, 40.9, 37.3, 28.3; IR (neat) 3383, 2924, 2854, 1722, 1656, 
1596, 1528, 1454, 1390, 1365, 1319, 1288, 1252, 1167, 1133, 1102, 1048, 1020, 803, 734, 
662 cm-1; HRMS (ESI) m/z = 843.4980 calc for C42H67N8O10 [M+H]+, found 843.4970; 




dimethylethoxy)carbonyl)guanidine) (5P). Following the general procedure A, the 
product was obtained as a dark yellow amorphous solid (9.7 mg, 0.01 mmol) in 13% yield: 
1H NMR (500 MHz, CDCl3) d 6.88 (d, J = 7.5 Hz, 2H), 6.71 (s, 2H), 6.62 (d, J = 7.5 Hz, 
2H), 3.95 (s, 4H), 3.70 (s, 2H), 3.41 (m, 4H), 2.82 (s, 4H), 2.66 (t, J = 7.0 Hz, 4H), 1.57-
1.54 (m, 4H), 1.54 (s, 36H), 1.50-1.48 (m, 10H); 13C NMR (125 MHz, CDCl3) Boc signals 
are coincident d 163.7, 158.2, 156.1, 153.4, 142.9, 128.1, 119.0, 116.3, 83.1, 79.2, 52.5, 
48.6, 40.8, 37.6, 29.4, 28.9, 28.1, 26.7; IR (neat) 3330, 2926, 2855, 1720, 1616, 1578, 1513, 
1440, 1414, 1393, 1366, 1329, 1273, 1253, 1228, 1154, 1132, 1055, 1027, 971, 869, 807, 
775, 735, 702, 635, 462 cm-1; HRMS (ESI) m/z = 955.6232 calc for C50H83N8O10 [M+H]+, 


















General Procedure B 
  
In a microwave vial, TFA (20.0 equiv) was slowly added to a solution of protected 
diamine (1.0 equiv) in anhydrous CH2Cl2 (0.1 M). The reaction mixture was stirred for 24 
h, concentrated, and chromatographed on an InfinityLabs Preparative-Scale LC 
Purification System(Luna Omega PS C18, 5 µm particle size, 100 Å pore size 250 x 4.6 
mm column; 500 μL/min; with a gradient of 0-100% H2O/MeCN) to yield the product.  
 
2,2'-(((Ethane-1,2-diylbis(2-hydroxy-4,1-
phenylene))bis(methylene))bis(azanediyl))bis(ethan-1-aminium) (5A). Following the 
general procedure B, the product was obtained as a light brown amorphous solid (15.1 mg, 
0.042 mmol) in 96% yield: 1H NMR (500 MHz, MeOD) d 7.21 (d, J = 7.4 Hz, 2H), 6.77 
(s, 2H), 6.73 (d, J = 7.4 Hz, 2H), 4.24 (s, 4H), 3.34-3.31 (m, 8H), 2.84 (s, 4H); 13C NMR 
(125 MHz, MeOD) d 156.2, 145.5, 131.2, 119.9, 115.0, 114.5, 46.9, 43.5, 37.0, 35.3; IR 
(neat) 3375, 3025, 2928, 1679, 1553, 1412, 1207, 1185, 1136, 1052, 1016, 924, 843, 811, 
724, 650, 625, 518 cm-1; HRMS (ESI) m/z = 359.2447 calc for C20H31N4O2 [M+H]+, found 





































phenylene))bis(methylene))bis(azanediyl))bis(hexan-1-aminium) (5B). Following the 
general procedure B, the product was obtained as an amorphous white solid (11.1 mg, 0.02 
mmol) in 79% yield: 1H NMR (500 MHz, MeOD) d 7.21 (d, J = 7.5 Hz, 2H), 6.78 (s, 2H), 
6.74 (d, J = 7.5 Hz, 2H), 4.16 (s, 4H), 3.32 (br, 4H), 3.04-2.93 (m, 10H), 2.86 (s, 4H), 1.76-
1.69 (m, 8H) 1.47-1.43 (m, 10H) ; 13C NMR (125 MHz, MeOD) d 156.1, 145.2, 131.0, 
119.8, 115.1, 114.9, 46.7, 46.4, 39.1, 37.0, 26.9, 25.7, 25.5, 25.3; IR (neat) 3380, 2957, 
2922, 2853, 1644, 1463, 1378, 1261, 546 cm-1; HRMS (ESI) m/z = 535.3296 calc for 
C29H53N4O3 [M+MeOH+H]+, found 535.3480; UPLC tR = 11.78 min method B. 
General Procedure C 
 
 To a 10 mL microwave vial was added bisphenol analog C2 (1.0 equiv), K2CO3 
(1.2 equiv), and HPLC grade acetone (0.2 M). The vial was sealed with a septum and, 
under an inert atmosphere, the alkyl bromide (0.90 equiv) added. The septum was replaced 
with a crimping cap and the vessel sealed and stirred for the indicated time at 60 °C.  When 
the reaction was finished, the mixture was quenched with H2O (15 mL). The mixture was 




























were washed with brine (5 x 10 mL), dried over Na2SO4, concentrated, and 
chromatographed (10% EtOAc/hexane) to afford the product. 
 
tert-Butyl (2-(2-(tert-butyl)-5-(4-(tert-butyl)-3-
hydroxyphenethyl)phenoxy)ethyl)carbamate (5J). Following the general procedure C, 
the product was obtained as a clear liquid (6.7 mg, 0.01 mmol) in 15% yield: 1H NMR (500 
MHz, CDCl3) d 7.19 (d, J = 7.5 Hz, 2H), 6.75 (d, J = 7.5 Hz, 2H) , 7.74 (d, J = 7.5 Hz, 2H), 
6.64 (s, 1H), 6.53 (s, 1H), 5.01 (br, 1H), 4.89 (br, 1H), 4.02 (t, J = 4.9 Hz, 2H), 3.57 (m, 
2H), 2.84 (m, 4H), 1.45 (s, 9H), 1.40 (s, 9H), 1.38 (s, 9H); 13C NMR (125 MHz, CDCl3) d 
157.1, 154.1, 140.91, 140.89, 135.6, 133.7, 127.0, 126.7, 120.4, 116.8, 112.6, 79.6, 66.9, 
40.3, 37.1, 36.8, 34.5, 34.2, 31.9, 30.0, 29.7, 29.4, 28.4; IR (neat) 3375, 2956, 2922, 2853, 
1694, 1612, 1505, 1463, 1417, 1367, 1251, 1171, 1087, 972, 862, 817, 721, 637 cm-1; 
HRMS (ESI) m/z = 470.3270 calc for C29H44NO4 [M+H]+, found 470.3253; UPLC tR = 
1.82 min method A. 
 
tert-Butyl (6-(2-(tert-butyl)-5-(4-(tert-butyl)-3-
hydroxyphenethyl)phenoxy)hexyl)carbamate (5K). Following the general procedure C, 
the product was obtained as a clear liquid (29.6 mg, 0.06 mmol) in 32% yield: 1H NMR 









(t, J = 6.7 Hz, 2H), 3.12-3.11 (m, 4H), 2.86-2.80 (m, 4H), 1.88-1.81 (m, 6H), 1.45 (s, 9H), 
1.40 (s, 9H), 1.37 (s, 9H); 13C NMR (125 MHz, CDCl3) d 157.7, 154.4, 141.0, 140.8, 135.6, 
133.7, 126.9, 126.5, 120.2, 119.7, 116.7, 112.2, 67.4, 37.3, 37.0, 34.6, 34.3, 33.7, 32.7, 
30.1, 30.0, 29.9, 29.7, 29.3, 28.4, 27.8, 26.0; IR (neat) 3347, 2921, 2852, 1687, 1612, 1507, 
1462, 1417, 1391, 1366, 1252, 1173, 1085, 865, 816, 721 cm-1; HRMS (ESI) m/z = 
526.3896 calc for C33H52NO4 [M+H]+, found 526.3878; UPLC tR = 2.60 min method A. 
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APPENDIX A:  SPECTROSCOPIC DATA 
A.1 Chapter 1 
 




































































A.2 Chapter 2 
 

























































































A.3 Chapter 3 
 
 





























































































































































































































































































































































































































A.4 Chapter 4 
 
 





























































































































































































































































































































































































APPENDIX B: UPLC CHROMATOGRAMS 
B.1 Chapter 3 
 




















































































B.2 Chapter 4 
 













































Figure B2.4 UPLC chromatogram of compound 5B 
 
 































































































































Figure B2.13 UPLC chromatogram of compound 5P 
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